Immunologic Signatures of Rejection
Francesco M. Marincola Ena Wang ●
Editors
Immunologic Signatures of Rejection
Editors Francesco M. Marincola Infectious Disease and Immunogenetics Section (IDIS) Department of Transfusion Medicine Clinical Center and Trans-NIH Center for Human Immunology (CHI) National Institutes of Health Bethesda, 20892 USA
[email protected]
Ena Wang Infectious Disease and Immunogenetics Section (IDIS) Department of Transfusion Medicine Clinical Center and Trans-NIH Center for Human Immunology (CHI) National Institutes of Health Bethesda, MD 20892 USA
[email protected]
ISBN 978-1-4419-7218-7 e-ISBN 978-1-4419-7219-4 DOI 10.1007/978-1-4419-7219-4 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: PCN Applied for © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Contents
Part I Preamble From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection”.................................................................................... Ena Wang and Francesco M. Marincola
3
Part II The Immune Biology of Rejection: Basic Principles The Yin Yang of Cancer Related Inflammation............................................ Alberto Mantovani, Cecilia Garlanda, Paola Allavena, Antonio Sica, and Massimo Locati
11
The Immune Rejection: Lessons from Experimental Models..................... Anil Shanker
17
Turning on and off the Immunological Switch: Immune Response Polarization and Its Control by IL-10 and STAT3....................... C. Andrew Stewart and Giorgio Trinchieri
27
The Angiogenic Switch: Role of Immune Cells............................................. Douglas M. Noonan, Agostina Ventura, Antonino Bruno, Arianna Pagani, and Adriana Albini
57
Chemokines and Cytotoxic Effector Molecules in Rejection....................... Alan M. Krensky and Carol Clayberger
77
Clinical Applications of Activated Immune Cells......................................... Luciano Castiello, Marianna Sabatino, Ping Jin, Francesco M. Marincola, and David Stroncek
93
v
vi
Contents
Part III Circulating Patterns Associated with Chronic and Acute Immune Pathology Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects............................................................................... 105 Damien Chaussabel, Nicole Baldwin, Derek Blankenship, Charles Quinn, Esperanza Anguiano, Octavio Ramilo, Ganjana Lertmemongkolchai, Virginia Pascual, and Jacques Banchereau Innate Signatures of Immune Mediated Resolution and Persistence of Hepatitis C Virus Infections............................................ 127 Robert E. Lanford Immune Signatures and Systems Biology of Vaccines.................................. 141 F.M. Buonaguro, M.L. Tornesello, and L. Buonaguro Immune Signatures Associated with the Cancer Bearing State.................. 169 Rebecca J. Critchley-Thorne, Hongxiang Yu, and Peter P. Lee Part IV Tissue-Specific Patterns Associated with Chronic Inflammatory Processes HTLV-1 Infected CD4+CD25+CCR4+ T-Cells Disregulate Balance of Inflammation and Tolerance in HTLV-1 Associated Neuroinflammatory Disease......................................................... 189 Yoshihisa Yamano and Steven Jacobson D/2 Predictors of Favorable Outcome in Cancer.......................................... 199 Zoltán Pós and Jérôme Galon The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance.................... 211 Lana E. Kandalaft and George Coukos Transcriptional Profiling of Melanoma as a Potential Predictive Biomarker for Response to Immunotherapy.............................. 229 Thomas F. Gajewski Functional Pathway Analysis for Understanding Immunologic Signature of Rejection: Current Approaches and Outstanding Challenges....................................... 239 Purvesh Khatri and Minnie M. Sarwal
Contents
vii
Part V Signatures Associated with Acute Rejection Chronic Graft Versus Host Disease: Inflammation at the Crossroads of Allo and Auto Immunity.............................................. 259 Frances T. Hakim Immune-Mediated Tumor Rejection.............................................................. 281 Ena Wang and Francesco M. Marincola Signatures Associated with Acute Rejection: Allograft Rejection........................................................................................... 305 Davide Bedognetti Index.................................................................................................................. 347
Part I
Preamble
From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection” Ena Wang and Francesco M. Marincola
This book collects salient observational data, derived predominantly from human studies, regarding the mechanism(s) of rejection in various pathologic conditions; the premise is that immune rejection, better defined as “immune-mediated, tissuespecific destruction” (TSD) (Wang et al. 2008), comprises a broad range of phenomena ranging from tumor regression, to clearance of pathogen through destruction of infected cells, autoimmunity, allograft rejection by the host and host vs. graft reactions. Like different hands can turn on or off a switch, distinct mechanisms can trigger TSD, however, a convergent pathway is ultimately observed when TSD occurs consisting of a dramatic switch from chronic to acute inflammation (Mantovani et al. 2008).
From the Delayed Allergy Reaction to the Immunologic Constant of Rejection The hypothesis that TSD is a pathophysiological mechanism shared by several diseases is not new; it was suggested long time ago by Jonas Salk, who observed that various phenomena leading to tissue destruction shared common patterns that he defined the “delayed allergy reaction” (Salk 1969). We recently expanded on this concept; comparing our data addressing the transcriptional changes associated with tumor rejection in response to immune manipulation with published observations derived from similar hypothesis-generating approaches applied predominantly (but not exclusively) to the analysis of human tissues during TSD. We concluded that a limited number of functional themes are consistently observed independent of the disease context (Wang et al. 2008). We reckon, therefore, that the mechanisms E. Wang (*) Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD 20892, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_1, © Springer Science+Business Media, LLC 2011
3
4
E. Wang and F.M. Marincola
leading to TSD are relatively conserved among pathologies and include a relatively small number of genes and pathways predominantly centered on the activation of interferon regulatory factor (IRF)-1. We referred to such convergence of mechanism(s) as the immunologic constant of rejection (ICR). The ICR is, in turn, based on four postulates: 1 . Tissue-specific destruction occurs independently of self-nonself discrimination. 2. The requirements for the induction of a cognate immune response differ from those associated with the development of an effector one. 3. While the mechanisms prompting tissue-specific destruction differ among immune pathologies the effector phase converges into a common activation of adaptive and innate cytotoxic mechanisms. 4. Adaptive immunity triggers a tissue-specific reaction but it is not always sufficient or necessary for tissue-destruction. This book was designed to solicit chapters from outstanding basic and/or observational scientists that have contributed to this area either by defining mechanisms relevant to the understanding of the inflammatory switch or by describing how this occurs in human tissues under different pathological conditions. At the time when this pre-amble is being prepared, Ena and I have not read the individual contributions but we are familiar with the authors’ previous publications. Therefore, we would like to entice our reader(s) to test with us, through, the subsequent reading, whether our hypothesis is correct; we predict that common themes will emerge from the reading particularly if attention will be paid to the general phenomenon of TSD rather than the peculiarities of individual pathologies. We want to emphasize that the ICR does not address “why” rejection occurs but rather “how.” We believe that the pathways leading to the final outcome are quite different in distinct conditions and only at the final effector phase converge into a common one. We also believe that the ICR is not necessarily applicable to all forms of TSD but to most of them; at the moment there is no evidence that either hyperacute rejection or fulminant hepatitis, predominantly complement mediated mechanisms, follow the ICR determinism. We hypothesize that several innate and/or adaptive immune mechanisms can contribute differently to TSD. However, the final mechanisms converge in the end to a relatively simple switch that leads to the activation of acute inflammatory process and, particularly, the simultaneous activation of most immune effectors mechanisms. Although, the ICR hypothesis may not contribute an explanation for the determinism of rejection, it provides, if correct, a simplified road map about the convergent common pathways leading to TSD. This offers the powerful benefit of identifying a common target for immune manipulation with therapeutic purposes. In particular, most ICR-related pathways have been found to be active only in the tissues in which TSD occurs while are shut off in the rest of the organism; this tissue discrimination provides the alluring opportunity of targeting for treatment a disease-specific pathway either with the goal of mitigating (autoimmunity, allograft rejection, graft versus host disease) or activating (clearance of pathogen or neoplastic cells) its key components.
From the “Delayed Allergy Reaction”
5
Interferon Regulatory Factor (IRF)-1: Master Switch of Inflammation It has been almost a decade since we first observed that the transcript most upregulated in melanoma metastases undergoing complete regression after immunotherapy was IRF-1 (Wang et al. 2002). This transcription factor has been subsequently recognized to represent a master switch for acute inflammatory process and identified by various groups who studied tissues undergoing TSD as a central modulator of TSD. At the cellular level, IRF-1 is believed to play a purely proinflammatory role activating the expression of cytokines such as IL-12 or IL-15 which have potent effects on immune effector mechanisms (Paun and Pitha 2007; Taniguchi 1997; Taniguchi et al. 2001; Honda and Taniguchi 2006; Honda et al. 2006). Furthermore, IRF-1 can also act as a negative regulator of transcription decreasing the expression of proangiogenic factors such as vascular endothelial growth factor (VEGF) which is involved in tissue repair and possess anti-inflammatory properties (Lee et al. 2008). Thus, our working hypothesis is that IRF-1 plays a central role in altering the cellular biology not only by activating proinflammatory stimuli but by simultaneously blocking anti-inflammatory ones. It is presently unclear what pathways regulate the activation of IRF-1 in different conditions although, IRF-1 is believed to be primarily expressed in response to IFN-g stimulation (Honda and Taniguchi 2006). However, we have observed IRF-1 activation in the absence of IFN-g or other IFNs (Worschech et al. 2009) and, on the other hand, we observed IRF-1 to be strongly activated in response to IL-2 stimulation of PBMCs suggesting either a direct or indirect activation of IRF-1 by this cytokine (Jin et al. 2007). Thus, it is likely that other pathways can activate this master regulator or inflammation. Similarly, the complete picture of what pathways are activated or inactivated by IRF-1 in different patho-physiological conditions is missing. It is likely that various pathways can be diversely influenced dependent upon the cellular environment in which IRF-1 interacts with other regulatory factors. Probably, IRF-1 acts differently in relation to the presence of other transcription factors that may be activated in different conditions and/or in different cell types. It is even possible that IRF-1, like other IRFs may affect the function of other master regulators of innate immunity such as the NF-kB complex by enhancing its proinflammatory effects while inhibiting the antiapoptotic ones (Honda and Taniguchi 2006). These questions are not addressed by this book but are salient areas for future investigation and will enhance further understanding of how TSD occurs and how it can be modulated effectively.
The Recurrent Themes Defining the Signatures of Rejection We recently summarized the common functional units associated with TSD. These include overlapping yet distinct themes that are consistently present when TSD occurs:
6
E. Wang and F.M. Marincola
1 . The STAT-1/IRF-1/T-bet/IFN-g, IL-15 path 2. The Granzyme A/B, TIA-1 pathway 3. The CXCR3 ligand chemokine pathway 4. The CCR5 ligand chemokine pathway We observed, in different disease models, their presence; studies in humans have identified these signatures to be associated with improved survival of patients with colon, lung and ovarian cancer or melanoma (Benencia et al. 2005; Pages et al. 2005; Dieu-Nosjean et al. 2008; Camus et al. 2009; Galon et al. 2006, 2007; Harlin et al. 2009); the same patterns were observed in neoplastic lesions undergoing rejection during immunotherapy both in humans (Wang et al. 2002; Panelli et al. 2002, 2006) and in experimental models (Shanker et al. 2007). Allo-rejection has been most studied by biopsing organs during the acute phases of rejection and several studies have reported recurrent themes (Sarwal et al. 2003; Hardstedt et al. 2005; Karason et al. 2006; Reeve et al. 2009; Saint-Mezard et al. 2009). In particular, Saint-Mezard et al. (2009) analyzed three independent data set of renal biopsies identifying a robust transcriptional signature of acute allograft rejection which well summarizes most of the components of the ICR. Imanguli et al (2009), observed similar patterns by studying biopsies of tissues suffering chronic graft vs. host disease and similar patters where observed in the liver during clearance of HCV infection (Bigger et al. 2001; He et al. 2006; Feld et al. 2007; Nanda 2008; Asselah et al. 2008). Recently similar signatures were observed in the destructive phases of acute cardiovascular events (Zhao et al. 2002; Okamoto et al. 2008) and chronic obstructive pulmonary disease (Costa et al. 2008). With the hope of having contributed with this book something novel and important, we wish our reader a pleasant journey in the wondrous land of immune-mediated, tissue-specific destruction.
References Asselah T, Bieche I, Narguet S et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57(4):516–524. Benencia F, Courreges MC, Conejo-Garcia JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12(5):789–802. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75(15):7059–7066. Camus M, Tosolini M, Mlecnik B et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009; 69(6):2685–2693. Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008; 133(1):26–33. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27):4410–4417. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46(5):1548–1563.
From the “Delayed Allergy Reaction”
7
Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960–1964. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67(5):1883–1886. Hardstedt M, Finnegan CP, Kirchhof N et al. Post-transplant upregulation of chemokine messenger RNA in non-human primate recipients of intraportal pig islet xenografts. Xenotransplantation 2005; 12(4):293–302. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69(7):3077–3085. He XS, Ji X, Hale MB et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006; 44(2):352–359. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6(9):644–658. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25(3):349–360. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113(15):3620–3630. Jin P, Wang E, Provenzano M, Stroncek D, Marincola FM. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 2007; 27(5):437–448. Karason K, Jernas M, Hagg DA, Svensson PA. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc Disord 2006; 6:29. Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta 2008; 1783(9):1654–1662. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2008; 371(9614):771–783. Nanda S, Havert MB, Calderon GM et al. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008; 3(10):e3442. Okamoto Y, Folco EJ, Minami M et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008; 102(2):218–225. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654–2666. Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3(7):RESEARCH0035. Panelli MC, Stashower M, Slade HB et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2006; 8(1):R8. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007; 89(6–7):744–753. Reeve J, Einecke G, Mengel M et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9(8):1802–1810. Saint-Mezard P, Berthier CC, Zhang H et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22(3):293–302. Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 1969; 164(2):365–380. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349(2):125–138. Shanker A, Verdeil G, Buferne M et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007; 179(10):6651–6662. Taniguchi T. Transcription factors IRF-1 and IRF-2: linking the immune responses and tumor suppression. J Cell Physiol 1997; 173(2):128–130.
8
E. Wang and F.M. Marincola
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. Irf family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19:623–655. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581–3586. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29(6):256–262. Worschech A, Chen N, Yu YA et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facets of oncolytic therapy. BMC Genomics 2009; 10:301. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFNgamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169(3):1556–1560.
Part II
The Immune Biology of Rejection: Basic Principles
The Yin Yang of Cancer Related Inflammation Alberto Mantovani, Cecilia Garlanda, Paola Allavena, Antonio Sica, and Massimo Locati
Introduction Smoldering, nonresolving inflammation is part of the tumor microenvironment (Balkwill and Mantovani 2001; Coussens and Werb 2002; Mantovani et al. 2008a). Inflammatory cells and mediators are present in the microenvironment of cancers epidemiologically related or unrelated to inflammatory or infectious conditions. Leukocyte infiltration and the presence of soluble mediators such as cytokines, and chemokines are key characteristics of CRI. Conditions predisposing to cancer (e.g., inflammatory bowel disease, IBD) or genetic events that cause neoplastic transformation orchestrate the construction of an inflammatory microenvironment. Indeed, alterations of oncogenes drive the production of inflammatory mediators. Thus, an intrinsic pathway of inflammation (driven in tumor cells), as well as an extrinsic pathway driven by chronic inflammatory conditions have been identified, both of which contribute to tumor progression (Mantovani et al. 2008a). CRI has therefore emerged as the seventh hallmark of cancer (Mantovani 2009). Tumorassociated macrophages (TAM) are a major component of leukocytic infiltrate of tumors and have served as a paradigm for cancer-related inflammation (De Palma et al. 2007; Mantovani et al. 2008a; Pollard 2009). Macrophages are a double edged sword, with the potential to express pro and antitumor activity (the macrophage balance, (Mantovani et al. 1992, 2002)), the former prevailing in established neoplasia. Here we will focus on selected molecular pathways underlying TAM recruitment and polarization, emphasizing the dual potential of cancerrelated inflammation (Mantovani et al. 2008b) and the diversity of pathways and functions in different tumors.
A. Mantovani (*) Istituto Clinico Humanitas IRCCS, via Manzoni 56, 20089 Rozzano, Italy Department of Translation Medicine, university of Milan, Milan, Italy e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_2, © Springer Science+Business Media, LLC 2011
11
12
A. Mantovani et al.
Recruitment of TAM Inflammatory chemokines have long been associated with macrophage recruitment in tumors (Bottazzi et al. 1983) and cancer cells have served as a major source for identification of members of these chemoattractants. They act in concert with adhesion molecules (Marttila-Ichihara et al. 2009). Yet, only recently has unequivocal genetic evidence been obtained that monocyte attracting inflammatory CC chemokines play a nonredundant role in carcinogenesis (Nibbs et al. 2007; Popivanova et al. 2009; Vetrano et al. 2010). The “robustness” of the chemokine system in terms of phagocyte recruitment (Mantovani 1999) until recently has prevented an unequivocal demonstration of a nonredundant function of individual inflammatory chemokines or their receptors using gene targeted mice. This missing genetic link has now been obtained taking advantage of the D6 atypical receptor which acts as a decoy and scavenger for most inflammatory CC chemokines (Mantovani et al. 2006). D6 deficient mice show increased susceptibility to skin carcinogenesis (Nibbs et al. 2007) and colitis-associated cancer, the latter being representative of a clinical paradigm of the inflammation-cancer connection (Vetrano et al. 2010) Thus, D6 targeted mice provide unequivocal genetic evidence that inflammatory CC chemokines are more than an epiphenomenon in clinically relevant carcinogenesis.
Plasticity of TAM and Promotion of Metastasis In most, but not all (Torroella-Kouri et al. 2009) tumors investigated, TAM have an M2-like phenotype. What signals in the tumor microenvironment are responsible for the protumor function of TAM? Tumor cell products, including extracellular matrix components, IL-10, M-CSF, activate macrophages and set them in an M2, cancer promoting mode (Hagemann et al. 2006; Kuang et al. 2007; Erler et al. 2009; Kim et al. 2009). Chemokines (CCL17 and CCL22) which interact with CCR4 have been shown to promote M2 polarization (Wallace et al. 2009). CCL2 has been shown to play a role not only in attracting tumor promoting macrophages prostate carcinoma but also in promoting their survival and M2 polarization (Roca et al. 2009). Anti CCL2 antibodies are undergoing evaluation in humans. Tumor products can instruct dendritic cells to prime IL-13 producing T cells which promote breast cancer (Aspord et al. 2007). Adaptive immune responses can shape the infiltration and function of TAM. In a primary mammary carcinoma model, CD4+ T cells promote metastasis by causing M2 activation via IL-4 (DeNardo et al. 2009). Interestingly, in multistage epithelial carcinogenesis in the skin driven by transgenic expression of HPV16, a different pathway of orchestration of inflammationmediated tumor promotion by adaptive immune responses is operative. Antibody production against extracellular matrix components orchestrates by remote control cancer-related inflammation (de Visser et al. 2005). Autoantibodies act via FcgR and regulate recruitment and M2-like polarization of myelomonocytic cells which promote tumor progression (Andreu et al. 2010).
The Yin Yang of Cancer Related Inflammation
13
A similarity has emerged in terms of transcriptional profile, functional properties and underlying transcription factors between TAM and “tolerant” macrophage (Porta et al. 2009). Tolerant macrophages belong to the wide spectrum and universe of M2-like polarized phagocytes. The finding that PMN have unsuspected plasticity and are subject to a N1-N2 balance in the tumor microenvironment (Fridlender et al. 2009 ) calls for a reappraisal of their role and significance in cancer related inflammation. Macrophages and some of their products (IL-1; TNF; IL-6) have long been known to increase metastasis (Mantovani et al. 2008a) and recent work has provided new evidence (Hagemann et al. 2005, 2006; Kulbe et al. 2007; Wyckoff et al. 2007; Kim et al. 2009) In particular, cells of hematopoietic origin and specifically myelomonocytic cells have been shown to home and condition the premetastatic niche. Here they form a secondary niche which favors secondary localization of cancer (Kaplan et al. 2005; Wels et al. 2008; Erler et al. 2009).
Protective Inflammation and Macrophage Activation Appropriate activation of innate immunity has antitumor potential (Duluc et al. 2009). IFNg has been shown to re-educate TAM (Duluc et al. 2009) and there is proof of principle evidence for antitumor activity of this molecule in minimal residual disease in humans (Colombo et al. 1992; Windbichler et al. 2000; Berek et al. 2003). Given the protumor function of TAM in many cancers, strategies have been directed at blocking recruitment (see above) targeting chemokines or M-CSF or inhibiting TAM directly (Luo et al. 2006; Ritchie and Smyth 2009; Song et al. 2009). Certain forms of inflammation are protective in a preventive or therapeutic setting (Nickoloff et al. 2005; Mantovani et al. 2008a; Kryczek et al. 2009). An immune response has long been known to contribute to the outcome of chemotherapy. It has now been shown that dying tumor cells can be cross presented by dendritic cells and trigger a protective immune response via a TLR4-MyD88 pathway (Apetoh et al. 2007). Inflammasome activation and IL-1b production underlie ultimate activation of protective immunity (Ghiringhelli et al. 2009). Association of TLR4 and PrX7 polymorphisms with clinical outcome are consistent with relevance of these pathways. Thus the challenge rests in blocking cancer promoting inflammation and activating tumor inhibitory innate responses (Mantovani et al. 2008b).
References Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., Naldini, L., de Visser, K., De Palma, M. and Coussens, L. M. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121–134. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J.,
14
A. Mantovani et al.
Andre, F., Delaloge, S., Tursz, T., Kroemer, G. and Zitvogel, L. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050–1059. Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., Marches, F., Banchereau, J. and Palucka, A. K. (2007). Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204: 1037–1047. Balkwill, F. and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357: 539–545. Berek, J. S., Schultes, B. C. and Nicodemus, C. F. (2003). Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21: 168s–174s. Bottazzi, B., Polentarutti, N., Acero, R., Balsari, A., Boraschi, D., Ghezzi, P., Salmona, M. and Mantovani, A. (1983). Regulation of the macrophage content of neoplasms by chemoattractants. Science 220: 210–212. Colombo, N., Peccatori, F., Paganin, C., Bini, S., Brandely, M., Mangioni, C., Mantovani, A. and Allavena, P. (1992). Anti-tumor and immunomodulatory activity of intraperitoneal IFNgamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51: 42–46. Coussens, L. M. and Werb, Z. (2002). Inflammation and cancer. Nature 420: 860–867. De Palma, M., Murdoch, C., Venneri, M. A., Naldini, L. and Lewis, C. E. (2007). Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28: 519–524. de Visser, K. E., Korets, L. V. and Coussens, L. M. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411–423. DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N. and Coussens, L. M. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91–102. Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M. and Jeannin, P. (2009). Interferon-gamma reverses the immunosuppressive properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 125: 367–373. Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q. T. and Giaccia, A. J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35–44. Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S. and Alberlda, S. M. (2009). Polarization of tumor-associated neutrophil (TAN) phenotype by TGF-beta: “N1” versus “N2” TAN – a new paradigm? Cancer Cell 16: 183–194. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J. L., Schlemmer, F., Tasdemir, E., Uhl, M., Genin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., Andre, F., Lidereau, R., McLaughlin, N. M., Haynes, N. M., Smyth, M. J., Kroemer, G. and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170–1178. Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Pluddemann, A., Charles, K., Gordon, S. and Balkwill, F. R. (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176: 5023–5032. Hagemann, T., Wilson, J., Kulbe, H., Li, N. F., Leinster, D. A., Charles, K., Klemm, F., Pukrop, T., Binder, C. and Balkwill, F. R. (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197–1205. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., Zhu, Z., Hicklin, D., Wu, Y., Port, J. L., Altorki, N., Port, E. R., Ruggero, D., Shmelkov, S. V., Jensen, K. K., Rafii, S. and Lyden, D. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820–827.
The Yin Yang of Cancer Related Inflammation
15
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L. and Karin, M. (2009). Carcinoma produced factors activate myeloid cells via TLR2 to stimulate metastasis. Nature 457: 102–106. Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., Chang, A., Coukos, G., Liu, R. and Zou, W. (2009). Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141–1149. Kuang, D. M., Wu, Y., Chen, N., Cheng, J., Zhuang, S. M. and Zheng, L. (2007). Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110: 587–595. Kulbe, H., Thompson, R., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., Gould, D., Ayhan, A. and Balkwill, F. (2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585–592. Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Lee, S. H., Dolman, C., Markowitz, D., Wu, W., Liu, C., Reisfeld, R. A. and Xiang, R. (2006). Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132–2141. Mantovani, A. (1999). The chemokine system: redundancy for robust outputs. Immunol Today 20: 254–257. Mantovani, A., Bonecchi, R., Locati, M. (2006). Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nature Reviews in Immunology 12: 907–918. Mantovani, A. (2009). Cancer: inflaming metastasis Nature 457: 36–37. Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008a). Cancer-related inflammation. Nature 454: 436–444. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S. and Ruco, L. (1992). The origin and function of tumor-associated macrophages. Immunol Today 13: 265–270. Mantovani, A., Romero, P., Paluka, A. and Marincola, F. (2008b). Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 371: 771–783. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555. Marttila-Ichihara, F., Auvinen, K., Elima, K., Jalkanen, S. and Salmi, M. (2009). Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 69: 7875–7883. Nibbs, R. J., Gilchrist, D. S., King, V., Ferra, A., Forrow, S., Hunter, K. D. and Graham, G. J. (2007). The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 117: 1884–1892. Nickoloff, B. J., Ben-Neriah, Y. and Pikarsky, E. (2005). Inflammation and cancer: is the link as simple as we think? J Invest Dermatol 124: x-xiv. Pollard, J. W. (2009). Trophic macrophages in development and disease. Nat Rev Immunol 9: 259–270. Popivanova, B. K., Kostadinova, F. I., Furuichi, K., Shamekh, M. M., Kondo, T., Wada, T., Egashira, K. and Mukaida, N. (2009). Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69: 7884–7892. Porta, C., Rimoldi, M., Raes, G., Brys, L., Ghezzi, P., Di Liberto, D., Dieli, F., Ghisletti, S., Natoli, G., De Baetselier, P., Mantovani, A. and Sica, A. (2009). Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A 106: 14978–14983. Ritchie, D. S. and Smyth, M. J. (2009). A new therapeutic target for leukemia comes to the surface. Cell 138: 226–228. Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C. and Pienta, K. J. (2009). CCL2 and IL-6 promote survival of human CD11b+- peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284: 34342–34354.
16
A. Mantovani et al.
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H. W., Sposto, R., Ara, T., Silverman, A. M., DeClerck, Y. A., Seeger, R. C. and Metelitsa, L. S. (2009). Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119: 1524–1536. Torroella-Kouri, M., Silvera, R., Rodriguez, D., Caso, R., Shatry, A., Opiela, S., Ilkovitch, D., Schwendener, R. A., Iragavarapu-Charyulu, V., Cardentey, Y., Strbo, N. and Lopez, D. M. (2009). Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69: 4800–4809. Vetrano, S., Borroni, E. M., Sarukhan, A., Savino, B., Bonecchi, R., Correale, C., Arena, V., Fantini, M., Roncalli, M., Malesci, A., Mantovani, A., Locati, M. and Danese, S. (2010). The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 59: 197–206. Wallace, K. L., Marshall, M. A., Ramos, S. I., Lannigan, J. A., Field, J. J., Strieter, R. M. and Linden, J. (2009). NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood 114: 667–676. Wels, J., Kaplan, R. N., Rafii, S. and Lyden, D. (2008). Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22: 559–574. Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E. and Marth, C. (2000). Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: 1138–1844. Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J. F., Goswami, S., Stanley, E. R., Segall, J. E., Pollard, J. W. and Condeelis, J. (2007). Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67: 2649–2656.
The Immune Rejection: Lessons from Experimental Models Anil Shanker
Abstract The mechanisms of immune rejection depend on a complex interplay between the elements of innate and adaptive immunity. Several studies in animal models of cancer and other conditions, including obesity and intestinal microbiome, over the past decade have provided evidence for an intricate cross-regulation of innate resistance and adaptive immunity. More recently, it became apparent that adaptive immunity, besides its effector function, also controls innate immune responses beyond its role in immune complex-Fc receptor interaction. This has led to a paradigm shift from the classical unidirectional notion of the innate instruction of adaptive immunity to a bidirectional partnership of the innate and adaptive immune system in controlling various pathological and physiological conditions. This chapter summarizes the advances in our understanding of the mechanisms of immune reactivity in the models of intestinal microbiota, acute infections, obesity, and cancer.
Introduction The immune system has evolved in multicellular organisms as a guard against life-threatening infections. Innate immune components provide a first line of defense and function to alert tissue-specific adaptive immunity against persistent tissue insult. Innate immunity is an evolutionarily conserved primitive but robust defense mechanism capable of protecting plants and invertebrate animals from a diverse threat of viral, prokaryotic and eukaryotic parasites and pathogens. Adaptive immunity evolved later at the time of differentiation of vertebrates between the jawless hagfish and lampreys by a gene conversion mechanism giving rise to
A. Shanker (*) Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute – Frederick, Frederick, MD, USA and Basic Science Program, SAIC-Frederick, Inc, Frederick, MD, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_3, © Springer Science+Business Media, LLC 2011
17
18
A. Shanker
v ariable lymphocyte receptors (Guo et al. 2009) and subsequent genomic invasion of a retroposon encoding site-specific recombinases (Hiom et al. 1998; Thompson 1995). These receptors achieved remarkable mechanisms of diversification as a result of hypervariability, rearrangement of receptor gene segments and clonal selection to allow the adaptive immune cells to provide specific recognition of unlimited pathogens, and develop long-term immunological memory of insult. Thus, adaptive immunity expanded the capacity of the immune system to recognize the pathogenic proteins, carbohydrates, lipids, and nucleic acids and combat the ever growing pool of diseases and their elaborate immune evasion strategies. Along with the co-evolution of pathogens, commensals and the immune system came stringent regulation of innate and adaptive immunity to avoid overproduction of inflammatory cytokines during an innate immune response or suppress a hyperactivated adaptive response. The innate and adaptive immunity cooperatively acted to maximize host defense while minimizing collateral damage to the host tissues: innate immunity generated help signals in the damaged tissues; adaptive immunity provided specific responses to the pathogenic insult or recruited other powerful innate effector cells that, though not specific by themselves, could act specifically by their guided recruitment. Conventional view suggests a linear progression from innate to adaptive immunity by innate signals following tissue insult triggering adaptive immune cells to respond to the pathogen or disease. However, several recent studies, as discussed in the following sections, demonstrate an equally indispensable adaptive control of the effector mechanisms of innate immunity. In this scheme, adaptive immunity thus assumes an additional role of providing a tighter control of innate immunity not only by regulating innate inflammation but also by activating innate effectors when they are specifically needed.
Rejection of Intestinal Microbiota Mammalian intestinal mucosal surfaces interface with an exceptionally diverse and dynamic microbiota that is ten times as numerous as the body’s cells. Given the enormous numbers of enteric bacteria and the persistent threat of opportunistic infections, immune mechanisms tightly limit the spread of the intestinal microbiota. Intestinal epithelial cells control enteric bacteria through cell-autonomous MyD88dependent toll-like receptor (TLR) activation, triggering expression of multiple microbial factors (Vaishnava et al. 2008). Recently, a flexible continuum between innate and adaptive immunity to maintain host-microbiota mutualism was observed in mice (Slack et al. 2009). Clean germ-free Myd88−/−Ticam−/− mice deficient in signaling through TLRs and IL-1/IL-18 receptors, or phagocyte oxidative burstdeficient Nos2−/−Cybb−/− mice spontaneously mounted a robust CD4+ T cell-dependent antibody response following intragastric exposure to high doses of Escherichia coli bacteria. Thus, adaptive immunity compensated for the defect in innate immune clearance of bacteria. Implication from these findings is that under conditions of
The Immune Rejection: Lessons from Experimental Models
19
deficiency in innate immune signaling adaptive immune cells possess the ability to function in antigen-independent innate-type responses. More work is required to dissect the alternate signaling pathways that allow adaptive immune cells to manifest innate-like immune phenomenon. Similar immune compensatory defense mechanisms have been noted in some TLR signaling-deficient IRAK-4−/− children (Ku et al. 2007a, b). The mechanisms of activation of adaptive immune cells to provide innate-type protection and the precise rules of the compensatory innate-adaptive immune collaboration in detecting and controlling bacterial commensals yet remain to be investigated. Nonetheless, it is clear that the innate and adaptive immune mechanisms collaborate and form an interdependent cooperative system.
Rejection of Acute Infections Mortality from acute infections can be caused by the pathogen as well as by a disproportionate immune response. T cells play important role in pathogen clearance and also in regulating innate-immunity-driven excessive inflammation. This control is in part provided by the activation of T cell effector mechanisms in the relevant tissues. Recently, effector and memory CD4+ T cells and, to a lesser extent, effector CD8+ T cells were demonstrated to suppress potentially damaging inflammation in a murine peritonitis model by blocking macrophage inflammasomemediated cryopyrin and caspase-1 activation, interleukin (IL)-1b release, IL-18 secretion and neutrophil recruitment in an antigen-dependent manner (Guarda et al. 2009). Surprisingly, the T cell-mediated contact-dependent blockade of the caspase-1 axis of inflammasome left the primary inflammatory response and release of inflammatory mediators such as CXCL2, IL-6, IL-12 and tumor necrosis factor (TNF) crucial for tissue healing intact. In this regard, it has also been reported that IFN-g produced during T cell responses to influenza infection in mice inhibits alveolar macrophages (Sun and Metzger 2008). Thus, T cells edit the quality of inflammatory mediators and effectors during excessive innate inflammatory response via TNF family ligands and IFN-g, while maintaining their competence in antigen-specific recognition and stimulation. Lymphocyte-deficient hosts die of acute infection due to not only their lack of an adaptive immune response to clear pathogens but also an uncontrolled innate immune response as seen in a mouse hepatitis viral infection (Kim et al. 2007). In this model, resting T cells were found necessary and sufficient to temper early innate responses by direct contact inhibition, requiring antigen-presenting major histocompatibility complex molecule, but no antigen. Hepatitis viral infection or administration of TLR3 ligand poly-inosinic:polycytidylic acid, which mimics viral double-stranded RNA, led to cytokine storm in lymphocyte-deficient mice. Consequently, infected mice that showed only negligible increases in viral load died from the high amounts of inflammatory cytokines secreted during an
20
A. Shanker
u nrestrained innate immune response due to the lack of control by T cells. The adaptive immune cells thus negatively regulate the unnecessary early innate response. In neonate mice, where the embryonic development of the innate immune system precedes that of the adaptive system (Levy 2007), a hypersensitivity to various forms of TLR stimulation and high mortality to acute infection is observed most likely due to insufficient numbers of T cells. Dendritic cells are present in larger number in neonatal mice than in adult mice and produce robust TNF-a and IL-6 cytokines (Zhao et al. 2008). Even in humans, the proportion of T cells is lower in peripheral blood of newborns, especially in infants who are small for gestational age (Heldrup et al. 1992; Kumar et al. 1994). Expectedly, highly increased levels of inflammatory cytokines such as TNF-a, IL-1 and IL-6 have been detected in some human newborns following acute infections (Atici et al. 1997; Blackwell et al. 2005; Ozdemir et al. 1994; Vege et al. 1998). B cell-produced IL-10 also is implicated in dampening the neonatal inflammatory response (Zhang et al. 2007). During herpes simplex virus infection in vaginal mucosa of mice, ablation of Treg cells delays the arrival of natural killer (NK) cells, DCs and effector T cells to the site of infection (Lund et al. 2008). Thus, Treg cells, in addition to limiting the extent of an inflammatory response, seem also to coordinate early protective responses to local viral infection by facilitating a timely entry of innate immune cells into the infected tissue. However, the precise signals that activate Treg cells during infection remain unclear. Moreover, rapid non-cognate activation of interferon (IFN)-g-producing CD8+ T cells within 15 h of bacterial infection in response to cytokines secreted by phagocytic cells forms an important component of immune defense against intracellular pathogens (Lertmemongkolchai et al. 2001). Indeed, early antigen nonspecific CD44highCD8+ T cells represent the major population of IFN-g-producers in response to bacterial and viral products (Berg et al. 2003; Kambayashi et al. 2003). The cooperativity of adaptive immunity and innate immunity thus appears essential in the rejection of acute infections. Identifying the underlying mechanisms responsible for this cooperativity between innate cells and the different populations of resting, effector, memory and regulatory T cells might lead to the discovery of new regulatory networks.
Chronic Inflammation in Obesity Obese adipose tissue shows the hallmarks of chronic inflammation that underlies the development of metabolic diseases. Infiltration of macrophages, T cells and B cells in obese adipose tissue has been described in both mice and humans (Duffaut et al. 2009; Hotamisligil 2006; Rausch et al. 2008; Wu et al. 2007). Lately, the sequence of events that comprises the inflammatory cascade during the development of obesity has become clear. The infiltration of CD8+T cells in the epididymal
The Immune Rejection: Lessons from Experimental Models
21
adipose tissue is an early event induced by a high-fat diet in mice, concomitant with a decrease in the numbers of CD4+T helper and regulatory cells (Nishimura et al. 2009). Unknown factors in the obese tissue activate CD8+T cell effectors, which, in turn, promote the recruitment, differentiation and activation of macrophages in this tissue by secreting substantial amounts of humoral factors such as IFN-inducible protein-10, monocyte chemoattractant protein (MCP)-1, MCP-3 and regulation upon activation, normal T cell expressed and secreted protein (RANTES). Thus, CD8+T cells contribute to the initiation and propagation of inflammation by increased expression of the proinflammatory cytokines IL-1, IL-6 and TNF-a, as well as of intercellular adhesion molecule-1 and matrix metalloproteinase-2 in epididymal adipose tissue, leading to systemic insulin resistance and metabolic disorder. Two other studies have also confirmed that obesity alters the balance between Th1 and Th2 stimuli in fat through the depletion of Th2 and adipose tissue Treg cells, and the increase in CD8+T and Th1 cells or both weeks before macrophages infiltrate fat (Feuerer et al. 2009; Winer et al. 2009). It would be interesting to know how other leucocytes such as NK cells, Th17, or B cells influence adipose tissue. These findings have relevance in atherosclerosis that involves the formation of inflammatory arterial lesions. Deposited underneath the endothelium of arteries, the lipid-laden macrophages lead to formation of obstructive atherosclerotic plaques (Erbay et al. 2009). T cells largely via IFN-g-mediated mechanisms regulate the magnitude of the atherogenic proinflammatory response of macrophages and the propensity for thrombus formation as reviewed recently (Andersson et al. 2010).
Tumor Rejection NK cells have been proposed to function as a “fail-safe” mechanism to lyse tumor cells that outgrow following effector T cell rejection and immunoselection (Coulie et al. 1999; Dunn et al. 2002; Shankaran et al. 2001). Recently, tumor antigen-specific CD8+T cells, in addition to their direct effector response, were found necessary to provide “help” to otherwise dormant NK cells in eliciting their antitumor function for the rejection of a mastocytoma tumor (Shanker et al. 2007). Surprisingly, antigenescape tumor variants could be lysed by NK cells only if activated CD8+ T cells were present locally in their surroundings. This study suggested a new role for the CD8+T cells to induce dormant NK cells into killer effectors at the site of tumor. A T cell-NK cell cooperative interaction that emerged from this study is illustrated in Fig. 1. The T cells could broaden the effector response by activating NK cells in their vicinity and could eliminate antigen-deficient tumor cells, leading to more effective clearance of tumor. The complete rejection of tumor became possible only when there was a productive interaction of activated T cells and NK cells. The cooperative action of CD8+ T cells and NK cells in tumor rejection was further confirmed when, under conditions of restricted T cell receptor diversity,
22
A. Shanker
Fig. 1 Broadening of effector response by T cell-NK cell cooperation. Tumor is completely cleared when there is a productive interaction between activated T cells and NK cells
tumor resistance was affected by the variation in precursor frequencies of tumor-specific CD8+ T cell and NK cell effectors. NK cells constituted an important component contributing to tumor resistance, in part through an NKG2D-mediated mechanism (Shanker et al. 2009). In another independent study, photodynamic therapy-induced CD8+ T cell-dependent control of distant late stage tumors was also found to require NK cells (Kabingu et al. 2007). Moreover, CD4+T cells have also been found to work in concert with NK cells for maximal antitumor effect in a bladder carcinoma mouse model (Perez-Diez et al. 2007). The exact T cell-dependent recruitment/activation signal for NK cells however remains unclear. CD56bright human NK cells expressing high affinity IL-2 receptor have been shown to use endogenous IL-2 produced by the antigen-activated T cells to stimulate IFN-g production (Fehniger et al. 2003). T cell-secreted IL-2, TNF-a or direct T cell-NK cell contact could contribute to NK cell activation. Thus, tumor rejection requires the cooperative mechanisms of innate and adaptive immunity. Adaptive immune cells alone, in at least highly immunogenic tumors, contribute to the development of tumor escape variants and the maintenance of the “occult” cancer in equilibrium (Koebel et al. 2007). Innate immune cells alone also fail to bring about complete rejection of tumor, albeit tumor-infiltrating NK cells,
The Immune Rejection: Lessons from Experimental Models
23
neutrophils, and macrophages have been shown to cause tumor regression in a spontaneous-regression/complete-resistance mouse model (Hicks et al. 2006a, b; Yu et al. 2009), and in a xenograft tumor model following oncolytic viral therapy (Worschech et al. 2009).
Concluding Remarks Immune reactivity depends on an intricate cooperativity between both innate and adaptive arms of immunity. Adaptive immune responses are necessary not only to provide effector response but also to mediate tissue specificity in a cognate manner by directing the innate effector response to the site of infection or disease following tissue insult. The concentration of pathogen-associated molecular patterns and/or danger-associated molecular patterns may be a critical parameter for this immune rejection. Although the triggers and magnitude controls that regulate an adaptive immune response during a given infection or disease are not yet precisely understood, it is clear that the immune system has evolved the capacity to generate a powerful immunological “orchestra,” where adaptive T lymphocytes seemingly play a role of “conductor.” The dynamics of this immune orchestra will become clear as more meaningful immune interactions and their regulatory networks in immune rejection are identified. Acknowledgments This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This Research was supported [in part] by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.
References Andersson, J., Libby, P., and Hansson, G.K. (2010). Adaptive immunity and atherosclerosis. Clin Immunol 134, 33–46. Atici, A., Satar, M., Cetiner, S., and Yaman, A. (1997). Serum tumor necrosis factor-alpha in neonatal sepsis. Am J Perinatol 14, 401–404. Berg, R.E., Crossley, E., Murray, S., and Forman, J. (2003). Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J Exp Med 198, 1583–1593. Blackwell, C.C., Moscovis, S.M., Gordon, A.E., Al Madani, O.M., Hall, S.T., Gleeson, M., Scott, R.J., Roberts-Thomson, J., Weir, D.M., and Busuttil, A. (2005). Cytokine responses and sudden infant death syndrome: genetic, developmental, and environmental risk factors. J Leukoc Biol 78, 1242–1254. Coulie, P.G., Ikeda, H., Baurain, J.F., and Chiari, R. (1999). Antitumor immunity at work in a melanoma patient. Adv Cancer Res 76, 213–242. Duffaut, C., Galitzky, J., Lafontan, M., and Bouloumie, A. (2009). Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun 384, 482–485.
24
A. Shanker
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991–998. Erbay, E., Babaev, V.R., Mayers, J.R., Makowski, L., Charles, K.N., Snitow, M.E., Fazio, S., Wiest, M.M., Watkins, S.M., Linton, M.F., and Hotamisligil, G.S. (2009). Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 15, 1383–1391. Fehniger, T.A., Cooper, M.A., Nuovo, G.J., Cella, M., Facchetti, F., Colonna, M., and Caligiuri, M.A. (2003). CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052–3057. Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15, 930–939. Guarda, G., Dostert, C., Staehli, F., Cabalzar, K., Castillo, R., Tardivel, A., Schneider, P., and Tschopp, J. (2009). T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269–273. Guo, P., Hirano, M., Herrin, B.R., Li, J., Yu, C., Sadlonova, A., and Cooper, M.D. (2009). Dual nature of the adaptive immune system in lampreys. Nature 459, 796–801. Heldrup, J., Kalm, O., and Prellner, K. (1992). Blood T and B lymphocyte subpopulations in healthy infants and children. Acta Paediatr 81, 125–132. Hicks, A.M., Riedlinger, G., Willingham, M.C., Alexander-Miller, M.A., Von Kap-Herr, C., Pettenati, M.J., Sanders, A.M., Weir, H.M., Du, W., Kim, J., et al. (2006a). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A 103, 7753–7758. Hicks, A.M., Willingham, M.C., Du, W., Pang, C.S., Old, L.J., and Cui, Z. (2006b). Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immun 6, 11. Hiom, K., Melek, M., and Gellert, M. (1998). DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell 94, 463–470. Hotamisligil, G.S. (2006). Inflammation and metabolic disorders. Nature 444, 860–867. Kabingu, E., Vaughan, L., Owczarczak, B., Ramsey, K.D., and Gollnick, S.O. (2007). CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer 96, 1839–1848. Kambayashi, T., Assarsson, E., Lukacher, A.E., Ljunggren, H.G., and Jensen, P.E. (2003). Memory CD8+ T cells provide an early source of IFN-gamma. J Immunol 170, 2399–2408. Kim, K.D., Zhao, J., Auh, S., Yang, X., Du, P., Tang, H., and Fu, Y.X. (2007). Adaptive immune cells temper initial innate responses. Nat Med 13, 1248–1252. Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., and Schreiber, R.D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907. Ku, C.L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., FilipeSantos, O., Chang, H.H., Lawrence, T., et al. (2007a). IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 44, 16–23. Ku, C.L., von Bernuth, H., Picard, C., Zhang, S.Y., Chang, H.H., Yang, K., Chrabieh, M., Issekutz, A.C., Cunningham, C.K., Gallin, J., et al. (2007b). Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 204, 2407–2422. Kumar, A., Jauhari, P., Singh, U., and Singla, P.N. (1994). Quantitation of T cells in venous blood of healthy neonates. Indian J Pediatr 61, 711–714. Lertmemongkolchai, G., Cai, G., Hunter, C.A., and Bancroft, G.J. (2001). Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 166, 1097–1105. Levy, O. (2007). Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7, 379–390.
The Immune Rejection: Lessons from Experimental Models
25
Lund, J.M., Hsing, L., Pham, T.T., and Rudensky, A.Y. (2008). Coordination of early protective immunity to viral infection by regulatory T cells. Science 320, 1220–1224. Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009). CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15, 914–920. Ozdemir, A., Oygur, N., Gultekin, M., Coskun, M., and Yegin, O. (1994). Neonatal tumor necrosis factor, interleukin-1 alpha, interleukin-1 beta, and interleukin-6 response to infection. Am J Perinatol 11, 282–285. Perez-Diez, A., Joncker, N.T., Choi, K., Chan, W.F., Anderson, C.C., Lantz, O., and Matzinger, P. (2007). CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346–5354. Rausch, M.E., Weisberg, S., Vardhana, P., and Tortoriello, D.V. (2008). Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 32, 451–463. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111. Shanker, A., Buferne, M., and Schmitt-Verhulst, A.-M. (2009). Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 129, 41–54. Shanker, A., Verdeil, G., Buferne, M., Inderberg-Suso, E.M., Puthier, D., Joly, F., Nguyen, C., Leserman, L., Auphan-Anezin, N., and Schmitt-Verhulst, A.M. (2007). CD8 T cell help for innate antitumor immunity. J Immunol 179, 6651–6662. Slack, E., Hapfelmeier, S., Stecher, B., Velykoredko, Y., Stoel, M., Lawson, M.A., Geuking, M.B., Beutler, B., Tedder, T.F., Hardt, W.D., et al. (2009). Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325, 617–620. Sun, K., and Metzger, D.W. (2008). Inhibition of pulmonary antibacterial defense by interferongamma during recovery from influenza infection. Nat Med 14, 558–564. Thompson, C.B. (1995). New insights into V(D)J recombination and its role in the evolution of the immune system. Immunity 3, 531–539. Vaishnava, S., Behrendt, C.L., Ismail, A.S., Eckmann, L., and Hooper, L.V. (2008). Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci U S A 105, 20858–20863. Vege, A., Rognum, T.O., Aasen, A.O., and Saugstad, O.D. (1998). Are elevated cerebrospinal fluid levels of IL-6 in sudden unexplained deaths, infectious deaths and deaths due to heart/ lung disease in infants and children due to hypoxia? Acta Paediatr 87, 819–824. Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009). Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15, 921–929. Worschech, A., Chen, N., Yu, Y.A., Zhang, Q., Pos, Z., Weibel, S., Raab, V., Sabatino, M., Monaco, A., Liu, H., et al. (2009). Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 10, 301. Wu, H., Ghosh, S., Perrard, X.D., Feng, L., Garcia, G.E., Perrard, J.L., Sweeney, J.F., Peterson, L.E., Chan, L., Smith, C.W., and Ballantyne, C.M. (2007). T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115, 1029–1038. Yu, Y.A., Galanis, C., Woo, Y., Chen, N., Zhang, Q., Fong, Y., and Szalay, A.A. (2009). Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8, 141–151. Zhang, X., Deriaud, E., Jiao, X., Braun, D., Leclerc, C., and Lo-Man, R. (2007). Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med 204, 1107–1118. Zhao, J., Liu, J., Feng, Z., Hu, S., Liu, Y., Sheng, X., Li, S., Wang, X., and Long, C. (2008). Clinical outcomes and experience of 20 pediatric patients treated with extracorporeal membrane oxygenation in Fuwai Hospital. ASAIO J 54, 302–305.
Turning on and off the Immunological Switch: Immune Response Polarization and Its Control by IL-10 and STAT3 C. Andrew Stewart and Giorgio Trinchieri
The innate and immunologic arms of host resistance to pathogenic infections use distinct patterns of cytokine production to direct appropriate tissue responses. This chapter discusses how this “Immunological Switch” is coordinated by distinct T helper cell lineages and how IL-10 and STAT3 signaling controls the inflammatory response. A particular emphasis is given to the role of IL-10 and STAT3 in tumor-associated immunosuppression, where the functional inhibition of either molecule results in acquiescence to proinflammatory and anti-tumor Th1 type immune responses.
T Helper Cell Lineages Adaptive immune responses are defined by their use of distinct lineages of CD4+ T helper (Th) cells (Fig. 1). Th cells are required for generation of antibody responses against thymus-dependent antigens and otherwise shape immune responses through their regulation of cytotoxic CD8+ T cell responses and by directly mediating effector mechanisms including the production of cytokines at inflammatory sites. Historically, the discovery that CD4 T cell clones had different patterns of cytokine gene expression defined the Th1/Th2 paradigm of immunity. This states that Th1 cells, through their production of IFN-g and IL-2, contribute to the activation of macrophages and dendritic cells (DC) to drive cellular-mediated immunity. On the other hand, Th2 cells produce IL-4, IL-5 and IL-13 that contribute to B cell class switching to the IgG1 and IgE isotypes, leading to protective cellular responses against worm infestation but also adverse effects such as allergic reactions and asthma (reviewed in Zhu et al. (2010)). More recently, additional subsets of Th cells have been identified. Furthermore, evidence has been found that the Th subsets, with the possible exception of well-differentiated Th1 cells, maintain some level of plasticity.
G. Trinchieri (*) Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_4, © Springer Science+Business Media, LLC 2011
27
28
a
C.A. Stewart and G. Trinchieri Lineage Cell
Inducing Cytokines
Th1
IL-12 IFN-γ
IL-12R T-bet/Eomes STAT1/STAT4 IL-18R
IL-4 IL-2
Th2
IL- 4R
GATA-3 STAT6
IL-33R
Th17
TGF-β IL-6 IL-21
IL-23R
RORγ t STAT3
IL-1R
iTreg
TGF-β IL-2
b
Cytokines Produced
Th2
Th9
Tumors Viruses Intracellular parasites (Mycobacterium)
IFN-γ IL-2
Macrophage/APC activation CD8+ T cell help
IL-4 IL-5 IL-13
B cell activation IgE production
Worms Parasites Allergens
Neutrophil accumulation Tissue repair
Bacteria Inflammation Wound healing (e.g. S. aureus)
IL-17 IL-22
IL-21 B cell activation +TGF-β
Role in Immunity
TGF-β Suppression of T cell responses IL-10
FoxP3 STAT5
Tfh
Mechanism
Prevention of autoimmunity Control of inflammation
TGF-β Oral tolerance
Th3
IL-9 Mast cell recruitment ? Th1
Th1 IL-10 IFN-α/β
Th0
? Tr1
IL-10 Limit Inflammation IFN-γ
? Th2
IL-2 Intermediate IL-4 state?
Fig. 1 CD4 T helper cell lineages. (a) Representation of T helper and inducible T regulatory cell lineages. Each lineage is associated with one or two master transcription factors along with an activating signal transducer and activator of transcription (STAT). For Th1, Th2 and Th17 cells, receptors for STAT-driving cytokines and IL-1 family cytokines are noted. The cytokines driving generation of T helper lineages from naïve T cells, and cytokines produced upon their stimulation are also shown. (b) Other T helper subsets, the cytokines they produce, the cytokines required for their generation, their function and their relationship to other T helper lineages (blue arrows and text)
The identification of the Th17 and inducible T regulatory (iTreg) lineages has rectified some shortcomings of the Th1/Th2 paradigm. Th17 cells produce IL-17A, IL-17F or IL-22, whose receptors are mainly expressed by non-hematopoietic tissue cells such as fibroblasts and epithelial cells and trigger them to produce neutrophilattracting chemokines, thus driving a type of inflammation characterized by abundant infiltration of neutrophils (Weaver et al. 2007a). Treg produce the potent anti-inflammatory cytokine TGF-b and through this and other less well-defined
Turning on and off the Immunological Switch
29
cell-mediated and humoral mechanisms suppress proliferation and activation of other CD4 T cells. They may also act directly on antigen presenting cells by modulating their ability to efficiently activate T cells. In addition to the main Th lineages, several other subsets of Th cells have been defined (Fig. 1b). T follicular helper cells produce IL-21 and drive B cell activation and maturation in germinal centers. TGF-b shifts the phenotype of Th2 cells into cells producing IL-9 (also known as Th9 cells) that may contribute to the recruitment of mast cells during a Th2-type response (Veldhoen et al. 2008). Th3 cells are a subset of regulatory cells identified as producers of TGF-b and important mediators of oral tolerance (Weiner 2001). Tr1 cells are induced by IL-10 and/or type I IFN (Roncarolo et al. 2001; Dikopoulos et al. 2005; Levings et al. 2001). They produce high levels of IL-10 and intermediate levels of IFN-g and are possibly related to the IL-10-producing Th1 cells often observed in infected individuals and probably important for limiting Th1-mediated inflammation (Anderson et al. 2007; Jankovic et al. 2007; Nylen et al. 2007; Roers et al. 2004; Trinchieri 2007). Th0 cells produce both IL-2 and IL-4 and are probably a stage preceding commitment to either Th1 or Th2 differentiation (Romagnani 1994).
Differentiation and Activation of T Helper Lineages In addition to their cytokine secretion profile, the Th lineages are defined by the culture conditions that give rise to their differentiation, by the signal transducer and activator of transcription (STAT) transcription factors that are activated in polarizing culture, and by one (or several) master transcription factors involved in their differentiation (Fig. 1). Through positive feedback on a lineage’s driving cytokine and transcription factor and through negative feedback on those of the other lineages, in vitro culture systems produce highly polarized lineage phenotypes. For example, the production of IFN-g by Th1 cells leads to STAT1 activation and transcription of T-bet, the Th1master transcription factor (Lighvani et al. 2001). In addition, IFN-g stimulates DC to produce IL-12, which in Th1 cells drives STAT4 activation and expression of T-bet, of the IL-12 receptor (IL-12Rb2), and of IFN-g (Usui et al. 2006; Robinson et al. 1997). Eomes is another T-box transcription factor involved in Th1 differentiation and together with T-bet, they induce IFN-g expression (Pearce et al. 2003). In this way, a positive feedback loop is created in Th1 polarizing cultures. Such loops also exist for Th2 cells involving the GATA3 and STAT6 transcription factors, for Th17 cells involving RORgt and STAT3 and for inducible Treg involving FoxP3 and STAT5 (for detailed discussion, see Zhu et al. (2010)). The exact mechanisms by which lineage commitment is induced by the combination of cytokines and other stimuli still remain controversial and may be qualitatively or quantitatively different in humans and in mice. Human Th1 clones maintain their phenotype when switched to Th2-inducing condition but Th2 clones can be converted into IFN-g producing cells in the presence of IL-12 (Manetti et al. 1994). Similarly, recent epigenetic studies in the Mouse have shown that Th1 cells completely
30
C.A. Stewart and G. Trinchieri
shut-off the genes encoding the transcription factor or the cytokine characteristic of other Th subsets (O’Shea and Paul 2010). However, the master regulator genes encoding the Th subset-specific transcription factors remain in a partially open chromatin conformation in Th2 or Th17 cells (O’Shea and Paul 2010), suggesting that the original observations in humans might be also reproduced in the murine system. The receptors for IL-12 and IL-23, two cytokines important for the terminal differentiation of Th1 and Th17 cells respectively, are not expressed in naïve CD4+ T cells and need to be induced by other stimuli (other cytokines, TCR signaling, or co-stimulation), yet they play an essential role in the generation of fully effective Th1 and Th17 cells and, at least in humans, IL-12 signaling is required for the irreversible commitment of high IFN-g-producing Th1 cells (Manetti et al. 1994). The three inflammatory T helper lineages, Th1, Th2 and Th17, are distinctly activated by members of the IL-1 family of cytokines and, when fully committed, differentially express their receptors. The IL-1 family cytokines, including IL-1a, IL-1b, IL-18 and IL-33, are important early mediators of inflammation that are often preformed and become available for cell signaling upon release from cell nuclei associated with cell death or senescence (IL-1a and IL-33) or are converted into an active form by inflammasome-dependent caspase-1-dependent processing prior to release (IL-1b and IL-18). Individual members are able to activate specific lineages of T helper cells. Thus, although maximal activation and cytokine production by the Th cell subsets require antigen-specific stimulation, TCR-independent production of IFN-g by Th1 cells can be induced by stimulation with IL-12 (in combination with IL-2 or IL-18 and co-stimulation), while Th2 cells produce TCRindependent cytokines in response to IL-33 and IL-4 and Th17 cells produce IL-17 when stimulated with IL-1 and IL-23 (Guo et al. 2009). TCR-independent effector functions conferred upon polarized T helper cells by the milieu of inflammationassociated cytokines could be important for the bystander activation of T cells that allows these cells to participate in innate mechanisms of resistance at the side of the typical innate effector cells (NK, NKT, Tg/d cells) but also to contribute to maintain a polarized inflammatory microenvironment in which antigen specific T cells will be reinforced in their commitment.
Function and Plasticity of Th and Treg Lineages In Vivo In vivo, mouse model systems and human diseases have demonstrated requirements for components of each of these lineages in immunoregulation and control of infectious pathogens. For example, patients with genetic defects in Th1 responses are highly susceptible to Mycobacterium infections (Zhang et al. 2008). In mice, host resistance to intestinal helminth infections is critically dependent upon the Th2 cytokines IL-4 and IL-13 (Wynn 2003). Humans with Job’s syndrome due to dominant-negative mutations in STAT3 are defective in Th17 responses and are susceptible to skin and lung infections with Staphylococcus aureus, and Candida
Turning on and off the Immunological Switch
31
species (Ma et al. 2008). However, while the T helper lineage functions are critical in host defense, the extent of T cell polarization in vivo is less clear. Using intracellular cytokine staining, it is possible to identify ex vivo T cells that produce both IL-4 and IFN-g or both IFN-g and IL-17. Conversely, highly polarizing conditions lead to a single prominent T helper cell type, such as the Th1 responses observed during MCMV or Toxoplasma gondii infections (Gaddi and Yap 2007). T cells are also capable of converting from one lineage to another, for example Th17 cells can switch to Treg or to IFN-g producers given the correct mixture of cytokines. This plasticity has been proposed as an important mechanism in CD8+ T cells that can switch from a Tc17 (cytotoxic T cells producing IL-17) to an IFNg-producing response. This switch may facilitate high levels of CD8 T cell accumulation along with optimal cytotoxic function and IFN-g production, thus leading to effective anti-tumor responses (Yen et al. 2009; Hinrichs et al. 2009). The Th response is regulated by immuno-suppressive Treg cells whose function is dependent upon the FoxP3 transcription factor. Mutations in the Foxp3 gene cause immune-dysfunction, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome (Bennett et al. 2001; Wildin et al. 2001). IPEX is a rare and lethal condition characterized by type I diabetes, infections, enteropathy, anemia, endocrinopathy and cachexia. This requirement for functional FoxP3 shows the necessity for Treg function in regulation of the immune system. In several models it has been shown that Treg-mediated control of Th1, Th2 and Th17 responses requires more than a generic Treg program. The transcription factors associated with the Th1, Th2 and Th17 lineages have been found to be expressed by Treg and this expression contributes to Treg-mediated suppression in vivo. For example, suppression of Th17 cells by Treg requires that the latter express STAT3, a transcription factor central in regulating Th17 cell differentiation. Thus, it appears that Treg at the site of effector immune response activate Th response-specific suppression mechanisms involving the activation of STATs that guide the differentiation of the corresponding class of the immune response (Chaudhry et al. 2009; Wohlfert and Belkaid 2010).
IL-10 Controls Inflammation The cytokines IL-10 and TGF-b are the major mediators of anti-inflammatory communication and immunosuppression (Sanjabi et al. 2009). IL-10 was described 20 years ago by Fiorentino et al. (1989) at DNAX as a cytokine produced by Th2 cells, but it is now known to be produced by other T cell subsets and by other cell types. The apparently conflicting roles for IL-10 as a suppressive cytokine under certain circumstances but a stimulant under others have made it a challenge to understand IL-10s action in vivo and identify safe clinical applications (Vicari and Trinchieri 2004; Mosser and Zhang 2008). Indeed, in subsets of CD8+ T cells, NK cells and B cells, IL-10 can act to drive proliferation and activation (see Moore et al. (2001)). Also, in monocytes IL-10 can induce receptors involved in immunecomplex recognition and phagocytosis (including CD14, CD16, CD32, CD64)
32
C.A. Stewart and G. Trinchieri
(Calzada-Wack et al. 1996; Rahimi et al. 2005). In contrast, IL-10 suppresses the proinflammatory activity of APC such as DC, monocytes and macrophages by inhibiting the production of pro-inflammatory cytokines such as TNF, IL-1b, IL-6, IL-8 and IL-12, and impairing APC maturation and upregulation of costimulatory molecules (Moore et al. 2001). As discussed below, in many situations in vivo, the anti-inflammatory effects of IL-10 override stimulatory effects, consistent with a predominant role as a regulator of inflammation through the suppression of APC function. IL-10 limits inflammation during multiple acute and chronic conditions and contributes to limit the pathology associated with unchecked inflammatory responses. IL-10 knockout mice develop chronic enterocolitis when housed under specific pathogen-free conditions that can be limited by administration of antibiotics and prevented in germ-free conditions, illustrating the requirement for commensal microbiota to drive colitis (Kuhn et al. 1993; Sellon et al. 1998). Cell-type specific knockouts of IL-10 have been used to demonstrate that T cells (arguably Tregs) are the critical source of IL-10 in prevention of colitis (Roers et al. 2004; Rubtsov et al. 2008). However, the systemic response to LPS challenge is greatly exacerbated in mice in which IL-10 is specifically suppressed in macrophages/neutrophils. These mice, but not those in which T cells are unable to produce IL-10, succumb to a 20-fold lower dose of LPS than control mice (Berg et al. 1995). Conversely, in the acute response to another TLR ligand, CpG oligonucleotides, protection is conferred by IL-10 from cells other than Tab cells, macrophages or neutrophils (Siewe et al. 2006). The extent of inflammation in many diseases including Th1, Th2 and Th17associated pathologies can be limited by IL-10 (reviewed in Moore et al. (2001)). During T. gondii infection, IL-10-deficient mice die due to immunopathology associated with an overproduction of Th1 cytokines (Gazzinelli et al. 1996). During chronic T. gondii infection it has been shown that the major producer of protective IL-10 is the same IFN-g-producing FoxP3−Tbet+ CD4+ Th1 cell subset that is responsible for the immunopathology and control of the parasite (Jankovic et al. 2007; Roers et al. 2004; Trinchieri 2007). Production of IL-10 by Th1 cells in T. gondii infection has been attributed to IL-27 (Stumhofer et al. 2007) but alternative data have proposed that NK cells producing IL-10 in response to IL-12 stimulation are responsible for the control of inflammation in this infection (Perona-Wright et al. 2009). The conditions that drive IL-10 in T and NK cells, in response to IL-27 and IL-12 respectively during infection, still remain to be determined. Production of IL-10 by Th1 cells also limits inflammation and allows the maintenance of chronic infection by certain Leishmania species, both in humans and mice (Anderson et al. 2007; Nylen et al. 2007). During Th2-type responses against Schistosoma mansoni, IL-10 is able to limit IL-4 and IL-13 production along with liver fibrosis and the growth of granulomas (Hoffmann et al. 2000). Th17 responses during experimental autoimmune encephalomyelitis (EAE) are also controlled by IL-10 and IL-10-deficient mice are unable to recover from CNS inflammation (reviewed in Moore et al. (2001) and O’Garra et al. (2008)). Th17 cells producing both IL-17 and IL-10 can be identified or produced during culture with IL-27 or TGF-b and IL-6 (Stumhofer et al. 2007; Fitzgerald et al. 2007;
Turning on and off the Immunological Switch
33
Jankovic and Trinchieri 2007; McGeachy et al. 2007). Th17 cells generated in this manner can control EAE caused by autoreactive Th17 cells in an IL-10-sensitive manner (McGeachy et al. 2007), suggesting that like Th1 cells (Anderson et al. 2007; Jankovic et al. 2007), Th17 cells may limit their pathogenesis by expressing IL-10 (reviewed in Jankovic and Trinchieri (2007)). Due to the wide-ranging control of immunopathology by T cell IL-10, the therapeutic induction of IL-10 in T cells is likely to provide considerable benefit in various autoimmune and allergic diseases (reviewed in O’Garra et al. (2008)). While IL-10 limits the inflammatory pathogenesis in many diseases, it can also contribute to long term persistence of pathogens. This is seen for the Leishmania major Friedlin strain, which causes self-healing but persistent infection in wild-type mice, but is eliminated in IL-10-deficient or in anti-IL10R antibody-treated mice (Belkaid et al. 2001). During experimental infections with some species of Mycobacterium (Mycobacterium avium), but not others, administration of anti-IL10R antibody can enhance responses to chemotherapy (Silva et al. 2001). Some viral infections also require IL-10 for persistence. The clone 13 strain of Lymphocytic choriomeningitis virus (LCMV) establishes persistent infection associated with high levels of IL-10 and impaired T cell responses. The treatment of persistently infected mice with anti-IL10R antibody is sufficient to cure the infection (Brooks et al. 2006; Ejrnaes et al. 2006). However, the role of IL-10 in persistence of other viruses and its susceptibility to therapy may be more difficult to define. Murine gammaherpesvirus 68 is a model for gammaherpesvirus infections including human EBV. It induces host production of IL-10 during infection, but IL-10-deficient mice are neither resistant to nor protected from persistent infection, and IL-10 plays a more prominent role in the control of inflammatory pathology associated with the virus (Peacock and Bost 2001; Nelson et al. 2009). During acute viral infections such as influenza, the control of lung inflammation mediated by IL-10 can prevent lethality of the infection (Sun et al. 2009). Therefore it is critical to assess the risk of immunopathology when considering therapies for persistent viral infections, including HCV, EBV and HIV by blockade of IL-10 signaling with or without immunization (Vicari and Trinchieri 2004; Blackburn and Wherry 2007; Brooks et al. 2008; Filippi and von Herrath 2008).
Regulation of IL-10 Production Given its importance in restraining inflammation, the regulation of IL-10s expression by many different cell types is highly complex and it involves a large number of regulatory transcription factors (reviewed in Mosser and Zhang (2008) and Saraiva and O’Garra (2010)). In addition, post-transcriptional regulation occurs at the level of transcript stability due to AU-rich elements (ARE) in the 3¢UTR and due to regulation by micro-RNA (Mosser and Zhang 2008; Sharma et al. 2009). IL-10 is produced by DC, monocytes/macrophages, neutrophils, eosinophils, mast cells, B cells, NK cells, CD8+ T cells, all CD4+ T-helper cell lineages and perhaps some tissue resident cells such as keratinocytes and endothelial cells. At the
34
C.A. Stewart and G. Trinchieri
promoter level, expression is regulated by many factors including Sp1, Sp3, C/EBPb, c-Maf, CREB, IRF, AP-1, NF-kB p50, PBX1, PREP1 and STAT3. Several of the signaling pathways involved in inducing expression of IL-10 are noteworthy. The MAPK (mitogen activated protein kinase) pathway, particularly the ERK pathway, but also p38, is critical for IL-10 induction in many cell types following diverse stimuli including TLR-ligand stimulation and FcR-gamma triggering in macrophages (Mosser and Zhang 2008; Saraiva and O’Garra 2010). During macrophage activation, this ERK signaling is associated with epigenetic changes at the IL-10 promoter and phosphorylation of Histone H3 and increased binding by Sp1 and STAT3 (Mosser and Zhang 2008; Lucas et al. 2005; Zhang et al. 2006). A differential requirement for STAT transcription factors and GATA-3 has been shown within the different T helper lineages. Thus during induction of IL-10 expression in T cells by TGF-b and IL-6, STAT3 is required, while IL-27-induced IL-10 production requires both STAT1 and STAT3 (Stumhofer et al. 2007). On the other hand, IL-10 expression by high antigen dose-stimulated Th1 cells requires IL-12 and STAT4 (Gerosa et al. 1996; Saraiva et al. 2009), and NK cells produce IL-10 in response to IL-2/ IL-12 stimulation via a STAT4-dependent pathway (Grant et al. 2008). The precise mechanisms by which various STATs activate IL-10 gene expression have yet to be defined. In Th2 cells, the Th2 lineage “master transcription factor,” GATA-3 is involved in chromatin remodeling at the IL-10 locus, facilitating expression of IL-10 by Th2 cells (reviewed in Mosser and Zhang (2008)). Finally, the potential involvement of suppressive factors including IL-10 itself and TGF-b in control of IL-10 expression suggests that positive feedback mechanisms may act to coordinate the immunosuppressive environment. In human macrophages, IL-10 has been described to induce its own expression via STAT3 (Staples et al. 2007). TGF-b enhances induction of IL-10 expression by macrophages and by T cells exposed to IL-6 or IL-27 (Stumhofer et al. 2007; Maeda et al. 1995), and a binding site for SMAD4 has been identified in the IL-10 promoter (Kitani et al. 2003). In addition, the neutralization of TGF-b leads to reduced development of FoxP3+ and FoxP3− IL-10-producing T cells in the gut (Maynard et al. 2007).
IL-10 Signaling and Role of STAT3 in its Regulatory Functions The IL10R is a member of the interferon family of cytokine receptors (Moore et al. 2001). It is a heterodimer composed of a unique high affinity IL-10R1 chain and the IL-10R2 chain that is shared with the receptors for IL-22, IL-26 and the IFN-ls (IL-28A, IL-28B and IL-29) (Uze and Monneron 2007). IL-10 itself is a dimer and brings together two receptor complexes upon binding. This activates the Jak1 and Tyk2 kinases, associated with the IL-10R1 and IL-10R2, respectively, and leads to phosphorylation of tyrosines within two YXXQ sites in IL-10R1. Upon phosphorylation these sites serve as docking sites for STAT3 and to a lesser extent, STAT1, which are themselves phosphorylated by Jak1/Tyk2. Phosphorylated STAT3 homodimers (or STAT1:STAT3 heterodimers or STAT1:STAT1 homodimers) then
Turning on and off the Immunological Switch
35
form and translocate into the nucleus to bind STAT-binding sites and modulate transcription (Moore et al. 2001; Weber-Nordt et al. 1996). It is well established that STAT3 plays a central role in the anti-inflammatory effects of IL-10. The Jak1-STAT3 pathway is required for anti-inflammatory function of IL-10 in vitro (Riley et al. 1999). Ectopic expression of constitutively active STAT3 in mouse and human macrophages is sufficient to inhibit cytokine production in response to LPS (Hoentjen et al. 2005; Williams et al. 2007). In the converse situation, Cre-loxP-mediated deletion of STAT3 in macrophages and neutrophils in vivo leads to phenotypes similar to IL-10-deficient mice: these mice are hypersensitive to LPS stimulation and develop chronic enterocolitis (Takeda et al. 1999). Thus, STAT3 is required for the anti-inflammatory action of IL-10. It is not clear whether the canonical scheme of STAT3 tyrosine phosphorylation is sufficient for the anti-inflammatory effect of IL-10 (see discussion on other STAT3-inducing cytokines and stimuli below). One study suggested that a Serinerich region in the C-terminus of the IL-10R was necessary for anti-inflammatory function (Riley et al. 1999), but this has been contradicted by another investigation (Williams et al. 2007) and the relevance of this region remains uncertain. Transcriptional regulation by STAT3 can occur in the absence of tyrosine phosphorylation, and phosphorylation at Serine 727 within its transcriptional activation domain can modulate its activity. Kinases implicated in this Serine phosphorylation include the MAP-kinases p38, ERK and JNK, mTOR PKCd and PKCe (Schindler et al. 2007; Aziz et al. 2007). Germline deletion of STAT3 is embryonic lethal (Takeda et al. 1997), but mice with Serine 727 of STAT3 mutated to Alanine survive and show reduced transcription of STAT3 sensitive genes (Shen et al. 2004). Recently it has been shown that STAT3 with phosphorylated Serine 727 (STAT3pS) is found in mitochondria and that it is required for upregulation of oxidative phosphorylation by the electron transport chain (Wegrzyn et al. 2009). Finally, unphosphorylated STAT3 plays several other roles in the cell. Unphosphorylated STAT3 binds to stathmin, a tubulin-binding protein that depolymerizes tubulin. Through inhibition of stathmin’s activity, STAT3 maintains the integrity of microtubules and is therefore important for cell motility (Gao et al. 2006; Ng et al. 2006). This microtubule-regulating function might be affected during STAT3 signaling, and could hypothetically explain why IL-10 inhibits trafficking of MHC class II from the MHC class II-loading compartment to the plasma membrane (Koppelman et al. 1997). Additionally, unphosphorylated STAT3 can interact with p65 and p50 of NF-kB and can repress or induce gene expression in cytokine and other genes including IL-8 and IFN-b (Yang et al. 2007). IL-10R has also been shown to signal through PI3-kinase (Williams et al. 2004). PI3K activation inhibits cytokine production in DC, as DC deficient in PI3K produce much higher IL-12 and other pro-inflammatory cytokines than wild type DC in response to LPS (Fukao et al. 2002). However, in this case, IL-10 is not required for PI3-kinase mediated suppression. A cytomegalovirus homolog of IL-10 has been reported to suppress TNF production in a PI3K-mediated manner (Spencer 2007), but other studies indicate PI3K is required for IL-10s effect on proliferation rather than for its inhibitory effect on cytokine production (Crawley et al. 1996).
36
C.A. Stewart and G. Trinchieri
IL-10 signaling is regulated at a number of levels. While the IL-10R2 chain is widely expressed, the IL-10R1 chain is expressed by most hematopoietic cells at only very low levels. These expression levels are reduced upon T cell activation and conversely are increased in activated monocytes (Moore et al. 2001). Though both STAT3 and STAT1 can be activated in response to IL-10 signaling, it is mainly STAT3 that is activated in myeloid cells (Finbloom and Winestock 1995). Crosstalk from other cytokine signaling systems can also modulate IL-10 signaling. For example, the priming of human macrophages with IFN-a leads to increased STAT1 activation and preformed dimerization, thus conferring a pro-inflammatory gain of function to IL-10 signaling which is then able to induce production of pro-inflammatory factors such as IFN-inducible chemokines (Sharif et al. 2004).
IL-10 has Superior Anti-Inflammatory Activity Compared with Other STAT3-Signaling Cytokines: Role of SOCS3 The anti-inflammatory signaling induced through the IL-10-STAT3 axis contrasts with other STAT3-inducing cytokines that drive more pro-inflammatory signaling. These include IL-6, IL-21, IL-23 and IL-27, some of which also participate in differentiation of T helper cell lineages as discussed above. One component of the difference between anti-inflammatory and pro-inflammatory STAT3-inducing cytokines can be explained by the downstream activity of suppressor of cytokine signaling 3 (SOCS3). SOCS3 is induced following STAT3 activation induced by multiple cytokines and growth factors including IL-10, IL-6 and EGF (Yoshimura et al. 2007; Cassel and Rothman 2009; O’Shea and Murray 2008). In common with other SOCS protein family members, it has a central src homology 2 (SH2) domain that targets it to specific phosphorylated tyrosines and a C-terminal SOCS box that serves as an E3 ubiquitin ligase. In addition, SOCS3 has an N-terminal kinase inhibitory region (KIR) that is required for its inhibition of Jak kinases. The selective effects of SOCS3-mediated suppression are believed to be due to its recognition of a specific phosphotyrosine (Y757) on the gp130 chain common to receptors for the cytokines IL-6, leukemia inhibitory factor (LIF) and IL-27 among others. In contrast, the IL-10 receptor lacks tyrosines capable of forming this interaction and is resistant to SOCS3-mediated suppression. In macrophages in which gp130 was mutated at Y757, the site responsible for binding SOCS3 and SHP-2 upon its phosphorylation, IL-6 acts in a similar manner to IL-10 by inducing prolonged STAT3 tyrosine phosphorylation and suppressing the response to LPS (Yasukawa et al. 2003; El Kasmi et al. 2006). The same conversion of IL-6 signaling from pro-inflammatory to anti-inflammatory is observed in macrophages lacking SOCS3 (Yasukawa et al. 2003; Croker et al. 2003; Lang et al. 2003), demonstrating a highly selective effect of the SOCS3-gp130 interaction. Thus SOCS3 limits the duration of STAT3 activation induced by IL-6 signaling. Indeed, it has been proposed that the sustained STAT3 activation resulting from IL-10 signaling is the sole required feature of an anti-inflammatory response (Yasukawa et al. 2003). However, it is also
Turning on and off the Immunological Switch
37
possible that STAT3 activation induced by anti-inflammatory signaling could differ qualitatively from the pro-inflammatory signaling (in terms of protein modification, cooperative partners or other) (O’Shea and Murray 2008).
Molecular Mechanisms of the IL-10-Mediated Anti-Inflammatory Effects The mechanisms by which IL-10 mediates its anti-inflammatory effects are diverse and their details and relative importance remain a matter of debate (Murray 2006; Page et al. 2009; Weaver et al. 2007b; Grutz 2005; Sabat et al. 2007). In the context of pro-inflammatory stimulation by TLR ligands, IL-10s regulatory effects are twofold: it suppresses the expression of proinflammatory genes, in particular cytokines and chemokines including TNF, IL-12, IL-1b, IL-6, KC, IL-8, and it induces the expression of suppressive factors and receptors including the IL-1 receptor antagonist (IL-1ra), TNF-R2, DUSP1, SOCS-3 and Bcl-3 (Moore et al. 2001; Williams et al. 2004). Mechanisms to explain the regulation of these genes must consider the coordinated activity of NF-kB induced during TLR stimulation (see Fig. 2). TLR signaling-induced transcription Pol II
Pro-Inflammatory Cytokine Genes
TLR Signaling NF-κB p65 p50
IL-10 Signaling STAT3pY Y-P YP
TLR and IL-10-induced transcription Chromatin Remodeling Coordinated promoter activaiton YP YP
TNF IL-1 IL-6 IL-12
IL-1ra SOCS3 ETV3 SBNO2
Pol II
Anti-Inflammatory Genes
Bcl-3 IκBNS DUSP1 TTP
1) Termination of Signaling Pol II by interruption of signaling pathways
2) Transcriptional Repression
Pol II
Pro-Inflammatory Cytokine Genes
3) Binding and Inhibition of NF-κB by nuclear IκBlike molecules
Pol II
? (5) Direct IL-10-induced repression ? Chromatin Remodeling Promoter inactivation YP
YP
Pro-Inflammatory Cytokine Genes
Pro-Inflammatory Cytokine Genes
4) Destabilization and degradation of Pro-Inflammatory Cytokine mRNA Pro-Inflammatory Genes
Fig. 2 Coordinated TLR and IL-10 signaling drives a multipart anti-inflammatory response. TLR signaling drives the expression of pro-inflammatory cytokine genes. IL-10 signaling, through STAT3 and in coordination with TLR signaling, induces expression of anti-inflammatory genes. These anti-inflammatory genes block the pro-inflammatory response at multiple levels. For detailed explanations of mechanisms, see text. (1) Extracellular cytokine signaling and intracellular cytokine signaling are inhibited by IL-1ra and SOCS3 respectively. (2) ETV3 and SBNO2 are transcriptional repressors/corepressors (depicted in red) that repress transcription of NF-kBresponsive genes. (3) Nuclear IkB-like molecules (in red) are induced by coordinated TLR + IL-10 signaling and bind, along with NF-kBp50 to promoters that have been inactivated. (4) IL-10 increases the expression of genes involved in destabilizing AU-rich element (ARE) containing mRNAs (including pro-inflammatory cytokine mRNAs). (5) Hypothetically, STAT3 driven by IL-10 signaling might also recruit pre-synthesized nuclear repressors (or repressors activated/ induced by TLR signaling alone) to downregulate expression of some pro-inflammatory genes
38
C.A. Stewart and G. Trinchieri
IL-10 can control levels of cytokine expression at the gene transcription and post-transcriptional levels. Earlier studies suggested post-transcriptional regulation for TNF and IL-1 in mouse macrophages, but that expression of genes including TNF, IL-12p35 and IL-12p40 is regulated at the transcriptional level in human monocytes (Aste-Amezaga et al. (1998) and references therein). Using a knockin mouse with the 3¢UTR of TNF replaced by the 3¢UTR of GAPDH, Murray assessed TNF transcription rates that were unaffected by 3¢UTR-mediated degradation. This study showed that, following LPS stimulation, IL-10 reduced generation of the knockin TNF transcript, and therefore that its negative regulation occurs at the transcriptional level (Murray 2005). In many studies the observation that cycloheximide blocked transcriptional repression by IL-10 led to the conclusion that de novo protein synthesis was required and transcriptional repression was due to induced secondary factors (but alternative explanations exist for the effect of cycloheximide – see discussion in next paragraph). Based on this observation, a recent screen for factors co-induced by LPS and IL-10 signaling identified ETV3, a transcriptional repressor, and SBNO2, a transcriptional co-repressor (El Kasmi et al. 2007). The induction of these factors was shown to be STAT3-dependent. Transfection-based studies also showed that they can suppress the activity of a kB- (but not an IRF7) responsive promoter (El Kasmi et al. 2007) (Fig. 2). It remains to be determined whether these factors are required for the in vivo IL-10-mediated anti-inflammatory response. The mechanisms underlying gene expression that is induced or positively regulated by the combination of TLR and IL-10 signaling can be explained by simpler models of transcription factor cooperation. It was recently observed that the drop in IL-10-mediated suppression caused by cycloheximide treatment coincided with blockade in Jak1 and Tyk2 activity and interruption of IL-10 signaling (Rossato et al. 2007). This finding gives an alternative explanation for the sensitivity of IL-10 suppression to cycloheximide and suggests that additional newly translated positive or negative factors may not be required. The same group recently described studies on how LPS and IL-10 synergize to induce expression of IL-1ra (Tamassia et al. 2010) (Fig. 2). IL-1ra is a powerful natural inhibitor of IL-1 inflammatory reactions whose gene mutation leads to potentially fatal systemic autoinflammatory disease (Reddy et al. 2009; Aksentijevich et al. 2009). Using chromatin immunoprecipitation and analysis of primary transcripts in human monocytes, Tamassia et al. (2010) showed that LPS and IL-10 coordinate to enable RNA polymerase II binding to the promoter and to drive IL-1ra primary transcript production. NF-kB was activated by LPS signaling alone, and STAT3 binding to the promoter required only IL-10 (and not LPS), but NF-kB p65 and p50 binding to the IL-1ra promoter required both IL-10 and LPS. It was not possible to coimmunoprecipitate STAT3 and NF-kB. Thus, the authors proposed that activated STAT3 remodels the chromatin to render it accessible for NF-kB binding (Tamassia et al. 2010). In embryonic stem cells STAT3 binds to transcriptionally active and inactive promoters (Kidder et al. 2008). Therefore, if de novo protein synthesis is affecting only the upstream events of IL-10R signaling, this model of STAT3/NF-kB coordinated binding might equally apply not only to positively regulated genes but also to negatively regulated genes during coordinated signaling with TLR.
Turning on and off the Immunological Switch
39
The IL-1ra and other negative regulators that are induced by IL-10 and LPS, including SOCS3, Bcl-3 and IkBNS, complement the inhibition of proinflammatory cytokine production and give IL-10 a broad anti-inflammatory action. SOCS3 may, in addition to its role in suppression of IL-6 and gp130-mediated signaling, play a role in suppression of TLR responses (Yoshimura et al. 2007), through suppression of the TAK1/TRAF6 (Frobose et al. 2006) or through inhibition of type I interferon signaling (Zeng et al. 2008). Bcl-3 is a nuclear IkB-like molecule, whose expression is also induced following LPS and IL-10 treatment of macrophages and may contribute significantly to the anti-inflammatory response (Kuwata et al. 2003; Lang et al. 2002). Using transfection studies, Kuwata et al. showed that Bcl-3 binds to the TNF promoter, but not to the IL-6 promoter. NF-kB p50 subunits share this selective binding to the TNF promoter and also associate with Bcl-3 (Kuwata et al. 2003). Bcl-3 overexpression did not affect the activation of NF-kB p50/p65, but reduced its binding to NF-kB binding sites. Higher levels of Bcl-3 reduced activity of the TNF promoter, while the Bcl-3 knockout displayed increased TNF production, confirming its role as a negative regulator of TNF expression (Kuwata et al. 2003). IkBNS is another nuclear IkB-like molecule that is induced by TLR signaling and can negatively regulate late genes including IL-6 and IL-12p40 (reviewed in Yamamoto and Takeda (2008)). IkBNS was found to be responsive to IL-10 as it is selectively expressed in the lamina propria of wild type but not IL-10-deficient mice. It was also found to regulate cytokine production and bind the IL-6, but not the TNF promoter in association with NF-kB p50 (Hirotani et al. 2005). It is still unclear exactly how different members of the NF-kB family, and particularly p50/ p50 homodimers (Driessler et al. 2004), contribute to positive and negative regulation of target gene expression. However, the role of the nuclear IkB-like molecules in modulation of different NF-kB activities in response to IL-10 is likely to play an important role in its anti-inflammatory activity (Fig. 2). Different cytokines, such as IL-6, IL-1a, KC (or CXCL8) and IL-12 do not share the same regulatory mechanism as TNF, and this contributes an additional level of complexity to IL-10s anti-inflammatory effect. As discussed above, IL-6 is not regulated by Bcl-3 in the same way as TNF (Kuwata et al. 2003). Additionally, comparison of cycloheximide-dependent and -independent effects of IL-10 on primary transcripts of IL-6 suggests that IL-6 transcription is positively regulated by cycloheximidesensitive factors in the absence of IL-10 rather than negatively regulated in its presence (Murray 2005). In other words, de novo protein synthesis induces a protein required for upregulation of IL-6, but only when low levels of IL-10 are present. In the context of LPS signaling, IL-10 increases the post-transcriptional regulation of cytokines including TNF and IL-1a (Fig. 2). mRNA stability and/or translation is repressed through interactions with ARE in the 3¢UTR (Murray 2005; Kontoyiannis et al. 2001; Denys et al. 2002). Tristetraprolin (TTP) is a protein that destabilizes ARE-containing mRNAs. A recent publication (Schaljo et al. 2009) suggests that IL-10 can influence the TTP/ARE mRNA degradation in two ways: firstly, IL-10 induces an increase in TTP expression. Secondly, IL-10 signaling increases the activity of TTP by reducing p38 MAPK phosphorylation because of increased levels of the phosphatase DUSP1 (also see Hammer et al. (2005)).
40
C.A. Stewart and G. Trinchieri
Thus, post-transcriptional regulation provides a mechanism for IL-10 to rapidly downregulate active cytokine signaling. Therefore at the cellular and molecular levels, IL-10 drives a wide range of transcriptional and post-transcription changes that contribute to its powerful antiinflammatory effects. The mechanism is known to require STAT3, but a detailed understanding of its inhibitory effects on NF-kB-responsive promoters is poorly defined. The recent emergence of the cyclic AMP response element binding protein, ATF3, as a negative regulator of TLR responses (reviewed in Thompson et al. (2009)) introduces another potential player in IL-10s anti-inflammatory effects (Stearns et al. 2004). Comprehensive chromatin immunoprecipitation studies on NF-kB responsive promoters with multiple factors including STAT3, ETV3, SBNO2, nuclear IkB-like molecules and ATF3 may therefore be required to elucidate the precise mechanisms of IL-10s transcriptional effects.
Roles of STAT3 in Health and Disease As previously discussed, the STAT3 transcription factor is essential for anti-inflammatory signaling by IL-10. Its sustained activation during proinflammatory activation of NF-kB either directly or in concert with secondary factors leads to downregulation of pro-inflammatory gene transcription and translation and upregulation of antiinflammatory genes. However, in addition to IL-10, STAT3 is critical for signaling of many different cytokine receptors, including the gp130-linked receptors for IL-6, IL-11, IL-27, and LIF, as well as other receptors such as those for IL-21, IL-22, leptin, G-CSF and IL-23 (Yu et al. 2009). Furthermore, STAT3 activation can be induced in transformed cells by receptor tyrosine kinases and non-receptor tyrosine kinases such as oncogenic Src. STAT3 is unique among STATs as its deletion results in early embryonic lethality (Takeda et al. 1997). It is also a necessary component of LIF signaling for maintaining the pluripotency of mouse, but not human embryonic stem cells (Raz et al. 1999; Sumi et al. 2004). Additional roles for unphosphorylated STAT3 and mitochondrial STAT3 have already been discussed. The recent identification of dominant-negative STAT3 mutations in patients with autosomal dominant hyper IgE syndrome (HIES, or Job’s syndrome) (Minegishi et al. 2007) has provided an important insight into the physiological relevance of different STAT3-dependent pathways in man (reviewed in Heimall et al. (2010)). The major symptoms of these patients are eosinophilia, high serum IgE levels and susceptibility to skin and pulmonary infections. Patients can also have a variety of connective tissue and skeletal abnormalities. A defect in differentiation of Th17 cells may explain the eosinophilia and increased IgE levels and susceptibility to Candida albicans infection. Defective IL-22 function, a cytokine that is produced by Th17 cells but also by other Th subsets and requires STAT3 for signaling, may play a role in impaired resistance to skin and pulmonary infection as, together with IL-17, it induces beta-defensin expression (Wolk et al. 2004; Liang et al. 2006). Increased IL-12 production and Th1 skewing in response to LPS stimulation of
Turning on and off the Immunological Switch
41
macrophages from these patients is observed possibly due to poor response to IL-10 (Holland et al. 2007). The identification of dominant-negative STAT3 as the etiological agent in Job’s syndrome not only provides a target for treatment of these patients, but also demonstrates the probable side effects that inhibition of STAT3 may cause.
Roles of STAT3 in Cancer STAT3 is a protooncogene that is hyperactivated in many blood and solid tumors including melanoma, head and neck, breast, prostate and lung cancers (reviewed in Buettner et al. (2002)). Its activation leads to improved cell survival, increased cell motility and decreased expression of pro-apoptotic genes. Classical activation of the Jak/STAT pathway leads to STAT3 activation in response to cytokines. However, in transformed cells, STAT3 activation can also be induced by receptor tyrosine kinases such as the EGF receptor and non-receptor tyrosine kinases such as Src, and this activation is required for Src-mediated cell transformation (Bromberg et al. 1998; Yu et al. 1995). Furthermore, stimulation with TLR-ligands LPS and CpG have also been reported to activate STAT3 (Kortylewski et al. 2009a; Samavati et al. 2009). While direct activation of STAT3 by non-cytokine/Jak/STAT pathways may occur under certain experimental conditions, cellular transformation can also lead to autocrine production and signaling through STAT3-inducing cytokines, particularly IL-6 (see Yu and Jove (2004)). Paracrine signaling through STAT3 may be more relevant in vivo during inflammation associated carcinogenesis. This has been demonstrated during colitis and colitis-associated cancer where IL-6, IL-11 and IL-22 from hematopoietic cells and STAT3 in the intestinal epithelial cell are required for optimal proliferation and repair of the intestinal mucosa and elevated carcinogenesis (Grivennikov et al. 2009; Bollrath et al. 2009; Pickert et al. 2009). Recently, Iliopoulos et al. (2009) identified a role for IL-6 in an epigenetic switch from the immortalized to the transformed cell state. They demonstrated that, by transient activation of the v-Src oncogene, an immortalized cell line (i.e., contactinhibited and unable to form tumors in vivo) could be converted into a transformed state (growing as mammospheres with cancer stem cells and forming tumors in vivo). Src activation triggered NF-kB signaling and transcription of Lin28b (Iliopoulos et al. 2009). Lin28b is an RNA-binding protein that binds the precursors of Let-7 microRNAs and prevents their processing (Viswanathan and Daley 2010). Let-7 microRNAs were found to block IL-6 mRNA expression and downstream events of STAT3 activation and VEGF production (Iliopoulos et al. 2009). Therefore NF-kB activation due to Src, combined with lower Let-7 microRNA levels, let to robust IL-6 production. This IL-6 was then required for high levels of IL-1 transcription (possibly leading to sustained NF-kB activation) and STAT3 activation, leading to the transformed phenotype. Lin28b and IL-6 were required for growth of transformed MCF10A cells (mammary epithelial line) in nude mice. Similarly, the blockade of IL-6, or Lin28b, or overexpression of Let-7 reverted the transformed
42
C.A. Stewart and G. Trinchieri
phenotype of lung, hepatocellular carcinoma, breast, prostate and colon cancer cell lines. Finally, human breast, prostate, and HCC cancer tissue was found to have low Let-7 expression and high IL-6 expression while the inverse was found in normal tissue. Together, their data describe an epigenetic switch involving triggering by NF-kB, maintenance by Lin28b, low Let-7 and high IL-6, and transformation of cells due to activation of STAT3 (Iliopoulos et al. 2009). Whether, in vivo, IL-6 is derived from tumor or inflammatory cells, the existence of such an epigenetic change requiring several factors for its maintenance provides a clear target for therapeutic intervention.
STAT3 and IL-10 in Cancer-Promoting Inflammation Activation of STAT3 leads to inflammatory processes that promote wound repair, but in the context of cancer, can contribute to tumor growth and invasion. Two key events are stimulation of angiogenesis through production of VEGF, whose promoter has binding sites for STAT3 and HIF-a (Niu et al. 2002; Gray et al. 2005), and suppression of antigen presenting cell functions. During chronic inflammatory conditions, a major role for IL-10 in activation of STAT3 is argued by observations that manipulation of either STAT3 or IL-10 leads to highly similar effects. For example, cell-specific deletion of STAT3 in macrophages and neutrophils leads to increased sensitivity to endotoxic shock and chronic colitis in aging mice – a phenotype that matches that of IL-10-deficient mice (Takeda et al. 1999). As discussed below, a prominent role of the IL-10-STAT3 pathway during chronic cancer-associated inflammation may explain why blockade of either molecule is effective in cancer immunotherapy.
IL-10 Inhibition Facilitates Immune Responses to Tumors Antigen presenting cells from tumors respond poorly to stimulation with TLR ligands or other stimuli compared with antigen presenting cells from other locations (O’Garra et al. 2008; Sica et al. 2000; Vicari et al. 2002; Perrot et al. 2007; Bell et al. 1999). In addition to DC, macrophages and myeloid-derived suppressor cells (MDSC) infiltrate the tumor microenvironment and the distinction between these populations based on function or phenotype is not trivial. Tumor infiltrating DC (TIDC) frequently have an immature phenotype with low expression of costimulatory molecules (reviewed in Gottfried et al. (2008), Rabinovich et al. (2007), and Zou (2005)). Similarly, tumor associated macrophages have an alternatively activated or “M2” phenotype (including expression of arginase, high IL-10 expression and low IL-12 production) that is linked to an altered NF-kB response (see Chap. “Cancer and Inflammation” by Mantovani) (Anderson and Mosser 2002; Biswas et al. 2006; Hagemann et al. 2009, 2008). A growing body of evidence
Turning on and off the Immunological Switch
43
from human and mouse studies shows that IL-10 plays a key role in producing a hyporesponsive phenotype by tumor associated macrophages and DC (Sica et al. 2000; Vicari et al. 2002; Perrot et al. 2007). Based on in vitro observations that tumor associated antigen presenting cells are defective in IL-12 production due to high levels of IL-10 production (Sica et al. 2000), Vicari et al. (2002) employed coordinated TLR9 stimulation using CpG oligodeoxyribonucleotide (ODN) and IL-10 signaling blockade with an anti-IL-10R antibody to develop an antitumor immune therapy regime. They observed that TIDC express low levels of MHC class II and costimulatory molecules CD86 and CD40 compared with lymph node DC and do not upregulate these molecules or produce IL-12p70 upon costimulation with LPS, IFN-g and anti-CD40 agonist antibody (Vicari et al. 2002). Addition of antagonistic anti-IL-10R antibody to cultures revived TIDC cytokine responses and antigen presentation capacity in mixed lymphocyte reaction and cross-presentation assays. The combination of antiIL10R and intra-tumor CpG in vivo, given as a weekly therapy for 3 weeks, led to rejection of established tumor in ~80% of mice, by a mechanism that required NK cells, CD4+ and CD8+ T cells for full effect (Vicari et al. 2002). A follow up study showed that tumor rejection could be attained with CpG alone in IL-10-deficient mice and that Treg have overlapping but separable roles during the immunosuppression (Dercamp et al. 2005). In this way, the removal of IL-10s anti-inflammatory activity permitted potent APC and cytokine responses, along with tumor rejection and immunity, in response to the CpG TLR ligand. The mechanisms behind CpG-mediated rejection in the absence of IL-10 were dissected in detail by Guiducci et al. (2005) using a modified protocol designed to draw antigen presenting cells into tumor tissue. They had previously shown that local administration of an adenoviral vector expressing the human chemokine CCL16 (AdCCL16; CCL16 is a ligand for CCR1, CCR2, CCR5 and CCR8) led to infiltration of T cells, macrophages and DC, retarded growth of TSA mammary tumor nodules and an adaptive immune response that prevented metastatic spread of tumor (Guiducci et al. 2004). A single treatment consisting of intratumoral injection of AdCCL16 at 36 h prior to systemic anti-IL10R antibody and local CpG administration led to rejection of established TSA mammary, MCA38 colon and 4T1 mammary tumors in 60–90% of mice (Guiducci et al. 2005). This effect involved local production of TNF, IL-12 and nitric oxide (NO) by tumor macrophages at ~6 h post-CpG injection, followed by TNF-dependent hemorrhagic necrosis at the tumor site. The complete treatment (AdCCL16 + anti-IL-10R + CpG), but not treatment lacking antiIL10R antibody, led to upregulation of costimulatory molecules and MHC class II on tumor-infiltrating DC along with production of IL-12 and TNF. In vitro, these DC were capable of driving T cells to proliferate and produce high levels of the Th1 cytokine IFN-g in a mixed leukocyte reaction assay. In vivo, DC migration was triggered, followed by activation of the adaptive immune system and tumor rejection that required CCR7 (a chemokine receptor involved in migration to the lymphatics), costimulation by CD40, and both chains of the cytokine IL-12 (Guiducci et al. 2005). In this way, blockade of IL-10 signaling permits a powerful local hemorrhagic necrosis, which the authors described as comparable to a localized Shwartzman
44
C.A. Stewart and G. Trinchieri
reaction, with high levels of TNF and NO and an IL-12-dependent Th1-type immune response. The very rapid necrotic response is fully dependent on the activation of innate resistance mechanisms and even if in a few hours it induces an almost complete destruction of the tumor mass, it is not by itself able to cure the animal: in the absence of an antigen-specific T cell response the tumors eventually progress and kill most of the treated animals. The type of inflammation that characterizes the tumor microenvironment supports tumor growth and dissemination, by favoring e.g., angiogenesis and through the effect of secreted metalloproteases that promote tumor invasion. It is also immunosuppressive, reducing the ability of the antigen-presenting cells in the tumor microenvironment to activate T cells and to migrate in the draining lymph nodes. The treatment of the mice with CpG and anti-IL-10R not only induces an acute type I inflammatory response that is responsible for the rapid necrosis but it also reverts the phenotypes of tumor-resident APC, allowing them to efficiently present tumor antigens to T cells and also to migrate rapidly to the draining lymph node for optimal T cell activation. Thus, effective eradication of the tumors requires the generation of both Th1 and cytotoxic T cell responses against the tumor antigen. This was clearly demonstrated by the fact that anti-IL-10R and CpG treatment induce tumor necrosis but do not cure in mice deficient for CD4 and/or CD8 T cells or in which the T cells and the APC have different MHC antigens than the tumor cells (Guiducci et al. 2005). In addition to the studies on inoculated subcutaneous tumors described above, therapy by TLR ligation and inhibition of IL-10 signaling has been successfully employed in several transgenic carcinogenesis models. Mice expressing SV40 T antigen (Tag) under control of the tyrosinase related protein 1 (TRP-1) promoter develop tumors from the retinal pigmented epithelium of the eye that become macroscopically visible at around 6 weeks of age (Penna et al. 1998). Treatment of TRP-1/Tag mice with anti-IL-10 antibody in conjunction with CpG ODN i.p. or with the TLR-7/8 ligand R848 delayed eye tumor development for the duration of the treatment in a large proportion of mice (Alain Vicari 2004, personal communication). Similarly, topical treatment of breast tumors in MMTVneu mice with the TLR-7 ligand, imiquimod, limited development of tumors during treatment but mice succumbed to tumor after its cessation. Additional treatment with anti-IL-10 antibodies led to prolonged survival of imiquimod-treated mice (Lu et al. 2010). The success of combination (TLR-L + IL-10-block) therapies in transgenic models probably requires effective adaptive immune responses (against immunogenic Tag or neu, respectively (Lu et al. 2010)). Furthermore, it demonstrates a broad applicability of the combination therapy and strengthens the prospects of its clinical use.
Targeting STAT3 Facilitates Anti-Tumor Immune Responses In 1999, the Yu laboratory described an observation that inhibition of STAT3 in tumors leads to more extensive cell death than could be explained by its immediate effects, suggesting that bystander effect was occurring (Kortylewski and Yu 2007;
Turning on and off the Immunological Switch
45
Niu et al. 1999). Using electroinjection of plasmid DNA that achieved no more than ~15% transfection efficiency into B16 melanomas, they observed that half the tumor cells could be driven to apoptosis when a dominant-negative STAT3b isoform was encoded on the plasmid, and that this effect led to tumor regression in ~50% of mice (Niu et al. 1999). This initial observation prompted a series of continuation studies by Hua Yu, in collaboration with Richard Jove and Drew Pardoll, into STAT3s anti-inflammatory and immunological roles in the tumor environment and its accessibility to therapeutic manipulation. Any viable mechanistic explanation of the bystander effect during inhibition of STAT3 should include changes in extracellular levels of pro-apoptotic factors or tumor-survival factors. Soluble factors, including TNF-related apoptosis-inducing ligand (TRAIL) were found to be expressed by STAT3b-transfected B16 cells and contributed to tumor cell apoptosis (Niu et al. 2001). STAT3 was linked to tumor angiogenesis through direct binding and activation of the VEGF promoter and through upregulation of AKT1 and HIF-1 in tumor cells (Niu et al. 2002; Xu et al. 2005). STAT3 was also shown to contribute to tumor cell survival through upregulation of factors including bcl-xl, bcl-2 and survivin and a role in tumor invasion was described through STAT3-mediated upregulation of matrix metalloproteases such as MMP-2 (reviewed in Aggarwal et al. (2009)). It is therefore apparent that STAT3-mediated regulation of extracellular factors could contribute to oncogenesis and complement STAT3s role in oncogene-mediated transformation (Bromberg et al. 1998; Yu et al. 1995; Iliopoulos et al. 2009). However, other functions of STAT3 in the tumor microenvironment, specifically its effects on inflammation, are required to fully explain the bystander effect of STAT3 inhibition. The demonstration that inhibition of STAT3 can lead to proinflammatory cytokine production and can reverse the suppressive effect of tumor culture supernatants on DC maturation provided a mechanistic framework for its anti-inflammatory role in tumors (Wang et al. 2004). Inhibition of STAT3 in a variety of tumor lines by ectopic expression of dominant-negative STAT3b or anti-sense RNA led to increases in expression of proinflammatory cytokines including TNF, IL-6, IFN-b and chemokines including CCL5 (RANTES) and CXCL10 (IP10). Similarly, STAT3 activation by Src-transformation or expression of a constitutively active STAT3 (STAT3C) suppressed expression of proinflammatory cytokines in response to LPS/IFN-g treatment (Wang et al. 2004). By inhibiting STAT3, tumor cells that would normally suppress DC and macrophage activation were capable of promoting DC maturation and macrophage NO production in vitro, and immunization of mice with STAT3-inhibited tumor cells led to enhanced antigen-specific responses. Furthermore, tumor-derived factors also induced STAT3 phosphorylation in DC and their suppression required STAT3. The authors finally demonstrated that IL-10 (and possibly VEGF) could mimic the suppressive effect of tumor cell supernatant in a STAT3-dependent manner, suggesting IL-10 to be a key mediator of DC suppression in the tumor microenvironment (Wang et al. 2004). The relevance of hematopoietic cell STAT3 was demonstrated using inducible deletion of STAT3 in all bone marrow-derived cells using Mx1-Cre;STAT3fl/fl mice (Kortylewski et al. 2005). STAT3-deficient DC from these mice produced
46
C.A. Stewart and G. Trinchieri
higher levels of IL-12 in response to LPS stimulation, and induced higher levels of antigen-specific T cell proliferation in culture. Furthermore, B16 tumor-infiltrating STAT3-deficient DC expressed higher levels of costimulatory CD86 and MHC class II compared with wild-type. Interestingly, STAT3 phosphorylation was triggered in neutrophils and NK cells by IL-10, and both cell types were more cytotoxic following hematopoietic STAT3-ablation. The higher cytotoxic activity of neutrophils may have been related to higher levels of FasL expression. In the tumor-infiltrating populations of STAT3-ablated mice, higher frequencies of IFN-g-producing tumor antigen-specific T cells and lower proportions of CD4+CD25+FoxP3+ Tregs were observed (Kortylewski et al. 2005). A profound effect of hematopoietic STAT3-ablation was observed in tumor immunity. Using MB49 (bladder carcinoma) and B16 tumors, hematopoietic STAT3-deficient mice were resistant to tumor growth and MB49 tumors were rejected by a mechanism requiring T cells (as shown by CD4 and CD8 depletion). Deletion of hematopoietic STAT3 following establishment of tumor also led to tumor regression (MB49) or slowed growth (B16). A similar T and NK cell-dependent anti-tumor effect could be observed with wild-type mice by administration of the STAT3 inhibitor, CPA7 (Kortylewski et al. 2005). Therefore hematopoietic STAT3 is a critical suppressor of anti-tumor immune responses and its genetic or pharmacological inhibition is sufficient to switch predisposition from tumor-promoting to anti-tumor inflammation. Deletion of STAT3 in hematopoietic cells also rendered tumors highly sensitive to peritumoral injection of CpG (Kortylewski et al. 2009a). Local CpG treatment of STAT3-deficient mice with 10mm diameter B16 tumors led to rapid tumor regression associated with neutrophil infiltration, production of nitric oxide and loss of vascular function as determined by the tracking of a systemic dye using intravital microcopy. The combined STAT3-deficiency and CpG treatment led to augmented costimulatory responses by tumor-draining lymph node DCs and increased frequencies of IFN-g producing tumor antigen-specific T cells. Furthermore, a single treatment of CpG led to tumor rejection in STAT3-deficient, but not STAT3sufficient mice, and long term protection required T cells (Kortylewski et al. 2009a). In wild type mice, the combination treatment could also be achieved using CPA7 to inhibit STAT3 function combined with peritumoral CpG injection (Kortylewski et al. 2009a). The efficacy of these combination treatments led Kortylewski et al. (2009b) to design a single molecule drug comprised of a CpG stimulatory ODN conjugated to siRNA for STAT3 (CpG-Stat3siRNA). CpG-Stat3siRNA was taken up by DC, B cells and macrophages in vitro and following peri-tumoral injection in vivo. Effective uptake and processing by Dicer required the CpG portion of the conjugate and was not achieved with a control GpC ODN conjugate, suggesting that TLR9 recognition and activation were important for processing. B16 tumor growth was blocked by a single peritumoral treatment by a mechanism that required NK cells and partially required T cells. Local injection of CpG-Stat3siRNA led to growth inhibition of multiple tumor types. Furthermore, systemic administration 2 days after i.v. inoculation of B16 tumor cells led to a much lower level of visible metastases. Injection of CpG-Stat3siRNA induced innate and adaptive immune
Turning on and off the Immunological Switch
47
responses including the expression of pro-inflammatory cytokines, tumor-infiltration of neutrophils and tumor cell apoptosis, and immunity against tumor-associated antigens (Kortylewski et al. 2009b). The mechanism and effect of combining CpG treatment with STAT3-deficiency in the Kortylewski studies (Kortylewski et al. 2009a, b) are highly reminiscent of the studies by Vicari et al. using CpG + anti-IL10R treatment to treat tumors (as discussed earlier (Vicari et al. 2002; Guiducci et al. 2005)) (Fig. 3). Despite the similarities, Kortylewski et al. (2009a) argue that IL-10 is not required for STAT3 phosphorylation in DCs following CpG treatment and that STAT3 activation can be directly induced by TLR9 triggering. However, this argument is based on studies using splenic DCs and may not hold for tumor-infiltrating populations because lymphoid organ DCs are more readily activated by TLR ligands than tumorinfiltrating APC (Sica et al. 2000; Vicari et al. 2002; Perrot et al. 2007). It is therefore possible that IL-10 plays a predominant role in activating STAT3 within tumor APC in the context of TLR signaling, and that this leads to the potent effects of blockade in IL-10 signaling. Indeed, an incomplete blockade of STAT3 activation by anti-IL10R antibody treatment may account for different therapeutic efficiencies between the Vicari and Kortylewski protocols: three treatments with CpG and anti-IL10R were used for tumor rejection (Vicari et al. 2002) compared with one CpG injection in the context of STAT3-ablation (Kortylewski et al. 2009a) and multiple CpG injections in the context of STAT3-inhibition using CPA7 (Kortylewski et al. 2009a). Alternatively, the use of poly(I:C) to trigger STAT3 ablation, though performed IL 10
IL-10 IL-10R
STAT3pY
TLR
IL-10R
TLR
STAT3pY
Tumor DC or macrophage Poor inflammatory response
Potent inflammatory response DC migration Th1 Immune Response Protection from tumor regrowth
Fig. 3 Inhibition or blockade of IL-10, IL-10R or STAT3 prevents anti-inflammatory action of IL-10 in the tumor microenvironment. Without IL-10/STAT3, TLR triggering of tumor dendritic cells (DC) and macrophages leads to robust pro-inflammatory cytokine production, DC migration and protective antigen-specific immune responses
48
C.A. Stewart and G. Trinchieri
four days prior to B16 tumor inoculation (Kortylewski et al. 2009a), may have resulted in sufficient type I IFN production to potentiate immunological priming against tumor-associated antigens (Trumpfheller et al. 2008). In either case, the resultant Th1 type immunity combined with local tumor tissue destruction makes the inhibition of IL-10 or STAT3 important enhancers of TLR-based immunotherapy and provides a foundation for effective clinical protocols.
Conclusions The tumor microenvironment if often characterized by infiltration of inflammatory cells and lymphocytes suggesting that the tumor is interacting with the organism defense mechanisms and not simply escaping them. It has been clearly demonstrated in a subset of cancer patients that an anti-tumor response may be activated and may slow tumor progression. However, in general the tumor microenvironment is characterized by a type of inflammation and possibly immune response that favor tumor growth and diffusion while impeding an effective immune response. This microenvironment is characterized by alternative activation of tumor-infiltrating hematopoietic cells and by production of soluble factors, including chemokines, cytokines, metalloproteases, growth factors, and pro-angiogenic factors that contribute to maintain the pro-tumor and immunosuppressive state. Certain tumorinfiltrating cell types, e.g., Treg and MDSC, play a major role determining the characteristics of the tumor microenvironment. Although many soluble factors and transcription factors also play a major role, the cytokine IL-10 and the transcription factor STAT3 seem to have key functions: blocking either one of them has similar and profound effects by switching the inflammatory response in the tumor to a type I inflammation that is unfavorable for tumor progression and by allowing the generation of an effective anti-tumor Th1/CTL adaptive immune response. Thus, these key factors in the immunological switch represent promising targets for immunotherapy of cancer in order to induce an effective curative anti-tumor immune response.
References Aggarwal, B.B., et al., Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci, 2009. 1171: p. 59–76. Aksentijevich, I., et al., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med, 2009. 360(23): p. 2426–37. Anderson, C.F. and D.M. Mosser, A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol, 2002. 72(1): p. 101–6. Anderson, C.F., et al., CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med, 2007. 204(2): p. 285–97.
Turning on and off the Immunological Switch
49
Aste-Amezaga, M., et al., Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol, 1998. 160(12): p. 5936–44. Aziz, M.H., et al., Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Mol Carcinog, 2007. 46(8): p. 646–53. Belkaid, Y., et al., The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med, 2001. 194(10): p. 1497–506. Bell, D., et al., In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 1999. 190(10): p. 1417–26. Bennett, C.L., et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 2001. 27(1): p. 20–1. Berg, D.J., et al., Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest, 1995. 96(5): p. 2339–47. Biswas, S.K., et al., A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood, 2006. 107(5): p. 2112–22. Blackburn, S.D. and E.J. Wherry, IL-10, T cell exhaustion and viral persistence. Trends Microbiol, 2007. 15(4): p. 143–6. Bollrath, J., et al., gp130-mediated Stat3 activation in enterocytes regulates cell survival and cellcycle progression during colitis-associated tumorigenesis. Cancer Cell, 2009. 15(2): p. 91–102. Bromberg, J.F., et al., Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol, 1998. 18(5): p. 2553–8. Brooks, D.G., et al., Interleukin-10 determines viral clearance or persistence in vivo. Nat Med, 2006. 12(11): p. 1301–9. Brooks, D.G., et al., IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med, 2008. 205(3): p. 533–41. Buettner, R., L.B. Mora, and R. Jove, Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res, 2002. 8(4): p. 945–54. Calzada-Wack, J.C., M. Frankenberger, and H.W. Ziegler-Heitbrock, Interleukin-10 drives human monocytes to CD16 positive macrophages. J Inflamm, 1996. 46(2): p. 78–85. Cassel, S.L. and P.B. Rothman, Chapter 3: Role of SOCS in allergic and innate immune responses. Adv Immunol, 2009. 103: p. 49–76. Chaudhry, A., et al., CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science, 2009. 326(5955): p. 986–91. Crawley, J.B., et al., Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J Biol Chem, 1996. 271(27): p. 16357–62. Croker, B.A., et al., SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol, 2003. 4(6): p. 540–5. Denys, A., et al., Evidence for a dual mechanism for IL-10 suppression of TNF-alpha production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-kappa B in primary human macrophages. J Immunol, 2002. 168(10): p. 4837–45. Dercamp, C., et al., Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res, 2005. 65(18): p. 8479–86. Dikopoulos, N., et al., Type I IFN negatively regulates CD8+ T cell responses through IL-10producing CD4+ T regulatory 1 cells. J Immunol, 2005. 174(1): p. 99–109. Driessler, F., et al., Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol, 2004. 135(1): p. 64–73. Ejrnaes, M., et al., Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med, 2006. 203(11): p. 2461–72. El Kasmi, K.C., et al., General nature of the STAT3-activated anti-inflammatory response. J Immunol, 2006. 177(11): p. 7880–8.
50
C.A. Stewart and G. Trinchieri
El Kasmi, K.C., et al., Cutting edge: a transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol, 2007. 179(11): p. 7215–9. Filippi, C.M. and M.G. von Herrath, IL-10 and the resolution of infections. J Pathol, 2008. 214(2): p. 224–30. Finbloom, D.S. and K.D. Winestock, IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol, 1995. 155(3): p. 1079–90. Fiorentino, D.F., M.W. Bond, and T.R. Mosmann, Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med, 1989. 170(6): p. 2081–95. Fitzgerald, D.C., et al., Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol, 2007. 8(12): p. 1372–9. Frobose, H., et al., Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol, 2006. 20(7): p. 1587–96. Fukao, T., et al., PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol, 2002. 3(9): p. 875–81. Gaddi, P.J. and G.S. Yap, Cytokine regulation of immunopathology in toxoplasmosis. Immunol Cell Biol, 2007. 85(2): p. 155–9. Gao, S.P. and J.F. Bromberg, Touched and moved by STAT3. Sci STKE, 2006. 2006(343): p. pe30. Gazzinelli, R.T., et al., In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol, 1996. 157(2): p. 798–805. Gerosa, F., et al., Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med, 1996. 183(6): p. 2559–69. Gottfried, E., M. Kreutz, and A. Mackensen, Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev, 2008. 19(1): p. 65–77. Grant, L.R., et al., Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun, 2008. 9(4): p. 316–27. Gray, M.J., et al., HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 2005. 24(19): p. 3110–20. Grivennikov, S., et al., IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 2009. 15(2): p. 103–13. Grutz, G., New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol, 2005. 77(1): p. 3–15. Guiducci, C., et al., Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol, 2004. 172(7): p. 4026–36. Guiducci, C., et al., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res, 2005. 65(8): p. 3437–46. Guo, L., et al., IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A, 2009. 106(32): p. 13463–8. Hagemann, T., et al., “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med, 2008. 205(6): p. 1261–8. Hagemann, T., et al., Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood, 2009. 113(14): p. 3139–46. Hammer, M., et al., Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur J Immunol, 2005. 35(10): p. 2991–3001. Heimall, J., A. Freeman, and S.M. Holland, Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol, 2010. 38(1): p. 32–8. Hinrichs, C.S., et al., Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009. 114(3): p. 596–9.
Turning on and off the Immunological Switch
51
Hirotani, T., et al., The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharideinduced IL-6 production in macrophages of the colonic lamina propria. J Immunol, 2005. 174(6): p. 3650–7. Hoentjen, F., et al., STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood, 2005. 105(2): p. 689–96. Hoffmann, K.F., A.W. Cheever, and T.A. Wynn, IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol, 2000. 164(12): p. 6406–16. Holland, S.M., et al., STAT3 mutations in the hyper-IgE syndrome. N Engl J Med, 2007. 357(16): p. 1608–19. Iliopoulos, D., H.A. Hirsch, and K. Struhl, An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 2009. 139(4): p. 693–706. Jankovic, D. and G. Trinchieri, IL-10 or not IL-10: that is the question. Nat Immunol, 2007. 8(12): p. 1281–3. Jankovic, D., et al., Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med, 2007. 204(2): p. 273–83. Kidder, B.L., J. Yang, and S. Palmer, Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One, 2008. 3(12): p. e3932. Kitani, A., et al., Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med, 2003. 198(8): p. 1179–88. Kontoyiannis, D., et al., Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J, 2001. 20(14): p. 3760–70. Koppelman, B., et al., Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity, 1997. 7(6): p. 861–71. Kortylewski, M. and H. Yu, Stat3 as a potential target for cancer immunotherapy. J Immunother, 2007. 30(2): p. 131–9. Kortylewski, M., et al., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 2005. 11(12): p. 1314–21. Kortylewski, M., et al., Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res, 2009. 69(6): p. 2497–505. Kortylewski, M., et al., In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol, 2009. 27(10): p. 925–32. Kuhn, R., et al., Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 1993. 75(2): p. 263–74. Kuwata, H., et al., IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood, 2003. 102(12): p. 4123–9. Lang, R., et al., Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol, 2002. 169(5): p. 2253–63. Lang, R., et al., SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol, 2003. 4(6): p. 546–50. Levings, M.K., et al., IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol, 2001. 166(9): p. 5530–9. Liang, S.C., et al., Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med, 2006. 203(10): p. 2271–9. Lighvani, A.A., et al., T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A, 2001. 98(26): p. 15137–42. Lu, H., et al., Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol, 2010. 184: p. 5360–7. Lucas, M., et al., ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol, 2005. 175(1): p. 469–77. Ma, C.S., et al., Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med, 2008. 205(7): p. 1551–7.
52
C.A. Stewart and G. Trinchieri
Maeda, H., et al., TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol, 1995. 155(10): p. 4926–32. Manetti, R., et al., Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med, 1994. 179(4): p. 1273–83. Maynard, C.L., et al., Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol, 2007. 8(9): p. 931–41. McGeachy, M.J., et al., TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol, 2007. 8(12): p. 1390–7. Minegishi, Y., et al., Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature, 2007. 448(7157): p. 1058–62. Moore, K.W., et al., Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001. 19: p. 683–765. Mosser, D.M. and X. Zhang, Interleukin-10: new perspectives on an old cytokine. Immunol Rev, 2008. 226: p. 205–18. Murray, P.J., The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A, 2005. 102(24): p. 8686–91. Murray, P.J., Understanding and exploiting the endogenous interleukin-10/STAT3-mediated antiinflammatory response. Curr Opin Pharmacol, 2006. 6(4): p. 379–86. Nelson, D.A., C.C. Petty, and K.L. Bost, Infection with murine gammaherpesvirus 68 exacerbates inflammatory bowel disease in IL-10-deficient mice. Inflamm Res, 2009. 58(12): p. 881–9. Ng, D.C., et al., Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol, 2006. 172(2): p. 245–57. Niu, G., et al., Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res, 1999. 59(20): p. 5059–63. Niu, G., et al., Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res, 2001. 61(8): p. 3276–80. Niu, G., et al., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 2002. 21(13): p. 2000–8. Nylen, S., et al., Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med, 2007. 204(4): p. 805–17. O’Garra, A., et al., Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev, 2008. 223: p. 114–31. O’Shea, J.J. and P.J. Murray, Cytokine signaling modules in inflammatory responses. Immunity, 2008. 28(4): p. 477–87. O’Shea, J.J. and W.E. Paul, Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science, 2010. 327(5969): p. 1098–102. Page, T.H., et al., Tyrosine kinases and inflammatory signalling. Curr Mol Med, 2009. 9(1): p. 69–85. Peacock, J.W. and K.L. Bost, Murine gammaherpesvirus-68-induced interleukin-10 increases viral burden, but limits virus-induced splenomegaly and leukocytosis. Immunology, 2001. 104(1): p. 109–17. Pearce, E.L., et al., Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science, 2003. 302(5647): p. 1041–3. Penna, D., A. Schmidt, and F. Beermann, Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1/SV40 T antigen transgenic mice. Oncogene, 1998. 17(20): p. 2601–7. Perona-Wright, G., et al., Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe, 2009. 6(6): p. 503–12. Perrot, I., et al., Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol, 2007. 178(5): p. 2763–9. Pickert, G., et al., STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med, 2009. 206(7): p. 1465–72.
Turning on and off the Immunological Switch
53
Rabinovich, G.A., D. Gabrilovich, and E.M. Sotomayor, Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol, 2007. 25: p. 267–96. Rahimi, A.A., et al., STAT-1 mediates the stimulatory effect of IL-10 on CD14 expression in human monocytic cells. J Immunol, 2005. 174(12): p. 7823–32. Raz, R., et al., Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2846–51. Reddy, S., et al., An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med, 2009. 360(23): p. 2438–44. Riley, J.K., et al., Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem, 1999. 274(23): p. 16513–21. Robinson, D., et al., IGIF does not drive Th1 development but synergizes with IL-12 for interferongamma production and activates IRAK and NFkappaB. Immunity, 1997. 7(4): p. 571–81. Roers, A., et al., T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med, 2004. 200(10): p. 1289–97. Romagnani, S., Lymphokine production by human T cells in disease states. Annu Rev Immunol, 1994. 12: p. 227–57. Roncarolo, M.G., et al., Type 1 T regulatory cells. Immunol Rev, 2001. 182: p. 68–79. Rossato, M., et al., IL-10 modulates cytokine gene transcription by protein synthesis-independent and dependent mechanisms in lipopolysaccharide-treated neutrophils. Eur J Immunol, 2007. 37(11): p. 3176–89. Rubtsov, Y.P., et al., Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity, 2008. 28(4): p. 546–58. Sabat, R., et al., Biology of Interleukin-10, In Class II Cytokines, Zdanov, A., Editor. 2007, Kerala, India: Transworld Research Network. p. 107–26. Samavati, L., et al., STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin6 production in response to lipopolysaccharide and live bacteria. Mol Immunol, 2009. 46(8–9): p. 1867–77. Sanjabi, S., et al., Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol, 2009. 9(4): p. 447–53. Saraiva, M. and A. O’Garra, The regulation of IL-10 production by immune cells. Nat Rev Immunol, 2010. 10(3): p. 170–81. Saraiva, M., et al., Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity, 2009. 31(2): p. 209–19. Schaljo, B., et al., Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J Immunol, 2009. 183(2): p. 1197–206. Schindler, C., D.E. Levy, and T. Decker, JAK-STAT signaling: from interferons to cytokines. J Biol Chem, 2007. 282(28): p. 20059–63. Sellon, R.K., et al., Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun, 1998. 66(11): p. 5224–31. Sharif, M.N., et al., IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol, 2004. 172(10): p. 6476–81. Sharma, A., et al., Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A, 2009. 106(14): p. 5761–6. Shen, Y., et al., Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol, 2004. 24(1): p. 407–19. Sica, A., et al., Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol, 2000. 164(2): p. 762–7. Siewe, L., et al., Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur J Immunol, 2006. 36(12): p. 3248–55.
54
C.A. Stewart and G. Trinchieri
Silva, R.A., T.F. Pais, and R. Appelberg, Blocking the receptor for IL-10 improves antimycobacterial chemotherapy and vaccination. J Immunol, 2001. 167(3): p. 1535–41. Spencer, J.V., The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes. J Virol, 2007. 81(4): p. 2083–6. Staples, K.J., et al., IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J Immunol, 2007. 178(8): p. 4779–85. Stearns, M.E., et al., Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 Cells. Mol Cancer Res, 2004. 2(7): p. 403–16. Stumhofer, J.S., et al., Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol, 2007. 8(12): p. 1363–71. Sumi, T., et al., STAT3 is dispensable for maintenance of self-renewal in nonhuman primate embryonic stem cells. Stem Cells, 2004. 22(5): p. 861–72. Sun, J., et al., Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med, 2009. 15(3): p. 277–84. Takeda, K., et al., Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A, 1997. 94(8): p. 3801–4. Takeda, K., et al., Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity, 1999. 10(1): p. 39–49. Tamassia, N., et al., Uncovering an IL-10-dependent NF-{kappa}B recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. FASEB J, 2010. 24: p. 1365–75. Thompson, M.R., D. Xu, and B.R. Williams, ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med, 2009. 87(11): p. 1053–60. Trinchieri, G., Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med, 2007. 204(2): p. 239–43. Trumpfheller, C., et al., The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A, 2008. 105(7): p. 2574–9. Usui, T., et al., T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med, 2006. 203(3): p. 755–66. Uze, G. and D. Monneron, IL-28 and IL-29: newcomers to the interferon family. Biochimie, 2007. 89(6–7): p. 729–34. Veldhoen, M., et al., Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol, 2008. 9(12): p. 1341–6. Vicari, A.P. and G. Trinchieri, Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol Rev, 2004. 202: p. 223–36. Vicari, A.P., et al., Reversal of tumor-induced dendritic cell paralysis by CpG immunosti mulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med, 2002. 196(4): p. 541–9. Viswanathan, S.R. and G.Q. Daley, Lin28: A microRNA regulator with a macro role. Cell, 2010. 140(4): p. 445–9. Wang, T., et al., Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med, 2004. 10(1): p. 48–54. Weaver, C.T., et al., IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol, 2007. 25: p. 821–52. Weaver, B.K., et al., ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol, 2007. 27(13): p. 4603–16. Weber-Nordt, R.M., et al., Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem, 1996. 271(44): p. 27954–61. Wegrzyn, J., et al., Function of mitochondrial Stat3 in cellular respiration. Science, 2009. 323(5915): p. 793–7. Weiner, H.L., Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev, 2001. 182: p. 207–14.
Turning on and off the Immunological Switch
55
Wildin, R.S., et al., X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet, 2001. 27(1): p. 18–20. Williams, L.M., et al., Interleukin-10 suppression of myeloid cell activation – a continuing puzzle. Immunology, 2004. 113(3): p. 281–92. Williams, L.M., et al., Expression of constitutively active STAT3 can replicate the cytokinesuppressive activity of interleukin-10 in human primary macrophages. J Biol Chem, 2007. 282(10): p. 6965–75. Wohlfert, E. and Y. Belkaid, Plasticity of T reg at infected sites. Mucosal Immunol, 2010. 3(3): p. 213–5. Wolk, K., et al., IL-22 increases the innate immunity of tissues. Immunity, 2004. 21(2): p. 241–54. Wynn, T.A., IL-13 effector functions. Annu Rev Immunol, 2003. 21: p. 425–56. Xu, Q., et al., Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 2005. 24(36): p. 5552–60. Yamamoto, M. and K. Takeda, Role of nuclear IkappaB proteins in the regulation of host immune responses. J Infect Chemother, 2008. 14(4): p. 265–9. Yang, J., et al., Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev, 2007. 21(11): p. 1396–408. Yasukawa, H., et al., IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol, 2003. 4(6): p. 551–6. Yen, H.R., et al., Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol, 2009. 183(11): p. 7161–8. Yoshimura, A., T. Naka, and M. Kubo, SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol, 2007. 7(6): p. 454–65. Yu, H. and R. Jove, The STATs of cancer – new molecular targets come of age. Nat Rev Cancer, 2004. 4(2): p. 97–105. Yu, C.L., et al., Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science, 1995. 269(5220): p. 81–3. Yu, H., D. Pardoll, and R. Jove, STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 2009. 9(11): p. 798–809. Zeng, B., et al., Tumor-induced suppressor of cytokine signaling 3 inhibits toll-like receptor 3 signaling in dendritic cells via binding to tyrosine kinase 2. Cancer Res, 2008. 68(13): p. 5397–404. Zhang, X., J.P. Edwards, and D.M. Mosser, Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol, 2006. 177(2): p. 1282–8. Zhang, S.Y., et al., Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev, 2008. 226: p. 29–40. Zhu, J., H. Yamane, and W.E. Paul, Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol, 2010. 28: p. 445–89. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 2005. 5(4): p. 263–74.
The Angiogenic Switch: Role of Immune Cells Douglas M. Noonan, Agostina Ventura, Antonino Bruno, Arianna Pagani, and Adriana Albini
Keywords Angiogenesis • Endothelial cells • Innate immunity • Specific immunity
Introduction Angiogenesis is a frequent hallmark of inflammation; in acute inflammation angiogenesis occurs to revascularize damaged tissues, with subsequent vascular pruning and maturation, which results in restoration of an adequate blood supply to the tissue involved. Angiogenesis is also a characteristic of chronic inflammation, and may be one of the links between inflammation and cancer (Colotta et al. 2009; Kobayashi and Lin 2009). In addition to excessively proliferating tumor cells, tumors are tissues that contain host components; these “nontransformed” components include stromal cells, an extensive, although poorly organized, vascular network and a characteristic inflammatory infiltrate. In the absence of host support, a tumor cannot grow to clinically relevant dimensions. Experimental studies have shown that tumors without a vasculature are limited to only a few cubic millimeter in dimension, as formation of a new blood supply is required to overcome physical limitations for diffusion of nutrients and oxygen, concepts born out in clinical application (Ferrara and Kerbel 2005; Folkman 2006; Hanahan and Folkman 1996; Hanahan and Weinberg 2000; Kerbel and Folkman 2002). A critical step in tumor progression is acquisition of the capacity to form a new vasculature, a process referred to as the angiogenic switch (Hanahan and Folkman 1996; Hanahan and Weinberg 2000). In the absence of an angiogenic switch, nascent tumors remain as small, clinically indolent hyperplastic foci, a condition often noted in autopsies of several tissues (Bergers and Benjamin 2003). The importance of the angiogenic
D.M. Noonan (*) Department of Experimental Medicine, Università degli Studi dell’Insubria, Varese, Italy e-mail:
[email protected]
F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_5, © Springer Science+Business Media, LLC 2011
57
58
D.M. Noonan et al.
switch, and particularly the concept that this could be prevented clinically, has led to extensive examination of what triggers it. One obvious source of angiogenic factors is the tumor cells themselves. Tumor cells are known to produce a wide range of pro-angiogenic substances, the most crucial is vascular endothelial growth factor: VEGF (Ferrara and Kerbel 2005). VEGF is a prototypic angiogenic factor involved in physiological angiogenesis, as hypoxia induces VEGF production largely through the hypoxia sensing factor HIF1a (Pouyssegur et al. 2006). While tumors may be hypoxic, this does not seem to be the only factor leading to VEGF over-expression, as oncogene activation and metabolic mechanisms appear to also induce tumor VEGF production even in normoxia (Kroemer and Pouyssegur 2008). Thus one mechanism for “flipping” on the angiogenic switch is oncogenesis itself. However, in addition to the role of tumor cells themselves, it is increasingly recognized that host cells also represent key sources of angiogenic agents and are likely prominent modulators of the angiogenic switch (Albini et al. 2005; Brigati et al. 2002; Coussens and Werb 2002; De Visser et al. 2006; Noonan et al. 2008; Orimo and Weinberg 2006). Particularly conspicuous is the role of tumor inflammation and immune cells in driving and orchestrating tumor angiogenesis (Albini et al. 2005; Brigati et al. 2002; Coussens and Werb 2002; De Visser et al. 2006; Mantovani et al. 2002; Noonan et al. 2008; Sica and Bronte 2007). Immune cells are also able to produce VEGF, the role of this is controversial, as ablation of VEGF specifically in all myeloid cells a murine model actually resulted in accelerated tumor growth (Stockmann et al. 2008), apparently due to a more organized and functional vascular network. VEGF from either myeloid or tumor compartments alone could support tumor angiogenesis and growth, loss of both led to a drastic reduction in angiogenesis, while expression in both compartments produced the typical poorly functional tumor vasculature (Stockmann et al. 2008). The observation that most tumors contain numerous inflammatory leukocytes led to the concept of a functional link between chronic inflammation and cancer (Sica and Bronte 2007). Tumor-associated inflammation is largely sustained by a constant influx of myelomonocytic cells that support the tissue remodeling and angiogenesis needed for tumor growth and progression (Sica and Bronte 2007). Clinical studies have provided evidence for a clear association between an increased number/density of tumor-associated macrophages (TAM) and poor prognosis in a variety of murine and human malignancies (Gordon 2003; Martinez et al. 2006; Sica and Bronte 2007). Thus many tumors require a constant influx of inflammatory cells to support the angiogenesis and stromal remodeling needed for their growth (Sica and Bronte 2007). This is mediated by tumorderived factors, which cause enhanced myelopoiesis and the accumulation and functional differentiation of myelomonocytic cells at the tumor site. In addition to innate immune cells, cells of the specific immune system also appear to influence the angiogenic switch (Brigati et al. 2002; De Visser et al. 2006; Noonan et al. 2008). Here we review the roles these diverse cell types may have flipping the angiogenic switch on, and potential approaches towards flipping off the angiogenic switch.
The Angiogenic Switch: Role of Immune Cells
59
Innate Immunity Macrophages and the Macrophage Polarization Paradigm Macrophage heterogeneity reflects the plasticity of these cells in response to microenvironmental signals, such as cytokines and microbial products, which in turn produces diverse functional programs and influences polarization of the specific immune system. Macrophages have a key role in promoting the orientation of the adaptive immune response typically towards either a Th1 or Th2 response, as well as by expressing specialized and polarized effector functions themselves (Goerdt and Orfanos 1999; Gordon 2003; Mantovani et al. 2002; Sica and Bronte 2007). Numerous data indicate that macrophages can be phenotypically polarized by the microenvironment to mount specific functional programs: either the classical (or M1) activation to potentially potent effector cells able, for example, to kill tumor cells, or the alternative M2 activation that is closely related to the tumor-associated macrophage (TAM) profile. M1 macrophages are generally characterized by an IL-12high, IL-23high, IL-10low phenotype, with obvious consequences in driving a Th1 response. These M1 cells also can produce copious amounts of reactive oxygen and nitrogen intermediates (Goerdt and Orfanos 1999; Gordon 2003; Mantovani et al. 2002; Sica and Bronte 2007). The M1 macrophages, a terminology mirroring the Th1 nomenclature, are part of the afferent and efferent limbs of Th1 responses; and help mediate resistance against intracellular parasites and tumors. On the other extreme we have alternatively activated, or “M2,” macrophages induced by cytokines such as IL-4 and IL-13. The M2-polarized functions are generally oriented to tissue remodeling and repair, immunosuppression and angiogenesis (Mantovani et al. 2008). M2 is a generic terminology for various forms of macrophage activation other than the classic M1 activation profile, and includes cells exposed IL-4 or IL-13, immune complexes, IL-10, and glucocorticoid hormones. M2 macrophages generally share an IL-12low, IL-23low, IL-10high phenotype. Substantial data show that an M2 polarized inflammation is a key feature of the tumor microenvironment (Mantovani et al. 2002; Sica and Bronte 2007), influencing angiogenesis, invasion and metastasis, as well as subversion of adaptive immunity. The diverse polarized macrophages differ in terms of receptor expression, cytokine production profiles, chemokine repertoires and effector function. Induction of an M2 phenotype appears to be due to STAT3 activation and/or inhibition of STAT1 phosphorylation (Hu et al. 2003; Ito et al. 1999; Mantovani et al. 2002; Riley et al. 1999), and down-regulation of p65 containing NF-kB along with generation of p50 NF-kB homodimers (Porta et al. 2009). NF-kB is a key axis in tumor angiogenesis, in endothelial cells induction of the angiogenic program involves NF-kB (Karin 2006), and numerous angiogenesis inhibitors block NF-kB activation (see Albini et al. (2007) for review). In addition, the cytotoxic chemotherapy and radiotherapy widely used in treatment of cancer patients also induces NF-kB both in normal and cancer cells (Nakanishi and Toi 2005), with the result of inducing inflammation, angiogenesis and reconstruction of the tumor. Simultaneous use of NSAIDs or cortisone could enhance the efficacy of these treatments.
60
D.M. Noonan et al.
Tumor Associated Macrophages (TAMs) Tumor inflammation was historically considered to be part of an abortive rejection process, now the role of tumor associated macrophages (TAMs), has undergone extensive re-evaluation (Fig. 1), TAMs are now considered to express properties that facilitate tumor growth and progression by stimulating tumor-cell proliferation, angiogenesis and favoring invasion and metastasis (Balkwill and Mantovani 2001; Lewis and Murdoch 2005; Mantovani et al. 2002; Pollard 2004). TAMs derived from circulating monocytic precursors are directed into the tumor by chemokines, largely through hypoxia-dependent mechanisms involving VEGF and the CXCL12/ CXCR4 axis (Mantovani et al. 2002; Saccani et al. 2006; Schioppa et al. 2003).
Tumor “Macro” environment VEGF CXCL12 GM-CSF… B cells
ICs “eDC” Tc, Th1
Treg, Th2 cells
CECs, CEPs…
TEM MDSC
M0 CFUProMonocyte Macrophage monocytic monocyte
ProCFUgranulocyte myelocyte
Dendritic cells
Eosinophilic cells
Neutrophil
Angioprevention
Hematopoietic pluripotent stem cell
mDC
Monocytic MDSC
T cells
Neutrophilic MDSC
Mast cells
iDC M2 TAM
M1 Macrophage
N2 Neutrophil
N1 Neutrophil
“dNK” cells
Tumor Microenvironment Mast cells NK cells
TGFβ, Chemotherapy Radiotherapy…
CD16+ NK cells
Antiangiogenic immunotherapy
Fig. 1 Tumors have a major influence on the immune system, and as a result the immune system becomes a driving force in tumor angiogenesis. Systemic “macroenvironment” effects include mobilization of endothelial precursors (circulating endothelial precursors (CEPs) and endothelial cells (CECs)) that participate in tumor vessel production by vasculogenesis; generation of myeloid derived suppressor cells (MDSCs), T cell skewing and suppressive Treg generation, B cell production of antibodies that form immune complexes (ICs). Local effects include polarization towards M2 Tumor infiltrating macrophages (TAMs), Tie2 expressing macrophages (TEMs), various forms of MDSCs, N2 pro-angiogenic neutrophils, possibly NK cells with potential activities similar to decidual NK cells (dNK), mast cells and immature dendritic cells (iDC) can contribute to angiogenesis as can dendritic transdifferentiation to endothelial cells (eDC). Chemotherapy and radiotherapy may also have similar local effects by activating NF-kB. Therapeutic approaches include angioprevention, inhibiting many activation processes before they start, or forcing an immune “reset” towards a Th1/M1/N1 polarization, eventually restoring a cytotoxic NK and T cell state
The Angiogenic Switch: Role of Immune Cells
61
Analyses of TAMs indicate that these express an M2-associated phenotype, with a similar transcriptome profile oriented toward tissue remodeling and repair, immuno-suppression and angiogenesis (Biswas et al. 2006; Mantovani et al. 2002; Murdoch et al. 2008). TAMs recruited into tumors accumulate in hypoxic areas; they are attracted and/or immobilized into avascular (Leek et al. 1996) and necrotic (Leek et al. 1999) areas of hypoxia, apparently by both specific factors produced by hypoxic tumor cells and by a direct immobilizing effect of hypoxia on macrophages (O’Sullivan and Lewis 1994). Higher numbers of TAMs extravasate from the bloodstream into tumors containing high levels of necrosis as compared to those with little or no necrosis (Harmey et al. 1998). Recent data show that TAMs are stimulated by hypoxia in such sites to cooperate with tumor cells to promote revascularization (Murdoch et al. 2008; Schioppa et al. 2003). The level of hypoxia present in ischemic areas of tumors stimulates the release of VEGF from human macrophages in vitro (Lewis et al. 1999). Moreover, TAMs upregulate VEGF in avascular and necrotic tumor areas (Lewis et al. 1999). TAMs respond to hypoxia through upregulation of transcriptional factors including HIFs 1 and 2 that activate a series of glycolytic, angiogenic, and proinvasive genes. TAMs are known to be an important source of proangiogenic factors such as VEGF (Leek et al. 2000), TNFa (Pusztai et al. 1994), IL-8 (Fujimoto et al. 2000), and CXCL12 (Schioppa et al. 2003). Angiogenesis is also facilitated by TAM-derived proteases released in tumors. These include the matrix metalloproteinases (MMPs 1, 2, 3, 9, and 12) (Deryugina and Quigley 2010; Egeblad and Werb 2002), urokinase plasminogen activator and its receptor (Pyke et al. 1993), and plasmin. These enzymes release various proangiogenic molecules bound to heparan sulfate on proteoglycans, as well as fragments of fibrin and collagen. Their combined action results in the degradation of the basement membrane and other ECM components, destabilization of the local vasculature and promotion of the migration and proliferation of endothelial cells. This proteolytic activity also contributes to the migration and extravasation of tumor cells during the metastatic process (Deryugina and Quigley 2010; Egeblad and Werb 2002). A series of studies have found that hypoxia itself promotes an invasive program that favors metastatic dissemination, and that VEGF based angiogenesis inhibition can result in a greater incidence in metastasis (reviewed in Schmidt (2009)).
Tie2 Expressing Macrophages A TAM subset that appears to have a particularly intriguing role in angiogenesis are the Tie2 expressing macrophages, or TEMs (De Palma et al. 2007; De Palma and Naldini 2009). These cells are closely associated with the forming vasculature, and are found outside the endothelial cells (Fig. 1). They do not appear, however, to incorporate into the vasculature as can other precursors. Specific deletion of this TAM subset results in inhibition of angiogenesis and repression of tumor growth, indicating that the TEMs are key targets for anti-angiogenic
62
D.M. Noonan et al.
therapy (De Palma et al. 2007; De Palma and Naldini 2009; Pulaski et al. 2009). Further, these cells also can be used as “Trojan horses” to vehicle anti-angiogenic and anti-tumor therapies (De Palma and Naldini 2009).
Myeloid Derived Suppressor Cells (MDSCS) Myeloid derived suppressor cells (MDSCs) represent a range of poorly differentiated myeloid precursor that shares markers for both monocyte and granulocytes (Serafini et al. 2006). These cells were originally identified in murine models due to their potent immuno-suppressive activity through a variety of mechanisms, including production of TGFb, high level expression of inducible nitric oxide synthase (NOS2) and arginase (Arg1) which deplete arginine within the tumor microenvironment, as well as mechanims that deplete of cystine and cysteine (Srivatsa et al. 2010), all of which contribute to T cell suppression and apoptosis (Bronte and Zanovello 2005; Kusmartsev and Gabrilovich 2006). There are diverse subsets of murine MDSCs with more monocytic or granulocytic phenotypes (Fig. 1), which apparently have diverse immuno-suppressive potentials (Bronte 2009; De Santo et al. 2005; Dolcetti et al. 2010). MDSCs are also powerful promoters of angiogenesis as well, by MMP production (Yang et al. 2004) as well as other mechanisms such as VEGF secretion (Sica and Bronte 2007). Stat3 activation in myeloid cells has been linked to production of angiogenic factors such as bFGF and VEGF (Kujawski et al. 2008) and angiogenesis. MDSC tumor infiltrates have been reported to be responsible for the resistance of tumors to anti-angiogenic therapy (Shojaei et al. 2007a, 2009), largely via production of diverse angiogenic factors such as Bv8 (Shojaei et al. 2007b) review: (Shojaei and Ferrara 2008). Myeloid precursors have also been found to be elevated in human cancers (Almand et al. 2001; Diaz-Montero et al. 2009; Ostrand-Rosenberg and Sinha 2009; Rodriguez et al. 2009) and to correlate with disease status (Diaz-Montero et al. 2009) where again represent a variety of myeloid cells blocked at different stages of maturation along the monocytic or granulocytic pathways (OstrandRosenberg and Sinha 2009). The role of human MDSCs in tumor angiogenesis is not fully understood. The question remains as to how to target these cells, approaches to this have largely focused on targeting the immune-suppressive activity, including use of NO donors such as Nitroaspirin (De Santo et al. 2005; Ugel et al. 2009), interfering with recruitment and subsequent angiogenesis by blocking the CSF-1 receptor (Priceman et al. 2010).
Granulocytes Neutrophils are the most abundant circulating leukocyte in humans and the primary granulocytes involved in angiogenesis. These cells play a key role in responses diverse infective agents, based mostly on pattern recognition mechanisms. They are
The Angiogenic Switch: Role of Immune Cells
63
quickly and massively recruited into areas producing danger signals, they store in granules several soluble mediators that can be rapidly secreted in both physiological and pathological conditions, as well as respiratory burst production of reactive oxygen species (O2−, H2O2, HOCl). These factors can produce tissue destruction and lysis, which result in significant anti-tumor activity (Di Carlo et al. 2001). Neutrophils are also sources for several cytokines (including TNFa, IL-1b, IL-1Ra, IL-12 and VEGF), and chemokines (including CXCL1, CXCL-8, CXCL9, CXCL10, CCL3, and CCL4) (Scapini et al. 2000). What neutrophils lack in terms of the levels produced for some secreted products is usually more than made up for by the abundance of these cells in many pathological conditions. These products can influence the immune response and polarization as well as promote tissue reconstruction and angiogenesis. We noted that neutrophils appeared to lead the invasion of vessel sprouts into a matrigel sponge containing tat (Benelli et al. 2000). The use of corneal pocket assays indicated that angiogenesis induced by IL-8 (CXCL8), a chemokine highly active on neutrophils and a known angiogenic factor acted, through CXCR2 receptors expressed on endothelial cells (Addison et al. 2000). However, not all endothelial cells express CXCR2 and subsequent studies demonstrated that neutrophils were required for an angiogenic response to CXCL8 and other chemokines active on neutrophils in vivo (Benelli et al. 2002). The link between CXCL8 production and subsequent tumor-associated neutrophil (TAN) recruitment leading to release of angiogenic factors by these cells that induce angiogenesis has been confirmed in tumor models, where this cascade was shown to be critical in linking ras oncogene expression to tumor growth and angiogenesis (Sparmann and BarSagi 2004). TANs have also been shown to be a key source of MMP9, a protease required for the angiogenic switch and tumor growth, in skin carcinogenesis and the Rip-Tag pancreatic cancer models (Coussens et al. 2000; Nozawa et al. 2006). Neutrophils are able to produce a broad range of angiogenic factors (Schruefer et al. 2005, 2006). The inflammation-associated angiogenic response during wound healing was significantly delayed in animals harboring genetic defects that compromise neutrophil recruitment, in particular deletion of CXCR2 (Devalaraja et al. 2000) or CD18 (Schruefer et al. 2006). Similarly, a dual src kinase knock-out that compromised neutrophil function also blocked the ability to induce angiogenesis in response to CXCL1 (Scapini et al. 2004). In this case the neutrophils were recruited into the site, but were unable to release VEGF, a factor critical for induction of the angiogenic response. Intriguingly, in a major site of physiological angiogenesis in adults, the endometrium, neutrophils closely associate with the growing vessels and appear to be the primary source of VEGF for these vessels (Gargett et al. 2001; Heryanto et al. 2004; Lin et al. 2006; Na et al. 2006), thus intimately nurture angiogenesis in this organ. The divergent roles for neutrophils, on one hand able to produce anti-tumor tissue destruction, on the other to supply angiogenic factors and tissue regeneration signals, lead to the speculation that several subsets of neutrophils may exist (Fig. 1), in particular pro- and anti-angiogenic subsets (Noonan et al. 2008). This speculation based on the observations of multiple neutrophil subsets previously reported
64
D.M. Noonan et al.
(Tsuda et al. 2004), as well as the role of neutrophils in pro- and anti-tumor effects on PPARa knock-out models (Kaipainen et al. 2007). Tumors injected into PPARa knock-out mice remained in an essentially dormant state. This was associated with notable neutrophil recruitment and production of the anti-angiogenic matrix molecule thrombospondin (Kaipainen et al. 2007). While neutrophil depletion in wildtype mice slowed tumor growth, consistent with a pro-angiogenic activity and previous observations (Nozawa et al. 2006; Pekarek et al. 1995), neutrophil depletion in the PPARa knock-out mice permitted angiogenesis and tumor growth, indicating an anti-tumor phenotype dictated by the loss of PPARa (Kaipainen et al. 2007). Additional support for the existence of multiple neutrophil subsets with either pro- or anti-tumor activity comes from analyses of the effects of TGFb blockades. TGFb is an immunosupressive cytokine that itself has a dichotomous activity in cancer; inhibitory at early stages, TGFb is frequently found in the tumor microenvironment at later stages where it enhances tumor progression and creates immuno-suppression (Bierie and Moses 2006). Blockage of TGFb in diverse tumor models can lead to enhanced CD8+ T cell activity and tumor repression (Ge et al. 2006; Nam et al. 2008; Suzuki et al. 2007). Under a TGFb blockade, there is also an accumulation of neutrophils within the tumor, associated with direct neutrophil killing of tumor cells as well as enhanced CD8+ T cell activation (Fridlender et al. 2009). Depletion of neutrophils under the TGFb blockade impaired CD8+ T cell activation and enhanced tumor growth, while in control animals TAN depletion resulted in slower growth and increased CD8+ activation (Fridlender et al. 2009), similar to the observations with PPARa knock-out mice. The authors suggested the existence of two different neutrophil subsets: pro-tumor neutrophils in control animals linked to the presence of TGFb, termed “N2” neutrophils in concordance with the M2/Th2 paradigm, and anti-tumor neutrophils that were recruited into tumors when TGFb was rendered inactive, concordantly termed “N1” neutrophils (Fig. 1). These findings were similar in two different tumor types (NSCLC and mesothelioma) and in three different mice strains, suggesting that the polarization of neutrophils may be a general feature of tumor microenvironment (Fridlender et al. 2009). The concept of N1–N2 polarization of TAN was supported by a limited transcription analysis with similarities to corresponding macrophage populations, based on eight key genes. The TGFb blockade resulted in significantly lower levels of arginase, CCL2, CCL3 and CCL5, and higher levels of ICAM1 and TNFa (Fridlender et al. 2009). The N2 cells also appeared to have enhanced expression of VEGF, which together with enhanced TNFa could promote vascularization, however the potential role in angiogenesis of these cells was not investigated.
Mast Cells Mast cells were initially suggested to be involved in vascularization during rheumatoid arthritis (Maruotti et al. 2007; Ribatti et al. 1988), and appear to play a key role in angiogenesis in allergic reactions as well (Crivellato et al. 2009). These cells are
The Angiogenic Switch: Role of Immune Cells
65
intimately involved in vascularization of hematoligic malignancies, (Ribatti et al. 2009), where they also appear to be able to integrate into the vessel wall by vascular mimicry (Nico et al. 2008). Mast cells play a significant role in angiogenesis in at diverse solid tumor types (Crivellato et al. 2008; Murdoch et al. 2008; Ribatti et al. 2001). In tumors, mast cells contribute to the angiogenic switch by production of diverse angiogenesis-associated cytokines and chemokines (Murdoch et al. 2008; Ribatti et al. 2004). Further, mast cell derived proteases promote premalignant angiogenesis (Coussens et al. 1999; Ranieri et al. 2009; Soucek et al. 2007), and are becoming a target for anti-angiogenic therapies (Galinsky and Nechushtan 2008; Liu et al. 2009).
Dendritic Cells Dendritic cells (DCs) constitute a heterogeneous population of antigen presenting cells found in virtually every tissue, which through their antigen presentation and cytokine secretion activity link innate and adaptive immunity (Lanzavecchia and Sallusto 2001; Steinman and Banchereau 2007). DC recruitment into tumors has been documented in several studies (Balkwill 2004; Sozzani et al. 2001; Ueno et al. 2007; Vicari et al. 2004), although their clinical relevance is a matter of debate. Within the tumor microenvironment, DCs generally show an immature phenotype characterized by the low costimulatory molecule expression and low IL-12 production (Vermi et al. 2003; Vicari et al. 2004), apparently due to cytokines such as IL-10, IL-6, TGFb, VEGF and M-CSF that block differentiation and maturation (Ratta et al. 2002; Steinman and Banchereau 2007). Tumor associated DCs maintain tolerance to tumor antigens, promote tumor progression and dissemination (Mantovani et al. 2002) as well as angiogenesis and tumor growth (Sozzani et al. 2007) (Fig. 1).
DCs and Angiogenesis DCs express a wide array of pro- and anti-angiogenic mediators that might have a significant role in those pathophysiological settings characterized by DC activation and angiogenesis, including inflammation, would healing, atherosclerosis and tumor growth (Sozzani et al. 2007). The pro- and anti-angiogenic mediators released by DCs belong to distinct families and can modulate neovascularization by different mechanisms of action (Mantovani 2004; Sozzani 2005). 1. DCs release classical angiogenic growth factors that act on the endothelium by engaging the corresponding signaling receptors on cell surface. Conventional DCs express VEGF-A, FGF2 and ET-1 (Guruli et al. 2004; Riboldi et al. 2005). Alternatively activated DCs can secrete high amounts of VEGF-A and low levels of FGF2 (Bourbie-Vaudaine et al. 2006; Piqueras et al. 2006).
66
D.M. Noonan et al.
2. DCs can release cytokines devoid of a direct pro-angiogenic activity but endowed with the capacity to increase the responsiveness of endothelial cells to classic angiogenic growth factors or upregulate the production of angiogenic growth factors by other cell types. These activities include upregulation of TNFa (Caux et al. 1994; de Graaf et al. 1996; Verhasselt et al. 1997), Osteopontin (OPN), (Konno et al. 2006) triggering TEM recruitment and activation (Naldini et al. 2006), IL-6 and TGFb, (Verhasselt et al. 1997), and the angiogenic chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL8 and CCL2 (Means et al. 2003; Scimone et al. 2005; Vermi et al. 2006). Activated plasmacytoid DCs can express the pro-angiogenic molecules CXCL8 and TNFa (Curiel et al. 2004; Penna et al. 2002; Piqueras et al. 2006). 3. DCs can transdifferentiate into endothelial cells (Coukos et al. 2005), similar to that suggested for diverse hematopoietic precursors, in particular circulating endothelial precursors (CEPs) and endothelial cells (CECs) (Dome et al. 2009). 4. In contrast, DCs can release cytokines that repress angiogenesis such as IL-12 (Albini et al. 2009; Noonan et al. 2008; Trinchieri 2003), IFNg (Trinchieri 2003) and the angiostatic chemokines CXCL9, CXCL10 and CCL21 (Piqueras et al. 2006). Plasmacytoid DCs are a source of IFNa (Asselin-Paturel and Trinchieri 2005) an anti-angiogenic cytokine (Albini et al. 2000; Brassard et al. 2002; Indraccolo et al. 2002). 5. DCs produce anti-angiogenic extracellular matrix (ECM) components including thrombospondin-1 (TSP-1) (Doyen et al. 2003; Rusnati and Presta 2006) and long-pentraxin-3 (PTX3) (Doni et al. 2003, 2006; Garlanda et al. 2005).
NK Cells Multiple human NK cells subsets have been found, the major subset of CD56dimCD16+ NK cells constitutes about 90–95% of peripheral blood NK cells, readily kill target cells upon proper recognition, and secrete low cytokine levels (Cooper et al. 2001). In contrast, the CD56brightCD16− NK cells (about 5–10% of peripheral blood NK cells) are poorly cytotoxic but produce large amounts of cytokines, including IFNg, TNFa, and GM-CSF. Only CD56bright NK cells express secondary lymphoid organ homing markers such as CCR7, CD62L, and CXCR3, resulting in an enrichment of this subset in lymphoid organs and sites of inflammation (Campbell et al. 2001; Fehniger et al. 2003; Ferlazzo et al. 2004b). The question of whether or not the development of the human subsets is interconnected has been under investigation for some time. Recently, a number of studies suggested that CD56brightCD16− NK cells are able to differentiate into CD56dimCD16+ NK cells upon prolonged activation (Chan et al. 2007; Romagnani et al. 2007), while the reverse may be possible in the presence of TGFb (Keskin et al. 2007).
The Angiogenic Switch: Role of Immune Cells
67
NK Localization NK subset distribution differs between distinct anatomical sites such as secondary lymphoid organs, lung, liver, and skin, suggesting specialization (Ferlazzo and Munz 2004; Ferlazzo et al. 2004a; Gregoire et al. 2007; Trinchieri 1989). A particular CD56superbrightCD16− NK cell subset is found in the deciduas during implanatation (Hanna et al. 2006; Hanna and Mandelboim 2007). Decidual or dNK cells are less cytotoxic (Kopcow et al. 2005), they guide decidual angiogenesis by producing angiogenic factors (Hanna et al. 2006) as well as promote decidual cellularity (Ashkar et al. 2000). The CD56brightCD16− NKcell subset is recruited into tumors (Carrega et al. 2008), and we have speculated that tumor infiltrating NK cells may be switched to an angiogenic phenotype (Fig. 1) similar to dNK cells (Noonan et al. 2008). However, NK cells infiltration appears to correlate with a better prognosis in gastric (Ishigami et al. 2000), colorectal (Coca et al. 1997), and lung carcinomas (Takeo et al. 1986; Villegas et al. 2002).
Specific Immunity Much of this volume will be dedicated to specific immunity, here we rapidly focus on the role T and B cells may play in tumor angiogenesis. Early studies indicated that an efficacious CD8+ cytotoxic T cell response against tumors required induction of an IFNg mediated angiogenesis blockade (Qin et al. 2003). However, an altered activation of CD4+ T cells can result in compromised macrophage effector function and enhanced angiogenesis and tumor growth in breast cancer models (DeNardo et al. 2009). The end result is a conditioning of a Th2 and Treg cell response (Fig. 1) that results in generation of a pro-tumor environment (Ruffell et al. 2010). In contrast, in a skin cancer model with induction of chronic inflammation, B cells were found to be necessary for tumor development (de Visser et al. 2005). The involvement of B cells was associated with deposition of immune complexes within the sites of early tumorigenesis (Fig. 1). Since most cells of the immune system have Fc receptors that modulate function, and in particular immune complexes play a role in generating M2b macrophages (Martinez et al. 2008), immune complexes could be expected to enhance angiogenesis (Fig. 1). However, if immune complexes are indeed angiogenic, then experimental use of function blocking antibodies to discern the role of specific components in angiogenesis needs to be taken with caution.
Conclusions Tumors induce both local microenvironmental conditioning as well as systemic (Macro-environmental) effects. Local effects include hypoxia, glycolysis and low extracellular pH, necrotic debris signals, TGFb and other cytokines, to skew most
68
D.M. Noonan et al.
immune cells into a chronic inflammation, would-healing, pro-tumor phenotype flipping on the angiogenic switch. Systemic effects often target the bone marrow through elevated cytokine and chemokines such as VEGF, CXCL12 and others that mobilized precursor (including endothelial) and immature cells (such as MDSCs) which also exert immuno-suppressive and pro-angiogenic effects when homing to the tumor. Chemotherapy and radiotherapy may well do their share in promoting a chronic inflammatory and pro-angiogenic state. The final question is how to flip off the inflammation associated angiogenic switch. One approach is to jam the switch before it can be turned on, increasing the threshold; this is the concept behind angioprevention (Tosetti et al. 2002). Another is use of NF-kB blocking agents (Albini et al. 2007; Baud and Karin 2009; Karin 2006; Nakanishi and Toi 2005), ideally targeting p50 homodimer formation (Porta et al. 2009), or the use of pathogen-associated molecular patterns (PAMPs) agonists (Damiano et al. 2007; Makkouk and Abdelnoor 2009; Smits et al. 2008) to force Th1/M1/N1 skewing, essentially taking the Coley toxin approach into modern medicine. Acknowledgements These studies were supported by grants from the AIRC (Associazione Italiana per la Ricerca sul Cancro), the Istituto Superiore della Sanità Alleanza contro il Cancro foundation, the Ministero della Sanità Progetto Finalizzato, the MIUR Progetto Finalizzato and FIRB, the Università degli studi dell’Insubria and the Compagnia di San Paolo. AV is the recipient of a FIRB (Fondazione Italiana per la Ricerca sul Cancro) fellowship, AB and AP are in the Molecular and Cellular Biology PhD program of the University of Insubria.
References Addison CL, Daniel TO, Burdick MD, et al. (2000). The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165: 5269–5277. Albini A, Marchisone C, Del Grosso F, et al. (2000). Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 156: 1381–1393. Albini A, Tosetti F, Benelli R, et al. (2005). Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 65: 10637–10641. Albini A, Noonan DM, and Ferrari N (2007). Molecular pathways for cancer angioprevention. Clin Cancer Res 13: 4320–4325. Albini A, Brigati C, Ventura A, et al. (2009). Angiostatin anti-angiogenesis requires iL-12: The innate immune system as a key target. J Transl Med 7: 5. Almand B, Clark JI, Nikitina E, et al. (2001). Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 166: 678–689. Ashkar AA, Di Santo JP, and Croy BA (2000). Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 192: 259–270. Asselin-Paturel C and Trinchieri G (2005). Production of type I interferons: Plasmacytoid dendritic cells and beyond. J Exp Med 202: 461–465. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4: 540–550. Balkwill F and Mantovani A (2001). Inflammation and cancer: Back to virchow? Lancet 357: 539–545.
The Angiogenic Switch: Role of Immune Cells
69
Baud V and Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev 8: 33–40. Benelli R, Barbero A, Ferrini S, et al. (2000). Human immunodeficiency virus transactivator protein (tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: Implications for tat-mediated pathogenesis. J Infect Dis 182: 1643–1651. Benelli R, Morini M, Carrozzino F, et al. (2002). Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. Faseb J 16: 267–269. Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410. Bierie B and Moses HL (2006). Tumour microenvironment: TGFbeta: The molecular jekyll and hyde of cancer. Nat Rev Cancer 6: 506–520. Biswas SK, Gangi L, Paul S, et al. (2006). A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112–2122. Bourbie-Vaudaine S, Blanchard N, Hivroz C, et al. (2006). Dendritic cells can turn cd4+ t lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J Immunol 177: 1460–1469. Brassard DL, Grace MJ, and Bordens RW (2002). Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71: 565–581. Brigati C, Noonan DM, Albini A, et al. (2002). Tumors and inflammatory infiltrates: Friends or foes? Clin Exp Metastasis 19: 247–258. Bronte V (2009). Myeloid-derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 39: 2670–2672. Bronte V and Zanovello P (2005). Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641–654. Campbell JJ, Qin S, Unutmaz D, et al. (2001). Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 166: 6477–6482. Carrega P, Morandi B, Costa R, et al. (2008). Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112: 863–875. Caux C, Massacrier C, Vanbervliet B, et al. (1994). Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180: 1263–1272. Chan A, Hong DL, Atzberger A, et al. (2007). CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J Immunol 179: 89–94. Coca S, Perez-Piqueras J, Martinez D, et al. (1997). The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79: 2320–2328. Colotta F, Allavena P, Sica A, et al. (2009). Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30: 1073–1081. Cooper MA, Fehniger TA, and Caligiuri MA (2001). The biology of human natural killer-cell subsets. Trends Immunol 22: 633–640. Coukos G, Benencia F, Buckanovich RJ, et al. (2005). The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 92: 1182–1187. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420: 860–867. Coussens LM, Raymond WW, Bergers G, et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382–1397. Coussens LM, Tinkle CL, Hanahan D, et al. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481–490. Crivellato E, Nico B, and Ribatti D (2008). Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett 269: 1–6. Crivellato E, Travan L, and Ribatti D (2009). Mast cells and basophils: A potential link in promoting angiogenesis during allergic inflammation. Int Arch Allergy Immunol 151: 89–97.
70
D.M. Noonan et al.
Curiel TJ, Cheng P, Mottram P, et al. (2004). Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64: 5535–5538. Damiano V, Caputo R, Garofalo S, et al. (2007). TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 104: 12468–12473. De Graaf JH, Tamminga RY, Dam-Meiring A, et al. (1996). The presence of cytokines in langerhans’ cell histiocytosis. J Pathol 180: 400–406. De Palma M and Naldini L (2009). Tie2-expressing monocytes (tems): Novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 1796: 5–10. De Palma M, Murdoch C, Venneri MA, et al. (2007). Tie2-expressing monocytes: Regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28: 519–524. De Santo C, Serafini P, Marigo I, et al. (2005). Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 102: 4185–4190. De Visser KE, Korets LV, and Coussens LM (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411–423. De Visser KE, Eichten A, and Coussens LM (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24–37. Denardo DG, Barreto JB, Andreu P, et al. (2009). CD4(+) t cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91–102. Deryugina EI and Quigley JP (2010). Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim Biophys Acta 1803:103–120. Devalaraja RM, Nanney LB, Du J, et al. (2000). Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115: 234–244. Di Carlo E, Forni G, Lollini P, et al. (2001). The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339–345. Diaz-Montero CM, Salem ML, Nishimura MI, et al. (2009). Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49–59. Dolcetti L, Peranzoni E, Ugel S, et al. (2010). Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40: 22–35. Dome B, Timar J, Ladanyi A, et al. (2009). Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol 69: 108–124. Doni A, Peri G, Chieppa M, et al. (2003). Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 33: 2886–2893. Doni A, Michela M, Bottazzi B, et al. (2006). Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: Stimulation by iL-10 and inhibition by IFN-gamma. J Leukoc Biol 79: 797–802. Doyen V, Rubio M, Braun D, et al. (2003). Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med 198: 1277–1283. Egeblad M and Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174. Fehniger TA, Cooper MA, Nuovo GJ, et al. (2003). CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity. Blood 101: 3052–3057. Ferlazzo G and Munz C (2004). NK cell compartments and their activation by dendritic cells. J Immunol 172: 1333–1339. Ferlazzo G, Pack M, Thomas D, et al. (2004a). Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A 101: 16606–16611.
The Angiogenic Switch: Role of Immune Cells
71
Ferlazzo G, Thomas D, Lin SL, et al. (2004b). The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172: 1455–1462. Ferrara N and Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438: 967–974. Folkman J (2006). Angiogenesis. Annu Rev Med 57: 1–18. Fridlender ZG, Sun J, Kim S, et al. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-b: “N1” versus “N2” tan. Cancer Cell 16: 183–194. Fujimoto J, Sakaguchi H, Aoki I, et al. (2000). Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 60: 2632–2635. Galinsky DS and Nechushtan H (2008). Mast cells and cancer–no longer just basic science. Crit Rev Oncol Hematol 68: 115–130. Gargett CE, Lederman F, Heryanto B, et al. (2001). Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils. Hum Reprod 16: 1065–1075. Garlanda C, Bottazzi B, Bastone A, et al. (2005). Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337–366. Ge R, Rajeev V, Ray P, et al. (2006). Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type i receptor kinase in vivo. Clin Cancer Res 12: 4315–4330. Goerdt S and Orfanos CE (1999). Other functions, other genes: Alternative activation of antigenpresenting cells. Immunity 10: 137–142. Gordon S (2003). Alternative activation of macrophages. Nat Rev Immunol 3: 23–35. Gregoire C, Chasson L, Luci C, et al. (2007). The trafficking of natural killer cells. Immunol Rev 220: 169–182. Guruli G, Pflug BR, Pecher S, et al. (2004). Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 104: 2107–2115. Hanahan D and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57–70. Hanna J and Mandelboim O (2007). When killers become helpers. Trends Immunol 28: 201–206. Hanna J, Goldman-Wohl D, Hamani Y, et al. (2006). Decidual nk cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12: 1065–1074. Harmey JH, Dimitriadis E, Kay E, et al. (1998). Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 5: 271–278. Heryanto B, Girling JE, and Rogers PA (2004). Intravascular neutrophils partially mediate the endometrial endothelial cell proliferative response to oestrogen in ovariectomised mice. Reproduction 127: 613–620. Hu X, Li WP, Meng C, et al. (2003). Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 170: 4833–4839. Indraccolo S, Gola E, Rosato A, et al. (2002). Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 9: 867–878. Ishigami S, Natsugoe S, Tokuda K, et al. (2000). Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577–583. Ito S, Ansari P, Sakatsume M, et al. (1999). Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93: 1456–1463. Kaipainen A, Kieran MW, Huang S, et al. (2007). Pparalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One 2: e260. Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.
72
D.M. Noonan et al.
Kerbel R and Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727–739. Keskin DB, Allan DS, Rybalov B, et al. (2007). TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16-NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A 104: 3378–3383. Kobayashi H and Lin PC (2009). Angiogenesis links chronic inflammation with cancer. Methods Mol Biol 511: 185–191. Konno S, Eckman JA, Plunkett B, et al. (2006). Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. J Interferon Cytokine Res 26: 562–567. Kopcow HD, Allan DS, Chen X, et al. (2005). Human decidual nk cells form immature activating synapses and are not cytotoxic. Proc Natl Acad Sci U S A 102: 15563–15568. Kroemer G and Pouyssegur J (2008). Tumor cell metabolism: Cancer’s achilles’ heel. Cancer Cell 13: 472–482. Kujawski M, Kortylewski M, Lee H, et al. (2008). Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118: 3367–3377. Kusmartsev S and Gabrilovich DI (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237–245. Lanzavecchia A and Sallusto F (2001). The instructive role of dendritic cells on t cell responses: Lineages, plasticity and kinetics. Curr Opin Immunol 13: 291–298. Leek RD, Lewis CE, Whitehouse R, et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625–4629. Leek RD, Landers RJ, Harris AL, et al. (1999). Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991–995. Leek RD, Hunt NC, Landers RJ, et al. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190: 430–436. Lewis C and Murdoch C (2005). Macrophage responses to hypoxia: Implications for tumor progression and anti-cancer therapies. Am J Pathol 167: 627–635. Lewis JS, Lee JA, Underwood JC, et al. (1999). Macrophage responses to hypoxia: Relevance to disease mechanisms. J Leukoc Biol 66: 889–900. Lin YJ, Lai MD, Lei HY, et al. (2006). Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology 147: 1278–1286. Liu J, Divoux A, Sun J, et al. (2009). Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 15: 940–945. Makkouk A and Abdelnoor AM (2009). The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 31: 331–338. Mantovani A (2004). Chemokines in neoplastic progression. Semin Cancer Biol 14: 147–148. Mantovani A, Sozzani S, Locati M, et al. (2002). Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555. Mantovani A, Allavena P, Sica A, et al. (2008). Cancer-related inflammation. Nature 454: 436–444. Martinez FO, Gordon S, Locati M, et al. (2006). Transcriptional profiling of the human monocyteto-macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol 177: 7303–7311. Martinez FO, Sica A, Mantovani A, et al. (2008). Macrophage activation and polarization. Front Biosci 13: 453–461. Maruotti N, Crivellato E, Cantatore FP, et al. (2007). Mast cells in rheumatoid arthritis. Clin Rheumatol 26: 1–4. Means TK, Hayashi F, Smith KD, et al. (2003). The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 170: 5165–5175.
The Angiogenic Switch: Role of Immune Cells
73
Murdoch C, Muthana M, Coffelt SB, et al. (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618–631. Na YJ, Yang SH, Baek DW, et al. (2006). Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. Human Reprod 21: 1846–1855. Nakanishi C and Toi M (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297–309. Naldini A, Leali D, Pucci A, et al. (2006). Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 177: 4267–4270. Nam JS, Terabe M, Mamura M, et al. (2008). An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68: 3835–3843. Nico B, Mangieri D, Crivellato E, et al. (2008). Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev 17: 19–22. Noonan DM, De Lerma Barbaro A, Vannini N, et al. (2008). Inflammation, inflammatory cells and angiogenesis: Decisions and indecisions. Cancer Metastasis Rev 27: 31–40. Nozawa H, Chiu C, and Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 12493–12498. O’sullivan C and Lewis CE (1994). Tumour-associated leucocytes: Friends or foes in breast carcinoma. J Pathol 172: 229–235. Orimo A and Weinberg RA (2006). Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5: 1597–1601. Ostrand-Rosenberg S and Sinha P (2009). Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 182: 4499–4506. Pekarek LA, Starr BA, Toledano AY, et al. (1995). Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181: 435–440. Penna G, Vulcano M, Roncari A, et al. (2002). Cutting edge: Differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol 169: 6673–6676. Piqueras B, Connolly J, Freitas H, et al. (2006). Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107: 2613–2618. Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78. Porta C, Rimoldi M, Raes G, et al. (2009). Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A 106: 14978–14983. Pouyssegur J, Dayan F, and Mazure NM (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437–443. Priceman SJ, Sung JL, Shaposhnik Z, et al. (2010). Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: Combating tumor evasion of anti-angiogenic therapy. Blood 115: 1461–1471. Pulaski HL, Spahlinger G, Silva IA, et al. (2009). Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 7: 49. Pusztai L, Clover LM, Cooper K, et al. (1994). Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 70: 289–292. Pyke C, Graem N, Ralfkiaer E, et al. (1993). Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911–1915. Qin Z, Schwartzkopff J, Pradera F, et al. (2003). A critical requirement of interferon gammamediated angiostasis for tumor rejection by CD8+ t cells. Cancer Res 63: 4095–4100. Ranieri G, Ammendola M, Patruno R, et al. (2009). Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol 35: 115–120. Ratta M, Fagnoni F, Curti A, et al. (2002). Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 100: 230–237.
74
D.M. Noonan et al.
Ribatti D, Contino R, and Tursi A (1988). Do mast cells intervene in the vasoproliferative process of the rheumatoid synovitis? J Submicrosc Cytol Pathol 20: 635–637. Ribatti D, Vacca A, Nico B, et al. (2001). The role of mast cells in tumour angiogenesis. Br J Haematol 115: 514–521. Ribatti D, Crivellato E, Roccaro AM, et al. (2004). Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 34: 1660–1664. Ribatti D, Crivellato E, and Molica S (2009). Mast cells and angiogenesis in haematological malignancies. Leuk Res 33: 876–879. Riboldi E, Musso T, Moroni E, et al. (2005). Cutting edge: Proangiogenic properties of alternatively activated dendritic cells. J Immunol 175: 2788–2792. Riley JK, Takeda K, Akira S, et al. (1999). Interleukin-10 receptor signaling through the jak-stat pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 274: 16513–16521. Rodriguez PC, Ernstoff MS, Hernandez C, et al. (2009). Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553–1560. Romagnani C, Juelke K, Falco M, et al. (2007). CD56brightCD16- killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178: 4947–4955. Ruffell B, Denardo DG, Affara NI, et al. (2010). Lymphocytes in cancer development: Polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 21: 3–10. Rusnati M and Presta M (2006). Extracellular angiogenic growth factor interactions: An angiogenesis interactome survey. Endothelium 13: 93–111. Saccani A, Schioppa T, Porta C, et al. (2006). P50 nuclear factor-kappaB overexpression in tumorassociated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66: 11432–11440. Scapini P, Lapinet-Vera JA, Gasperini S, et al. (2000). The neutrophil as a cellular source of chemokines. Immunol Rev 177: 195–203. Scapini P, Morini M, Tecchio C, et al. (2004). CXCL1/macrophage inflammatory protein-2induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172: 5034–5040. Schioppa T, Uranchimeg B, Saccani A, et al. (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391–1402. Schmidt C (2009). Why do tumors become resistant to antiangiogenesis drugs? J Natl Cancer Inst 101: 1530–1532. Schruefer R, Lutze N, Schymeinsky J, et al. (2005). Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol 288: H1186–H1192. Schruefer R, Sulyok S, Schymeinsky J, et al. (2006). The proangiogenic capacity of polymorphonuclear neutrophils delineated by microarray technique and by measurement of neovascularization in wounded skin of CD18-deficient mice. J Vasc Res 43: 1–11. Scimone ML, Lutzky VP, Zittermann SI, et al. (2005). Migration of polymorphonuclear leucocytes is influenced by dendritic cells. Immunology 114: 375–385. Serafini P, Borrello I, and Bronte V (2006). Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53–65. Shojaei F and Ferrara N (2008). Refractoriness to antivascular endothelial growth factor treatment: Role of myeloid cells. Cancer Res 68: 5501–5504. Shojaei F, Wu X, Malik AK, et al. (2007a). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25: 911–920. Shojaei F, Wu X, Zhong C, et al. (2007b). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825–831. Shojaei F, Wu X, Qu X, et al. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106: 6742–6747.
The Angiogenic Switch: Role of Immune Cells
75
Sica A and Bronte V (2007). Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155–1166. Smits El, Ponsaerts P, Berneman ZN, et al. (2008). The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859–875. Soucek L, Lawlor ER, Soto D, et al. (2007). Mast cells are required for angiogenesis and macroscopic expansion of myc-induced pancreatic islet tumors. Nat Med 13: 1211–1218. Sozzani S (2005). Dendritic cell trafficking: More than just chemokines. Cytokine Growth Factor Rev 16: 581–592. Sozzani S, Allavena P, and Mantovani A (2001). Chemokines and dendritic cells. In Dendritic cells: Biology and clinical applications, Thomas G, and Lotze M, eds. (London: Acadimic), pp. 203–211. Sozzani S, Rusnati M, Riboldi E, et al. (2007). Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28: 385–392. Sparmann A and Bar-Sagi D (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447–458. Srivastava MK, Sinha P, Clements VK, et al. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70: 68–77. Steinman RM and Banchereau J (2007). Taking dendritic cells into medicine. Nature 449: 419–426. Stockmann C, Doedens A, Weidemann A, et al. (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456: 814–818. Suzuki E, Kim S, Cheung Hk, et al. (2007). A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351–2359. Takeo S, Yasumoto K, Nagashima A, et al. (1986). Role of tumor-associated macrophages in lung cancer. Cancer Res 46: 3179–3182. Tosetti F, Ferrari N, De Flora S, et al. (2002). Angioprevention’: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: 2–14. Trinchieri G (1989). Biology of natural killer cells. Adv Immunol 47: 187–376. Trinchieri G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133–146. Tsuda Y, Takahashi H, Kobayashi M, et al. (2004). Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 21: 215–226. Ueno H, Klechevsky E, Morita R, et al. (2007). Dendritic cell subsets in health and disease. Immunol Rev 219: 118–142. Ugel S, Delpozzo F, Desantis G, et al. (2009). Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9: 470–481. Verhasselt V, Buelens C, Willems F, et al. (1997). Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: Evidence for a soluble CD14-dependent pathway. J Immunol 158: 2919–2925. Vermi W, Bonecchi R, Facchetti F, et al. (2003). Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200: 255–268. Vermi W, Facchetti F, Riboldi E, et al. (2006). Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granuloma. Blood 107: 454–462. Vicari AP, Treilleux I, and Lebecque S (2004). Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol 14: 161–169. Villegas FR, Coca S, Villarrubia VG, et al. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35: 23–28. Yang L, Debusk LM, Fukuda K, et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409–421.
Chemokines and Cytotoxic Effector Molecules in Rejection Alan M. Krensky and Carol Clayberger
Abstract Increased or de novo expression of chemokines and cytotoxic effector molecules is part of the “immunologic constant of rejection” and are central to the “signature” of broad activation of proinflammatory and cytotoxic cells. Although several chemokines are associated with rejection and provocative results have been obtained in animal models, no real breakthroughs have occurred in translating these findings to clinical transplantation. In contrast, the cytotoxic effector molecules, granulysin, granzymes and perforin have proven to be important biomarkers for rejection. Keywords Chemokine • Cytotoxic T lymphocyte (CTL) • Granulysin • Granzymes • Natural killer (NK) cell • Perforin In 1984, we set out to identify genes expressed by human T lymphocytes 3–5 days after activation, reasoning that these molecules would be relevant to organ transplant rejection. The molecules identified using subtractive hybridization were RANTES (CCL5) (Schall et al. 1988), a chemokine, and granulysin (Jongstra et al. 1987), a cytolytic and proinflammatory molecule. Twenty-five years later, these molecules and functionally related families have been shown to be important in transplant rejection and are being investigated as potential diagnostics, prognostics (biomarkers), and/or therapeutics. Although a number of interrelated immune responses are involved in transplant rejection, this chapter focuses on the roles of chemokines and cytotoxic effector molecules in this process.
A.M. Krensky (*) Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4256, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_6, © Springer Science+Business Media, LLC 2011
77
78
A.M. Krensky and C. Clayberger
Chemokines Movement of inflammatory cells from the bloodstream to peripheral sites of inflammation is a multistep process involving a variety of cell surface and secreted molecules. Chemokines are chemoattractant cytokines instrumental in regulating leukocyte extravasation from the bloodstream and selective migration into tissues. Most chemokines are small, secreted molecules, although a few are larger and two are cell surface bound. They coordinate leukocyte migration by interacting with two types of receptors: (1) nonsignaling glycosaminoglycans on endothelial cells and extracellular matrix and (2) signaling seven membrane spanning G protein coupled serpentine receptors on inflammatory cells. There are approximately 50 chemokines and 20 G protein coupled chemokine receptors. Chemokines are basic proteins and interact with glycosaminoglycans based upon charge. These chemokine-glycosaminoglycan interactions immobilize and concentrate chemokines in sites of inflammation where they are recognized by the specific G protein coupled chemokine receptors (Fig. 1). This interaction then induces expression of integrins and immunoglobulin gene superfamily members, resulting in firm adhesion by inflammatory
Fig. 1 RANTES (CCL5) chemokine attracts immune cells from peripheral blood to sites of inflammation. Inflammatory leukocytes interact with selectins to “roll” along the vascular endothelium. RANTES, presented by glycosaminoglycans on the endothelium, attracts immune cells by haptotaxis. The leukocytes are activated to express adhesion molecules, adhere firmly and diapedese from the bloodstream into the tissue. The immune cells release metalloproteinases and move through tissues following the RANTES chemokine gradient. T cells, once activated by specific antigen, make more RANTES, amplifying the inflammatory response in time and space. Figure is reprinted with permission from Nature Clinical Practice Nephrology (Krensky and Ahn 2007)
Chemokines and Cytotoxic Effector Molecules in Rejection
79
cells to the endothelium and transmigration of immune cells from the bloodstream into tissues. Chemokines can attract inflammatory cells along a soluble gradient (chemotaxis) or bound to a solid surface (haptotaxis) (Wiedermann et al. 1993). Haptotaxis occurs on the endothelium. Chemokines freely released into the blood go downstream and would fail to recruit cells to the inflammatory site. Binding to the glycosaminoglycans insures localization to the inflammatory site. Although diverse sets of chemokines and receptors are present in allografts undergoing rejection (Table 1) (Tan and Zhou 2005), only a few chemokine pathways appear to have central roles in allograft rejection (Table 2) (Viola and Luster 2008). Different chemokines and receptors are involved with early changes in expression due to the organ trauma associated with brain death, surgical manipulation and ischemia/reperfusion compared to later changes associated with acute and chronic rejection. Earliest changes are associated with neutrophil and monocyte infiltration. With antigen activation, the adaptive immune response is associated with the presence of monocytes and T lymphocytes. Early events. The earliest cellular infiltrates associated with transplant rejection are composed of neutrophils and monocytes. CXCR1 and CXCR2 are the major neutrophil chemokine receptors in man (Murphy 1997), and CXCL8 (IL-8), the Table 1 Chemokine receptor expression in allograft rejection from Tan and Zhou (2005) Organ/tissue Receptors in rejection Heart CXCR3, CCR5, CCR3, CCR2, CCR1, CXCR1 Kidney CCR1, CCR2, CCR5, CXCR3, CXCR2 Islet CXCR3, CCR5, CCR2, CCR1 Liver CCR5, CCR6, CXCR3, CXCR4 Bone marrow CCR2 Skin CXCR3 Lung CXCR3, CXCR2, CCR5, CCR2 Although most chemokines and receptors have been associated with some stage of transplant rejection, the review by Tan and Zhou (2005) concluded that CXCR3 and CCR5 are the most generally involved in rejection Table 2 Chemokines with central roles in transplant rejection Neutrophils CXCL1, CXCL2, CXCL8 Early Monocytes CCL2 CXCR1 CXCR2 CCL2, CCL4, CCL5, CX3CL1 Monocytes Later CXCL9, CXCL10, CXCL11 Th1 DCCCL3, CCL4, CXCL9, CXCL10 CD8 CCR1 CXCL13 B CCR5 CCR6 CXCR1 CCR1 CCR5 CXCR3 Adapted from Viola and Luster (2008)
80
A.M. Krensky and C. Clayberger
major neutrophil attracting/activating ligand, is induced by inflammatory stimuli, including ischemia-reperfusion injury (De Perrot et al. 2002). There is no murine homolog for CXCR1 or its major ligand CXCL8 (Fan et al. 2007). CXCL1 (KC/ MIP-2 in mouse and MIP-II in rat) are thought to be functional orthologs for the human chemokine (Miura et al. 2003; King et al. 2000). In addition, CCL2, CCL7, CCL8 and CCL13 are involved in early monocyte attraction and activation (Romagnani 2002). Acute rejection. The adaptive immune response to the allograft is induced when naïve antigen specific T lymphocytes encounter dendritic cells presenting foreign alloantigens (MHC/HLA) (Krensky et al. 1990). The T cell-antigen presenting cell interaction occurs in secondary lymphoid organs and involves CCR7 and its ligands, CCL19 and CCL21 (Forster et al. 2008). Dendritic cells present antigen after migrating to the T cell area of the lymph node. Immature dendritic cells express CCR1, CCR5, CCR6 and CXCR1. Expression of these chemokine receptors decreases and they are replaced by CCR7, CXCR4 and CCR4 as the dendritic cells mature and enter the afferent lymphatics and lymph nodes (Colvin et al. 2008). T cell entry into the lymph nodes is regulated by CCR7 on the T cells interacting with CCL19 on the dendritic cells and CCL21 on high endothelial venules (Forster et al. 1999). CXCL12 and CCL5 provide additional proinflammatory signals (Molon et al. 2005). Before activated T cells leave the lymph node, they downregulate CCR7 and upregulate other chemokine receptors involved in movement through the bloodstream and lymphatics and into tissues and organs. For example, some CD4+ T cells increase CXCR5 expression and localize to the lymph node follicle where they provide help to B cells (Cyster 2005). B cell entry into secondary lymphoid tissues depends on CCR7, CXCR4 and CXCR5 (Cyster 2005). Paradoxically, although CCR7 and CXCR5 are important in generation of alloreactive T cells, they are dispensable for the alloresponse in vivo. Only modest prolongation of heart graft survival occurs in CCR7 (−/−) mice (see below) (Beckmann et al. 2004; Muller et al. 2003). CCR1, CCR5 and CXCR3 recruit monocytes, macrophages and effector T cells during acute and chronic rejection (Fischereder 2007). CCR1 binds CCL3, CCL4, CCL5, CCL7, CCL8 and other chemokines (Anders et al. 2006). CCR5 binds CCL3, CCL4, CCL5 and CCL8 (Balistreri et al. 2007). In addition to sharing several ligands, CCR1 and CCR5 are expressed on similar cell types, but they act at different stages of leukocyte recruitment and activation. For example, peripheral blood monocytes are high for CCR1 expression but low for CCR5. In contrast, CD45RO+ memory T cells are low for CCR1 and high for CCR5. CCR5 expression is markedly increased in both acute and chronic rejection. T cells upregulate CXCR3 after activation (Panzer et al. 2004). CXCR3 is also expressed by B and NK cells and is commonly increased in expression in transplant rejection along with its ligands CXCL9, CXCL10 and CXCL11 (Hoffmann et al. 2006). Chemokine receptors are differentially expressed by T helper subsets (Mantovani et al. 2004). Th1 cells generally express CCR5 and CXCR3 while Th2 cells express CCR3, CCR4 and CCR8. CCR7 expression has been used to divide memory T cells into two subsets: CCR7+ “central” memory T cells migrate into lymph nodes and
Chemokines and Cytotoxic Effector Molecules in Rejection
81
peripheral organs while CCR7− “effector” memory cells do not re-enter lymph nodes (Sallusto et al. 2000). Although a large variety of chemokines has been associated with transplant rejection, the major chemokines implicated in CD8+ T cells in transplant rejection are CCL3, CCL4 and CCL5, interacting with CCR5 and CXCL9, and CXCL10, interacting with CXCR3. Antigen activated CTL release CCR5 ligands, CCL2 and CCL3 (Selleri et al. 2008), and attract NK cells (Salazar-Mather et al. 1998; Morris and Ley 2004). Activated dendritic cells and B lymphocytes produce the CXCR3 ligand chemokines (Drayton et al. 2006; Deola et al. 2008). As described below, the CCR5 ligands do appear to be clinically relevant in transplant rejection. Even though CXCR3 and its ligands CXCL-9, CXCL10 and CXCL11 are induced in transplant rejection and were thought to be important mediators of CTL infiltration (Lazzeri and Romagnani 2005; Kobayashi et al. 2006), the functional importance of CXCR3 is now controversial based upon results in animal models (see below). Chronic rejection. The chemokines and receptors expressed in chronic rejection are the same as in acute rejection and most preclinical studies implicate similar pathways, including CCR1, CCR5 and CXCR3 (Viola and Luster 2008).
Translation to Clinical Utility The fact that chemokines and their receptors are induced and highly expressed at various stages of transplant rejection suggests that they may prove targets for diagnostics, prognostics (biomarkers) and/or therapeutics. Although animal models have implicated a number of chemokines for these uses, results to date moving preclinical observations to the clinics have been disappointing. This is likely due to the considerable differences between mouse and man, the redundancy of the chemokine-receptor interaction network, the pleiotropic effects of many chemokines, and kinetic/microenvironment considerations. Preclinical evaluation. The major approaches to studying chemokines in transplant rejection involve studies with targeted gene deletion animals, blocking antibodies, small molecules, and gene therapy. Gene deletion mice. Preclinical studies using chemokine receptor deficient mice implicated CCR1, CXCR2 and CCR5 in acute allograft rejection (Gao et al. 2000, 2001; El-Sawy et al. 2005). Based upon results in experimental animals, CCR7 and CXCR3 now appear less involved. Only modest prolongation of heart allografts was found with CCR7(−/−) mice (Beckmann et al. 2004), and, although mice deficient for CXCR3 were initially described as highly resistant to acute allograft rejection (Hancock et al. 2000), subsequent studies failed to confirm this observation (Halloran and Fairchild 2008). Of note, a chemoattractant lipid, sphingosine-1-phosphate (S1P), interacts with a G protein coupled receptor to control lymphocyte egress from lymphoid organs (Cyster 2005). Remarkably, S1P1-deficient lymphocytes fail to exit secondary tissues (Matloubian et al. 2004). Based on these observations, an inhibitor of S1P,
82
A.M. Krensky and C. Clayberger
FTY720, was developed and advanced to clinical trials but proved no better than existing therapies for transplantation (Mansoor and Melendez 2008). Neutralizing antibodies. Blocking antibodies have proven useful in inhibiting cell surface interactions for integrins and immunoglobulin superfamily genes. Examples include anti-LFA-1 and anti-VLA4 treatments for multiple sclerosis and Crohn’s disease (Ulbrich et al. 2003; Ghosh et al. 2003; Miller et al. 2003). G protein coupled receptors would appear to be excellent potential therapeutic targets. CXCR1 and CXCR2 antibodies block the neutrophil infiltrate associated with ischemia-reperfusion injury (Sbrana et al. 2005; Cugini et al. 2005; Bertini et al. 2004). Neutralizing antibodies against CXCR2 and its ligands CXCL1, CXCL2 and CXCL3, prolong graft survival in a variety of mouse and rat allograft rejection models (El-Sawy et al. 2005). Anti-CXCL2 and CXCL3 antibodies prolong kidney graft survival in mice (Cugini et al. 2005; Bertini et al. 2004). Anti-CXCR1 and CXCR2 blocks rejection in the rat (Cugini et al. 2005; Bertini et al. 2004). CXCR2 antibodies block heart rejection and reduce infiltrate and graft injury in lung transplants (El-Sawy et al. 2005; Belperio et al. 2005). Small molecules and modified chemokines. Small molecules, including modified chemokines, have also been used to inhibit transplant rejection in animal models. Since CCR5 was shown to be a receptor for HIV entry into cells, many small molecules and modified RANTES (CCL5) have been developed and tested as potential HIV therapeutics (Tan and Zhou 2005). In agreement with data from CCR5 deficient mice (Abdi et al. 2002a), TAK-779, a small molecule antagonist for CCR5 and CXCR3, prolonged allograft survival in both acute and chronic cardiac and islet models in mice (Akashi et al. 2005). After the amino terminus was shown to be important for the chemokine specificity of CCL5, several modifications, including Met-RANTES, AOP-RANTES and other amino terminal modifications were developed (Grone et al. 1999; Proudfoot et al. 1996; Simmons et al. 1997; Lederman et al. 2004). Met-RANTES, a functional antagonist for both CCR1 and CCR5 (Grone et al. 1999), reduces damage and prolongs graft survival in both acute and chronic rejection models (Yun et al. 2004). On the negative side, MET-RANTES causes glomerular damage and proteinuria, undercutting its clinical potential (Anders et al. 2003). BX471, a CCR1 receptor antagonist, is effective in rat heterotopic heart, rabbit orthotopic kidney and a rat chronic kidney allograft rejection models (Horuk et al. 2001a, b). Gene transfer. There is much less data involving gene transfer of chemokines or chemokine inhibitors in transplantation but a few studies are notable. Vassalli and colleagues used gene transfer of the chemokine antagonist RANTES (CCL5) 9-68 (Vassalli et al. 2006) and terminal deletion mutants of CCL5 (RANTES) and CCL2 (MCP-1) to prolong cardiac allograft survival in rats (Fleury et al. 2006). AntiCCL2 (MCP-1) gene therapy also attenuated graft vasculopathy (Saiura et al. 2004) and transduction-mediated overexpression of CXCR4 significantly improved marrow engraftment of cultured peripheral blood stem cells (Brenner et al. 2004). Clinical data. Inhibitors of CCR1 and CCR5 are being tested in human diseases and may eventually be available in transplantation (Fischereder 2007). Early results
Chemokines and Cytotoxic Effector Molecules in Rejection
83
with some CCR1 antagonists for multiple sclerosis (Zipp et al. 2006) and rheumatoid arthritis (Pease and Horuk 2005) and CCR5 antagonists for HIV have failed (Kuritzkes 2009), but several additional compounds and studies continue to move forward (Pease and Horuk 2009a; Pease and Horuk 2009b). Perhaps the single most relevant clinical observations to date involve the CCR5∆32 null allele. Approximately 1% of people of Northern European descent have a 32 base pair deletion in the CCR5 coding region resulting in a null allele. A study of a large cohort of renal transplant patients showed a significant prolongation in graft survival for patients with this homozygous deletion (Fischereder et al. 2001). There are additional chemokine polymorphisms of clinical relevance in transplantation (Abdi et al. 2002b). These include decreased transplant rejection associated with the CCR2-64I allele (Kruger et al. 2002) or CCR5 59029-A/G allele (Yigit et al. 2007) and decreased transplant survival for the G allele of CCL2/-2518 promoter (increased CCL2 expression) (Kruger et al. 2002). Summary. In general, exciting results from animal studies have been poorly translated to humans for a variety of reasons. Knock out animals are not the same as small molecule or neutralizing antibody inhibitors in localization or kinetics. Zlotnik points out the major differences between mouse and man in chemokine expression and function (Fig. 2) (Zlotnik et al. 2006). He documents that some chemokine genes are present in one species but not the other. CXCL8, noted above is an example
Fig. 2 Human and mouse chemokine genes differ. The lack of correlation is evident as genes that exist in one species but not the other, as functional equivalents but not identical, and/or as chemokines with different functions between the species. Adapted from Zlotnik et al. (2006) and Viola and Luster (2008)
84
A.M. Krensky and C. Clayberger
of a chemokine gene present in man but not mouse. Alternatively, a given chemokine may be related to more than one ortholog in the other species or the match may not be exact. These differences are due to independent gene duplication events. The complexity of multiple ligands for many receptors, multiple receptors on any particular cell and the hierarchy of potential combinatorial interactions (and potential for redundancies) functionally multiply and complicate differences between individual chemokine molecules. An additional level of complexity is due to the pleiotropic effects of any given chemokine. For example, CCL5 is produced and released by a wide variety of cell types, including lymphocytes, macrophages, fibroblasts, platelets, smooth muscle, endothelial and epithelial cells. Its can bind CCR1, CCR3 and CCR5. Furthermore, it can produce other activating and proinflammatory events in addition to chemoattraction. Lastly, differences in microenvironments (local effects) and kinetics provide ultimate complexity.
Cytotoxic Effector Molecules Transplant rejection usually includes infiltration of CTL and NK cells and broad activation of expression of cytotoxicity associated gene products (Krensky 2000). The other late expressed T cell molecule we first identified by subtractive hybridization was granulysin, originally named 519 (Jongstra et al. 1987). Granulysin is expressed constitutively by natural killer (NK) cells and after antigen stimulation in cytotoxic T lymphocytes (CTL) (Krensky and Clayberger 2009). It is present in cytolytic granules of these cell types, overlapping with other cytolytic effectors, granzymes and perforin. Much of the immune effector function in the transplant literature focuses on granzymes because mice and rats do not express granulysin. Granulysin is expressed in man, cows, pigs and horses. Cell-mediated cytotoxicity occurs by two pathways (Clayberger 2009). A nonsecretory pathway involves the interaction of fas with fas ligand, giving rise to apoptosis. The secretory pathway involves directional release of cytolytic granules onto target cells, also resulting in caspase activation and cell death by apoptosis. Granulysin and perforin and granzymes and perforin collaborate in cell death while granulysin and granzymes function in entirely separate mechanistic pathways. Like most chemokines, these cytolytic effector molecules are not expressed by resting cells but are induced by T cell activation. They have proven to be potent biomarkers for rejection as activated T lymphocytes are intimately associated with this process. Granulysin. Granulysin was first identified by subtractive hybridization in a search for genes expressed “late” (3–5 days) after T cell activation (Jongstra et al. 1987). It is present in CTL and NK cell cytotoxic granules with perforin and granzymes and is directionally released at target cells upon antigen activation (Krensky and Clayberger 2009). Recombinant granulysin kills tumor targets by causing ion fluxes that increase intracellular calcium and decrease intracellular potassium.
Chemokines and Cytotoxic Effector Molecules in Rejection
85
Mitochondria are damaged, giving rise to cell death via apoptosis. Recombinant granulysin has broad antimicrobial and tumorcidal activity. In addition to its cytotoxic activity, it is a chemoattractant and proinflammatory, activating expression of a number of cytokines and chemokines, including RANTES, MCP-1, MCP-3, MIP1a, IL-1, IL-6, IL-10 and IFNa. There is no mouse homolog for granulysin, although cows, pigs and horses express homologs. Granulysin is highly expressed in a wide variety of diseases (Krensky and Clayberger 2009). Increased granulysin expression is associated with good outcomes in a number of cancers. Granulysin is highly expressed in cell-mediated transplant rejection and may be a biomarker for steroid resistance (Sarwal et al. 2001). Urinary mRNA for granulysin is an excellent noninvasive biomarker for transplant rejection (Kotsch et al. 2004). Perforin. Perforin is also a cytolytic molecule present in granules of CTL and NK cells (Chavez-Galan et al. 2009). It is homologous to complement proteins C8 and C9 involved in the membrane attack complex (MAC) of the complement cascade. Upon degranulation, perforin inserts itself into the target cell membrane, forming pores. Perforin works in concert with molecules like granulysin or granzyme B to induce apoptosis in target cells. Studies with perforin knockout mice led to the discovery of the Fas-Fas ligand pathway for cell death and underscored the importance of perforin in the immune response to tumors and viruses (Kagi et al. 1996). Remarkably, although perforin expression correlates strongly with allograft rejection in man and experimental models, perforin knockout mice reject allografts with the same kinetics as wild type recipients (Bose et al. 2003). There is a perforin deficiency state in man, first described in 1999 (Stepp et al. 1999). Hemophagocytic Lymphohistiocytosis (HLH) is a complex syndrome including high fevers, hepatosplenomegaly, cytopenias and hemophagocytosis, due to many entities, including perforin deficiency. Skin rashes, hepatic and central nervous system dysfunction often accompany the other symptoms. There is a breakdown in normal immunoregulation due to defects in both innate and adaptive immunity. These patients show uniform deficiency in NK function but variable CTL responses, suggesting some redundancy in CTL-mediated cytotoxic mechanisms (Janka 2007). Granzymes. Granzymes are caspase-like serine proteases that are released by CTL to kill viruses and tumors (Trapani and Smyth 2002). There are several more granzymes in mouse than man. Man expresses granzymes A, B, H and M while mice express A, B, C, D, E, F, G and M. While it appears that both granzymes A and B are important in killing target cells in collaboration with perforin, granzyme B appears to be the most important in inducing apoptosis and has been highly associated with allograft rejection in animal models and man (Trapani and Sutton 2003). Cell death is mediated by granzyme B via Bid cleavage and subsequent caspase activation and mitochondrial damage. Granzyme A functions by inducing DNA damage through noncaspase pathways. Compared to Granzyme B, Granzyme A is less important in target cell lysis and a less specific marker of organ transplant rejection (Li et al. 2001).
86
A.M. Krensky and C. Clayberger
Clinical utility. Although direct inhibition of these cytotoxic effector molecules have yet to be effective targets for inhibition of transplant (or tumor) rejection, they do appear to be useful biomarkers for rejection in tissues, urinary mRNA and perhaps peripheral blood (Clayberger 2009). They may also have prognostic significance in discrimination of steroid resistance (Sarwal et al. 2001). These CTL associated genes are expressed more highly in steroid free patients with stable graft function than patients treated with steroids. Therefore, these markers should be applied differently in patients who are taking steroids vs. those that are not (Satterwhite et al. 2003). There are recent studies that suggest these cytolytic effector molecules may also be expressed in regulatory T cells (Treg) (Grossman et al. 2004). Gondek et al. (2008) reported in a mouse skin transplant model that granzyme B expression by FoxP3+ cells is required for transplant tolerance. As noted above, a variety of molecular profiling studies have identified perforin, granzyme B, granulysin and FasL in allograft rejection (Nickel et al. 2001; Sharma et al. 1996). Hidalgo and colleagues examined gene expression in CTL and NK cells and in transplant rejection. They first evaluated CD8+ CTL, CD4+ CTL and NK cell transcripts after subtracting out B cell and monocyte mRNA (Hidalgo et al. 2008a). Both CD4+ and CD8+ CTL have similar profiles and no transcripts were identified that differentiated them. NK cells were different from CTL, but more like CD8+ CTL than CD4+ CTL. High levels of the cytotoxic molecule transcripts were identified in all three groups, with granulysin the highest expressed transcript by CTL. Of particular note, they found that the CD4+ CTL expressed high levels of granzymes and granulysin and that CD8+ CTL expressed high levels of FasL. This is in contrast to the commonly held notion that CD8+ CTL primarily function via granule exocytosis while CD4+ CTL generally kill via the nonsecretory pathway. It must be stressed that these studies were examining mRNA, not protein, expression and that, although the populations were more than 90% pure, small contaminating populations could impact these results (Hidalgo et al. 2008a). In a second report, this group found that the same hierarchy of CTL-associated transcripts was present in renal transplant biopsies undergoing rejection (Hidalgo et al. 2008b). These CTL associated transcripts was strongly correlated with T cell infiltration of the graft. Early studies of cytotoxic gene expression in blood and urine underscored the utility of noninvasive transcriptional profiling for diagnosis of transplant rejection (Kotsch et al. 2004; Li et al. 2001; Vasconcellos et al. 1998). Recent studies have not always reproduced these findings and have suggested other markers, including lower expression of ICOS and CD154 (Alakulppi et al. 2007) or increased expression of FoxP3 (Aquino-Dias et al. 2008) may prove more useful as biomarkers.
Conclusion Genes that are markedly increased in expression after T cell activation are associated with transplant rejection and other T cell-mediated diseases. When we undertook to identify such genes 25 years ago, we identified RANTES (CCL5) (Schall et al. 1988)
Chemokines and Cytotoxic Effector Molecules in Rejection
87
and granulysin (Jongstra et al. 1987). We now understand that these are important molecules in a large number of human diseases and that are members of large families of molecules of mechanistic relevance (Krensky and Clayberger 2009; Krensky and Ahn 2007; Nelson and Krensky 2001). Chemokines and cytotoxic effector molecules are important diagnostics and biomarkers and may prove useful in development of new therapies for transplant rejection and/or the development of transplant tolerance. Acknowledgment This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute Laboratory of Cellular and Molecular Biology.
References Abdi, R., R.N. Smith, L. Makhlouf, N. Najafian, A.D. Luster, H. Auchincloss, Jr., and M.H. Sayegh. 2002. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51:2489–2495. Abdi, R., T.B. Tran, A. Sahagun-Ruiz, P.M. Murphy, B.M. Brenner, E.L. Milford, and D.H. McDermott. 2002. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13:754–758. Akashi, S., M. Sho, H. Kashizuka, K. Hamada, N. Ikeda, Y. Kuzumoto, Y. Tsurui, T. Nomi, T. Mizuno, H. Kanehiro, M. Hisanaga, S. Ko, and Y. Nakajima. 2005. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80:378–384. Alakulppi, N.S., L.E. Kyllonen, J. Partanen, K.T. Salmela, and J.T. Laine. 2007. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. Transplantation 83:791–798. Anders, H.J., M. Frink, Y. Linde, B. Banas, M. Wornle, C.D. Cohen, V. Vielhauer, P.J. Nelson, H.J. Grone, and D. Schlondorff. 2003. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 170:5658–5666. Anders, H.J., V. Ninichuk, and D. Schlondorff. 2006. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 69:29–32. Aquino-Dias, E.C., G. Joelsons, D.M. da Silva, R.H. Berdichevski, A.R. Ribeiro, F.J. Veronese, L.F. Goncalves, and R.C. Manfro. 2008. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int 73:877–884. Balistreri, C.R., C. Caruso, M.P. Grimaldi, F. Listi, S. Vasto, V. Orlando, A.M. Campagna, D. Lio, and G. Candore. 2007. CCR5 receptor: biologic and genetic implications in age-related diseases. Ann N Y Acad Sci 1100:162–172. Beckmann, J.H., S. Yan, H. Luhrs, B. Heid, S. Skubich, R. Forster, and M.W. Hoffmann. 2004. Prolongation of allograft survival in ccr7-deficient mice. Transplantation 77:1809–1814. Belperio, J.A., M.P. Keane, M.D. Burdick, B. Gomperts, Y.Y. Xue, K. Hong, J. Mestas, A. Ardehali, B. Mehrad, R. Saggar, J.P. Lynch, D.J. Ross, and R.M. Strieter. 2005. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115:1150–1162. Bertini, R., M. Allegretti, C. Bizzarri, A. Moriconi, M. Locati, G. Zampella, M.N. Cervellera, V. Di Cioccio, M.C. Cesta, E. Galliera, F.O. Martinez, R. Di Bitondo, G. Troiani, V. Sabbatini, G. D’Anniballe, R. Anacardio, J.C. Cutrin, B. Cavalieri, F. Mainiero, R. Strippoli, P. Villa, M. Di Girolamo, F. Martin, M. Gentile, A. Santoni, D. Corda, G. Poli, A. Mantovani, P. Ghezzi, and F. Colotta. 2004. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101:11791–11796.
88
A.M. Krensky and C. Clayberger
Bose, A., Y. Inoue, K.E. Kokko, and F.G. Lakkis. 2003. Cutting edge: perforin down-regulates CD4 and CD8 T cell-mediated immune responses to a transplanted organ. J Immunol 170:1611–1614. Brenner, S., N. Whiting-Theobald, T. Kawai, G.F. Linton, A.G. Rudikoff, U. Choi, M.F. Ryser, P.M. Murphy, J.M. Sechler, and H.L. Malech. 2004. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells 22:1128–1133. Chavez-Galan, L., M.C. Arenas-Del Angel, E. Zenteno, R. Chavez, and R. Lascurain. 2009. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6:15–25. Clayberger, C. 2009. Cytolytic molecules in rejection. Curr Opin Organ Transplant 14:30–33. Colvin, B.L., B.M. Matta, and A.W. Thomson. 2008. Dendritic cells and chemokine-directed migration in transplantation: where are we headed? Clin Lab Med 28:375–384, v. Cugini, D., N. Azzollini, E. Gagliardini, P. Cassis, R. Bertini, F. Colotta, M. Noris, G. Remuzzi, and A. Benigni. 2005. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 67:1753–1761. Cyster, J.G. 2005. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127–159. De Perrot, M., Y. Sekine, S. Fischer, T.K. Waddell, K. McRae, M. Liu, D.A. Wigle, and S. Keshavjee. 2002. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 165:211–215. Deola, S., M.C. Panelli, D. Maric, S. Selleri, N.I. Dmitrieva, C.Y. Voss, H. Klein, D. Stroncek, E. Wang, and F.M. Marincola. 2008. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 180:1362–1372. Drayton, D.L., S. Liao, R.H. Mounzer, and N.H. Ruddle. 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 7:344–353. El-Sawy, T., J.A. Belperio, R.M. Strieter, D.G. Remick, and R.L. Fairchild. 2005. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112:320–331. Fan, X., A.C. Patera, A. Pong-Kennedy, G. Deno, W. Gonsiorek, D.J. Manfra, G. Vassileva, M. Zeng, C. Jackson, L. Sullivan, W. Sharif-Rodriguez, G. Opdenakker, J. Van Damme, J.A. Hedrick, D. Lundell, S.A. Lira, and R.W. Hipkin. 2007. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 282:11658–11666. Fischereder, M. 2007. Chemokines and chemokine receptors in renal transplantation--from bench to bedside. Acta Physiol Hung 94:67–81. Fischereder, M., B. Luckow, B. Hocher, R.P. Wuthrich, U. Rothenpieler, H. Schneeberger, U. Panzer, R.A. Stahl, I.A. Hauser, K. Budde, H. Neumayer, B.K. Kramer, W. Land, and D. Schlondorff. 2001. CC chemokine receptor 5 and renal-transplant survival. Lancet 357:1758–1761. Fleury, S., J. Li, E. Simeoni, E. Fiorini, L.K. von Segesser, L. Kappenberger, and G. Vassalli. 2006. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther 13:1104–1109. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23–33. Forster, R., A.C. Davalos-Misslitz, and A. Rot. 2008. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8:362–371. Gao, W., P.S. Topham, J.A. King, S.T. Smiley, V. Csizmadia, B. Lu, C.J. Gerard, and W.W. Hancock. 2000. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 105:35–44. Gao, W., K.L. Faia, V. Csizmadia, S.T. Smiley, D. Soler, J.A. King, T.M. Danoff, and W.W. Hancock. 2001. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72:1199–1205.
Chemokines and Cytotoxic Effector Molecules in Rejection
89
Ghosh, S., E. Goldin, F.H. Gordon, H.A. Malchow, J. Rask-Madsen, P. Rutgeerts, P. Vyhnalek, Z. Zadorova, T. Palmer, and S. Donoghue. 2003. Natalizumab for active Crohn’s disease. N Engl J Med 348:24–32. Gondek, D.C., V. Devries, E.C. Nowak, L.F. Lu, K.A. Bennett, Z.A. Scott, and R.J. Noelle. 2008. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol 181:4752–4760. Grone, H.J., C. Weber, K.S. Weber, E.F. Grone, T. Rabelink, C.M. Klier, T.N. Wells, A.E. Proudfood, D. Schlondorff, and P.J. Nelson. 1999. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 13:1371–1383. Grossman, W.J., J.W. Verbsky, B.L. Tollefsen, C. Kemper, J.P. Atkinson, and T.J. Ley. 2004. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104:2840–2848. Halloran, P.F., and R.L. Fairchild. 2008. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 8:1578–1579. Hancock, W.W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J.A. King, S.T. Smiley, M. Ling, N.P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192:1515–1520. Hidalgo, L.G., G. Einecke, K. Allanach, and P.F. Halloran. 2008. The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells. Am J Transplant 8:627–636. Hidalgo, L.G., G. Einecke, K. Allanach, M. Mengel, B. Sis, T.F. Mueller, and P.F. Halloran. 2008. The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant 8:637–646. Hoffmann, U., S. Segerer, P. Rummele, B. Kruger, M. Pietrzyk, F. Hofstadter, B. Banas, and B.K. Kramer. 2006. Expression of the chemokine receptor CXCR3 in human renal allografts–a prospective study. Nephrol Dial Transplant 21:1373–1381. Horuk, R., C. Clayberger, A.M. Krensky, Z. Wang, H.J. Grone, C. Weber, K.S. Weber, P.J. Nelson, K. May, M. Rosser, L. Dunning, M. Liang, B. Buckman, A. Ghannam, H.P. Ng, I. Islam, J.G. Bauman, G.P. Wei, S. Monahan, W. Xu, R.M. Snider, M.M. Morrissey, J. Hesselgesser, and H.D. Perez. 2001. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 276:4199–4204. Horuk, R., S. Shurey, H.P. Ng, K. May, J.G. Bauman, I. Islam, A. Ghannam, B. Buckman, G.P. Wei, W. Xu, M. Liang, M. Rosser, L. Dunning, J. Hesselgesser, R.M. Snider, M.M. Morrissey, H.D. Perez, and C. Green. 2001. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 76:193–201. Janka, G.E. 2007. Hemophagocytic syndromes. Blood Rev 21:245–253. Jongstra, J., T.J. Schall, B.J. Dyer, C. Clayberger, J. Jorgensen, M.M. Davis, and A.M. Krensky. 1987. The isolation and sequence of a novel gene from a human functional T cell line. J Exp Med 165:601–614. Kagi, D., B. Ledermann, K. Burki, R.M. Zinkernagel, and H. Hengartner. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14:207–232. King, W.J., R.M. Comer, T. Hudde, D.F. Larkin, and A.J. George. 2000. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 70:1225–1233. Kobayashi, N., T. Kondo, H. Takata, S. Yokota, and M. Takiguchi. 2006. Functional and phenotypic analysis of human memory CD8+ T cells expressing CXCR3. J Leukoc Biol 80:320–329. Kotsch, K., M.F. Mashreghi, G. Bold, P. Tretow, J. Beyer, M. Matz, J. Hoerstrup, J. Pratschke, R. Ding, M. Suthanthiran, H.D. Volk, and P. Reinke. 2004. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 77:1866–1875. Krensky, A.M. 2000. Molecular biology of transplantation. Nephron 86:260–265.
90
A.M. Krensky and C. Clayberger
Krensky, A.M., and Y.T. Ahn. 2007. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 3:164–170. Krensky, A.M., and C. Clayberger. 2009. Biology and clinical relevance of granulysin. Tissue Antigens 73:193–198. Krensky, A.M., A. Weiss, G. Crabtree, M.M. Davis, and P. Parham. 1990. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322:510–517. Kruger, B., B. Schroppel, R. Ashkan, B. Marder, C. Zulke, B. Murphy, B.K. Kramer, and M. Fischereder. 2002. A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13:2585–2589. Kuritzkes, D.R. 2009. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 4:82–87. Lazzeri, E., and P. Romagnani. 2005. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5:109–118. Lederman, M.M., R.S. Veazey, R. Offord, D.E. Mosier, J. Dufour, M. Mefford, M. Piatak, Jr., J.D. Lifson, J.R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485–487. Li, B., C. Hartono, R. Ding, V.K. Sharma, R. Ramaswamy, B. Qian, D. Serur, J. Mouradian, J.E. Schwartz, and M. Suthanthiran. 2001. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344:947–954. Mansoor, M., and A.J. Melendez. 2008. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. Rev Recent Clin Trials 3:62–69. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686. Matloubian, M., C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, V. Brinkmann, M.L. Allende, R.L. Proia, and J.G. Cyster. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360. Miller, D.H., O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, M.A. Libonati, A.J. Willmer-Hulme, C.M. Dalton, K.A. Miszkiel, and P.W. O’Connor. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23. Miura, M., T. El-Sawy, and R.L. Fairchild. 2003. Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma. Am J Pathol 162:509–519. Molon, B., G. Gri, M. Bettella, C. Gomez-Mouton, A. Lanzavecchia, A.C. Martinez, S. Manes, and A. Viola. 2005. T cell costimulation by chemokine receptors. Nat Immunol 6:465–471. Morris, M.A., and K. Ley. 2004. Trafficking of natural killer cells. Curr Mol Med 4:431–438. Muller, G., P. Reiterer, U.E. Hopken, S. Golfier, and M. Lipp. 2003. Role of homeostatic chemokine and sphingosine-1-phosphate receptors in the organization of lymphoid tissue. Ann N Y Acad Sci 987:107–116. Murphy, P.M. 1997. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 34:311–318. Nelson, P.J., and A.M. Krensky. 2001. Chemokines, chemokine receptors, and allograft rejection. Immunity 14:377–386. Nickel, P., J. Lacha, S. Ode-Hakim, B. Sawitzki, N. Babel, U. Frei, H.D. Volk, and P. Reinke. 2001. Cytotoxic effector molecule gene expression in acute renal allograft rejection: correlation with clinical outcome; histopathology and function of the allograft. Transplantation 72:1158–1160. Panzer, U., R.R. Reinking, O.M. Steinmetz, G. Zahner, U. Sudbeck, S. Fehr, B. Pfalzer, A. Schneider, F. Thaiss, M. Mack, S. Conrad, H. Huland, U. Helmchen, and R.A. Stahl. 2004. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 78:1341–1350. Pease, J.E., and R. Horuk. 2005. CCR1 antagonists in clinical development. Expert Opin Investig Drugs 14:785–796. Pease, J.E., and R. Horuk. 2009. Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 19:39–58.
Chemokines and Cytotoxic Effector Molecules in Rejection
91
Pease, J.E., and R. Horuk. 2009. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 19:199–221. Proudfoot, A.E., C.A. Power, A.J. Hoogewerf, M.O. Montjovent, F. Borlat, R.E. Offord, and T.N. Wells. 1996. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271:2599–2603. Romagnani, S. 2002. Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38:881–885. Saiura, A., M. Sata, K. Hiasa, S. Kitamoto, M. Washida, K. Egashira, R. Nagai, and M. Makuuchi. 2004. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 24:1886–1890. Salazar-Mather, T.P., J.S. Orange, and C.A. Biron. 1998. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 187:1–14. Sallusto, F., A. Langenkamp, J. Geginat, and A. Lanzavecchia. 2000. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 251:167–171. Sarwal, M.M., A. Jani, S. Chang, P. Huie, Z. Wang, O. Salvatierra, Jr., C. Clayberger, R. Sibley, A.M. Krensky, and M. Pavlakis. 2001. Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. Hum Immunol 62:21–31. Satterwhite, T., M.S. Chua, S.C. Hsieh, S. Chang, J. Scandling, O. Salvatierra, and M.M. Sarwal. 2003. Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant 7:53–58. Sbrana, S., S. Bevilacqua, M. Buffa, D. Spiller, M.S. Parri, J. Gianetti, R. De Filippis, and A. Clerico. 2005. Post-reperfusion changes of monocyte function in coronary blood after extracorporeal circulation. Cytometry B Clin Cytom 65:14–21. Schall, T.J., J. Jongstra, B.J. Dyer, J. Jorgensen, C. Clayberger, M.M. Davis, and A.M. Krensky. 1988. A human T cell-specific molecule is a member of a new gene family. J Immunol 141:1018–1025. Selleri, S., S. Deola, Z. Pos, P. Jin, A. Worschech, S.L. Slezak, C. Rumio, M.C. Panelli, D. Maric, D.F. Stroncek, E. Wang, and F.M. Marincola. 2008. GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med 6:17. Sharma, V.K., R.M. Bologa, B. Li, G.P. Xu, M. Lagman, W. Hiscock, J. Mouradian, J. Wang, D. Serur, V.K. Rao, and M. Suthanthiran. 1996. Molecular executors of cell death–differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 62:1860–1866. Simmons, G., P.R. Clapham, L. Picard, R.E. Offord, M.M. Rosenkilde, T.W. Schwartz, R. Buser, T.N. Wells, and A.E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276–279. Stepp, S.E., R. Dufourcq-Lagelouse, F. Le Deist, S. Bhawan, S. Certain, P.A. Mathew, J.I. Henter, M. Bennett, A. Fischer, G. de Saint Basile, and V. Kumar. 1999. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286:1957–1959. Tan, J., and G. Zhou. 2005. Chemokine receptors and transplantation. Cell Mol Immunol 2:343–349. Trapani, J.A., and M.J. Smyth. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2:735–747. Trapani, J.A., and V.R. Sutton. 2003. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 15:533–543. Ulbrich, H., E.E. Eriksson, and L. Lindbom. 2003. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24:640–647. Vasconcellos, L.M., A.D. Schachter, X.X. Zheng, L.H. Vasconcellos, M. Shapiro, W.E. Harmon, and T.B. Strom. 1998. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66:562–566.
92
A.M. Krensky and C. Clayberger
Vassalli, G., E. Simeoni, J.P. Li, and S. Fleury. 2006. Lentiviral gene transfer of the chemokine antagonist RANTES 9-68 prolongs heart graft survival. Transplantation 81:240–246. Viola, A., and A.D. Luster. 2008. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171–197. Wiedermann, C.J., E. Kowald, N. Reinisch, C.M. Kaehler, I. von Luettichau, J.M. Pattison, P. Huie, R.K. Sibley, P.J. Nelson, and A.M. Krensky. 1993. Monocyte haptotaxis induced by the RANTES chemokine. Curr Biol 3:735–739. Yigit, B., N. Bozkurt, I. Berber, I. Titiz, and T. Isbir. 2007. Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival. Cell Biochem Funct 25:423–426. Yun, J.J., D. Whiting, M.P. Fischbein, A. Banerji, Y. Irie, D. Stein, M.C. Fishbein, A.E. Proudfoot, H. Laks, J.A. Berliner, and A. Ardehali. 2004. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 109:932–937. Zipp, F., H.P. Hartung, J. Hillert, S. Schimrigk, C. Trebst, M. Stangel, C. Infante-Duarte, P. Jakobs, C. Wolf, R. Sandbrink, C. Pohl, and M. Filippi. 2006. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 67:1880–1883. Zlotnik, A., O. Yoshie, and H. Nomiyama. 2006. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243.
Clinical Applications of Activated Immune Cells Luciano Castiello, Marianna Sabatino, Ping Jin, Francesco M. Marincola, and David Stroncek
Introduction Adoptive immune therapy has been used for many years to treat viral diseases, hematologic malignancies and cancer. While some diseased have been effectively treated with adoptive T cell immune therapy, many have not. Most successful T cell therapies have required ex vivo T cell expansion and some have required ex vivo T cell sensitization. NK cells and genetically engineered T cells have also be used for adoptive immune therapy. Dendrtic cells have been extensively used and studied to enhance immune therapies and dendritic cell polarized toward Th1 cells appears to be essential to their effectiveness.
Immune Therapy for Viral Infections Cytomegalovirus Cytomegalovirus (CMV) remains a serious opportunist pathogen in hematopoietic stem cell transplant recipients. Antiviral drugs can be used to treat CMV infection, but they are associated with serious toxicities including suppression of hematopoiesis and renal toxicity. CMV-specific T cells are essential for the control of CMV infections (Peggs 2009). Typically, in healthy subjects who have been infected with CMV a very large proportions of all their CD4+ and CD8+ T cells, 3–5%, are CMV-reactive (Sylwester et al. 2005). Furthermore, following hematopoietic transplantation the risk of CMV-infection is inversely correlated with the reconstitution of CMV-specific T cell immunity. The reconstitution of CD8+ T cells specific for the immune dominant
D. Stroncek (*) Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1184, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_7, © Springer Science+Business Media, LLC 2011
93
94
L. Castiello et al.
CMV protein pp65 provides protective immunity (Cwynarski et al. 2001; Gratama et al. 2001), but long term control of CMV infection is associated with reconstitution of CMV-specific CD4+ cells responses (Hebart et al. 2002). T cell adoptive immune therapy has been successful in preventing CMV-infection and in treating CMV disease. The adoptive transfer of ex vivo expanded CMV-specific donor derived T cells is effective in preventing and treating CMV disease. Walter et al. (1995) have shown that CMV-specific cytotoxic CD8+ T cell clones from CMVseropostive hematopoietic transplant donors expanded ex vivo with CMV-infected fibroblasts and infused following the transplant prevent CMV infection. Another successful CMV adoptive immune therapy strategy makes use of oligo or polyclonal CD8+ T cells, CD4+ T cells or a mixed population. These CMVspecific T cells have been generated by ex vivo expansion of peripheral blood T cells from CMV-positive donors using lyzed CMV infected cells as a source of antigens or by expanding T cells with monocyte-derived dendritic cells (DCs) loaded with CMV-lysate or peptides derived from CMV pp65. These ex vivo expanded CMV-specific T cells have been used to prevent and treat CMV-infections (Einsele et al. 2002; Peggs et al. 2003; Micklethwaite et al. 2007). CMV-specific T cells have also been produced ex vivo using EBV-transformed B cell lines (EBVLCL) transduced with an adenovirus vector containing CMV pp65. Cytotoxic T cells produced with these EBV-LCL are specific for EBV, CMV and adenovirus (Leen et al. 2006). The infusion of these cells to 11 hematopoietic stem cell transplant patients resulted in the in vivo expansion of multispecific cytotoxic lymphocytes and was associated with a reduction in the levels of all three viruses with the resolution of virus-associated symptoms and signs (Leen et al. 2006). CMV-specific CTLs can also be selected directly from peripheral blood mononuclear cells (Peggs 2009). HLA-Class I multimers loaded with CMV immune dominant peptides have been used to select the CTLs. This strategy is effective due to the large proportion of CMV-specific T cells in the peripheral blood of CMV-seropositive subjects. Direct selection of CTLs avoids lengthy ex vivo expansion and allows for the rapid preparation of CMV-specific cytotoxic T cells. HLA class I CMV peptide tetramers coupled to paramagnetic beads have been used to isolate CMV-specific T cells from the peripheral blood mononuclear cells collected from hematopoietic stem cell transplant donors by apheresis (Cobbold et al. 2005). When used clinically in hematopoietic stem cell transplant patients CMV viremia was reduced in all nine patients treated and was cleared completely in eight of the patients (Cobbold et al. 2005).
Immune Therapy for Viral Induce Malignancies Posttransplant EBV-Associated Lymphoproliferative Disease Patients receiving transplants from HLA-matched unrelated donors or mismatched unrelated related donors are at risk for Epstein–Barr virus (EBV)-positive lympho proliferative disease (EBV-LPD). These EBV-associated lymphomas are highly immunogenic tumors that express immune dominant viral antigens such as
Clinical Applications of Activated Immune Cells
95
EBNA3 protein. Immune therapy has been effective for treating EBV-associated lymphomas. Since most people have been infected with EBV and have circulating cytotoxic T cells specific for EBV, peripheral blood leukocytes from hematopoietic stem cell transplant donors have been given to transplant recipients to treat EBV-LPD. The infusion of donor leukocytes isolated from the blood has been found to be effective in 70% of patients. However, donor leukocyte infusions can induce or worsen acute GVHD. To avoid or reduce the risk of developing acute GVHD, many centers are using donor leukocytes that have been highly enriched for EBV-specific cytotoxic T lymphocytes (CTLs) to treat EBV-LPD. These adoptively transferred EBVspecific CTLs are produced by culturing the transplant donor’s T cells with EBV-LCLs. A multicenter trial has found that EBV-specific CTLs produced with EBV-LCLs were 100% effective in preventing EBV-associated lymphomas in 101 at risk patients and were effective in treating EBV-associated lymphomas in 11 of 13 patients treated (Heslop et al. 2010). Gene marking studies showed that the EBV-specific CTLs could be detected in the circulation for up to 9 years (Heslop et al. 2010).
Immune Therapy for Leukemia Donor Leukocyte Infusions Peripheral blood mononuclear cells (PBMCs) collected by apheresis from allogeneic hematopoietic stem cell (HSC) transplant donors are often given to the transplant recipient as posttransplant adoptive immune therapy (Tomblyn and Lazarus 2008; Loren and Porter 2008). Unmanipulated or minimally manipulated PBMCs are given to speed immune recovery and to prevent leukemia relapse following transplantation with T cell depleted grafts. They are also used to treat leukemia relapse following transplantation. They are most effective treating relapse of CML. They are effective in treating CML relapse in more than 60% of patients and in treating molecular relapse of CML in 90% of cases (Tomblyn and Lazarus 2008). Donor leukocyte infusions (DLIs) are also effective in treating relapsed multiple myeloma with a 40–50% response rate. The major complication of DLI therapy is the development of GVHD. Approximately one-third of patients treated with DLIs develop acute or chronic GVHD. Some of these donor leukocyte products are processed extensively. For example, some hematopoietic stem cell transplant recipients are given donor T cells treated to polarized them to a TH2 phenotype to maintain antiviral and antitumor immunity while avoiding GVHD (Fowler et al. 2006).
NK Cells NK cells have potent antitumor activity and play an important role in the treatment of leukemia by allogeneic transplantation. The mismatching of transplant donor
96
L. Castiello et al.
NK cell inhibitor killer-like receptors (KIR) with its HLA Class I antigen ligands expressed in the recipient has been associated with less leukemia relapse in recipients of unrelated donor transplants and in mismatched related donors transplants. Recently, some groups have been using NK cells as primary immune therapy to treat cancer and hematologic malignancies. One challenge of NK cell therapy is delivering an adequate dose of NK cells. Typically NK cells are isolated from PBMC concentrates collected by apheresis. To increase the number of effecter NK cells for clinically therapy NK cells are expanded either in vivo or in vitro. In vivo expansion has been accomplished by the administration of IL-2 and lymphocyte depleting chemotherapy with high dose cyclophosphamide and fludaribine. Lymphocyte depletion results in a transient increase in circulating IL-15 levels. The elevated levels of IL-2 and IL-15 induce in vivo expansion in most patients. This approach has been used with NK cells isolated from HLA haplotype identical donors to treat patients with hematogic malignancies and was associated with hematological remission in 5 of 19 poor prognosis patients with acute myelogenous leukemia (Miller et al. 2005). Two methods have been reported for in vitro expansion. One protocol involves stimulating NK cells with IL-5 and K562 cells that have been transduced with 4-1BB ligand (Imai et al. 2005). Another protocol uses IL-2 and EBV-LCLs to stimulate NK cells (Berg et al. 2009). This approach results in more than 100-fold expansion of NK cells and is being used to treat patients with cancer. Adoptive immune cancer clinical trials with NK cells expanded in vitro with EBV-LCLs are underway, but the results are not yet available.
Immune Therapy for Cancer Tumor Infiltrating Leukocytes for Melanoma Adoptive immune therapy with cytotoxic T cells has been effective in treating cancer. Rosenberg and colleagues have found that tumor infiltrating leukocytes (TIL) from metastatic melanoma lesions expanded ex vivo and administered along with intravenous IL-2 therapy induces objective clinical responses in approximately 31–35% of patients with metastatic melanoma (Rosenberg and Dudley 2009). Clinical responses were associated with the in vitro lysis of autologous tumor by the administered TIL. Gene marking studies, however, found that these cells were short lived with less than 0.1% circulating for more than 1 week. Even better clinical responses have been obtained when TIL are given to patients with metastatic melanoma who have been given nonmyeloablative chemotherapy with cyclophosphamide and fludarabine prior to the administration of TIL and IL-2 therapy. They have also treated melanoma patients with the same nonmyeloablative chemo therapy followed by low dose whole body irradiation and autologous CD34+ cell rescue before TIL infusion. With these modifications the object response rate of
Clinical Applications of Activated Immune Cells
97
TIL therapy increases to 49–72%. Favorable response rate were associated with persistence of the infused cells (Rosenberg and Dudley 2009).
Dendritic Cells Dendritic cells (DCs) are being used for adoptive immune cancer therapy. DCs are key players in both innate and adaptive immune responses. The use of DC-based cellular therapies to enhance innate and adoptive immune mediated tumor rejection is a promising regimen which has shown evidence of improving patient survival and objectively enhancing tumor elimination. DCs are considered essential for the initiation, programming and regulation of antigen-specific immune responses (Steinman and Banchereau 2007). They play a fundamental role in supporting the survival and the effector function of primed T cells while coordinating communication among cells of the immune system. Since DCs were first generated ex vivo for immunotherapy (Mayordomo et al. 1995) and used in clinical trials (Hsu et al. 1996; Nestle et al. 1998), they have been found to be effective in treating patients with lymphoma, melanoma and renal cell carcinoma (Kalinski et al. 2009), although their potential utilization is wider and goes beyond cancer therapy. However, the clinic response rates of DC therapies are only 10–15% (Kalinski et al. 2009). Various reasons for the limited efficacy of DC-based vaccines have been hypothesized, with inefficient activation of Th1polarized responses due to incomplete DC maturation being the most sited (Kalinski et al. 2009; Lee et al. 2008; Giermasz et al. 2009). Most DC adoptive immune therapy protocols produce DCs from peripheral blood monocytes. The frequency of DCs in the peripheral blood is naturally low and they are difficult to separate from other peripheral blood leukocytes (Nicolette et al. 2007). Large quantities of mononuclear cells can easily be collected from the peripheral blood by leukapheresis and monocytes can be isolated from the other leukocytes with high purity by adherence, elutriation, or selection using immunomagnetic beads (Felzmann et al. 2003; Wong et al. 2001; Berger et al. 2005). In order to produce immature DCs (iDCs), monocytes are usually incubated with GM-CSF and IL-4. Because mature DCs (mDCs) are superior to iDCs for the stimulation of cytotoxic T-cells, iDCs derived from monocytes are often treated with various exogenous stimuli known to induce DCs maturation (Gilboa 2007; Albert et al. 2001). The DC maturation process is complicated: DCs can secrete different cytokines, growth factors and chemokines that can, in turn, attract different immune cells and differentially influence their activation in situ (Muthuswamy et al. 2008; Messmer et al. 2003; Moller et al. 2008). Moreover, the methods that are currently used to produce DCs for adoptive immune therapy may not be optimized: immune responses against tumors, pathogens and autoimmunities need different Th specific polarization (Kalinski and Moser 2005a). For these reasons Th-specific immune responses should be obtained by the stimulation of DCs to produce cells with a
98
L. Castiello et al.
specific Th polarizing ability that has still not well understood, characterized and re-produced ex vivo (Kalinski and Moser 2005b). Several strategies have been used to produce mature DCs, which are characterized by high immune cell activation potential. Factors used to mature immature DCs included lipopolysaccharide (LPS), CD40 ligand (CD40L), tumor necrosis factor-a (TNF-a), IFN-g, IFN-g and cocktails combining several factors, to better re-create the inflammation environment, such as prostaglandin E2 (PGE2), interleukin-1b (IL-1b, IL-6, polyinosinic:polycytidylic acid (poly (I:C)). Global gene expression micro arrays have been used to compare DCs matured with various maturation protocols. DC maturation with LPS plus IFN-g was associated with waves of gene expression changes and the genes upregulated during DC maturation included many involved with immune function, cell differentiation, and migration (Jin et al. 2010). Some genes were upregulated or downregulated throughout maturation and others were upregulated or downregulated after 4 and 8 h of maturation but then returned to baseline levels after 24 h. The upregulated genes were most likely to be in pathways involved with the cellular immune response, cytokine signaling, transcriptional regulation and the inflammatory response, while downregulated genes were most likely to belong to metabolic pathways. The expression of inflammatory chemokine ligands including CCL2/MCP-1, CCL3/MIP1a, CCL4/MIP1b, CXCL1/GROa, CXCL9/MIG and CXCL11/ITAC reached a peak at hour 4 h of LPS plus IFN-g maturation, but then returned to baseline levels (Jin et al. 2010). The expression of chemokines CCL5/RANTES, CCL8/ MCP-2, and CXCL10/IP-10 peaked after 8 h and sustained high expression levels through hour 24. Chemokine ligands that were part of Toll-like receptor signaling pathways such as CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11 were all upregulated more than sevenfold during maturation. The levels of most of these genes peaked at hour 4 except for CCL5 and CXCL10 which peaked at hour 8 and sustained high levels of expression through hour 24. Chemokine ligands that preferentially attract Th1 T cells such as CXCL9, CXCL10, and CXCL11 were also markedly increased after 4 h. However, two chemokine ligands for CCR4, which are important attractants of Th2 cells CCL17/TARC and CCL22/MDC, were only slightly upregulated or showed no significant change after 24 h of maturation (Jin et al. 2010). Although after 24 h of LPS and IFN-g maturation DCs were well-armed to induce Th1 responses as exemplified by significant elevations in the expression of the Th1 cell attractants CXCL9, CXCL10, CXCL11 and CCL5 (Jin et al. 2010), another study has found that prostaglandin E2 (PGE2),induces mature DCs which produced high levels of the regulator T cell (Treg) attracting cytokines CCL22 and CXCL12 (Muthuswamy et al. 2008). These Treg cells can counter the effects of Th1 responses by cytotoxic T cells, Th1 cells, and NK cells. In contrast, LPS and IFN-g maturated DCs did not increase the levels of CCL22 and CXCL12 expression (Jin et al. 2010). We have also reviewed the results of DNA microarray data on the maturation of DCs in order to compare different conditions of maturation (Castiello et al. 2010).
Clinical Applications of Activated Immune Cells
99
Fig. 1 Immune pathways activated during the maturation of DCs. When iDCs are matured with LPS, the interaction of LPS with Toll-like receptors leads to a cascade of events leading to the activation of NF-kb, p38-MAPK, ERK1/2 and JNK. Although IL-1, CD40L and TNF-a bind different receptors, when they activate iDCs their downstream signals activate the NF-kb RelA/B complex. In contrast, IFNs stimulate a different pathway that includes the activation of JAKs, TYK2 and STAT1/2
We categorized the various maturation protocols based on the level of overlap of canonical pathways identified by the gene expression data that were believed to be primarily activated by each compound (Fig. 1) (Castiello et al. 2010). We clustered various maturation protocols into three major categories: LPS, CD40L/TNF-a, and IFN-g dependent maturation strategies. In addition, a fourth category was needed for protocols that included cocktails of factors that represented a combination of the other categories. For instance, LPS interacts with Toll-like receptors (TLR)-4 leading to the activation of different transcription factors including nuclear factor -kB (NF-kB), p38 mitogen-activated protein kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), and extracellular signal-regulated protein kinase (ERK1/2). On the other hand, although both CD40L and TNF-a activate NF-kB, this activation occurs through different and only partially overlapping signaling cascades. Quite differently, IFN- and IFN-g signal through the Janus kinase (JNK) and tyrosine kinase (TYK) cascade leading to activation of signal transducer and activator of transcription proteins (STATs), which lead to down-stream effects where the action of NF-kB is also complemented by the action of several interferon regulatory factors (IRFs). LPS consistently induced CCL5, CCL4, CCL18, CCL19, CCL20, CCL23 and IMCAM1, SOD2 and MAPK inhibitors (Table 1) (Castiello et al. 2010). Interferons induced the Th1-polarizing factors CXCL9, CXCL10, CXCL11, MXa, and ISG-15. TNFa and CD40L induced the Th2-polarizing factors CCL17, CXCR4, and IL-10R.
100
L. Castiello et al.
Table 1 Genes consistently induced by each maturation agent and their immune related functions Maturation compound Induced genes Effect Recruitment of a variety of LPS Chemokines: CCL5, CCL4, immune cells; activation CCL20, CCL18, CCL19, of a primary immune CCL23 response against a Inflammatory-related genes: pathogen ICAM1, SOD2 MAPK inhibitors: DUSP1, DUSP5, TNFAIP3 Activation of the Th2-polarized TNF-a/CD40L Chemokines: CCL17 immune response Surface proteins: CXCR4, IL-10R, IL-13R, GM-CSFR Activation of the Th1-polarized IFNs IFN stimulated genes: CXCL-9, immune response CXCL-10, CXCL-11, MXa, ISG-15 Immune-mediated tissue rejection genes: STAT-1, IRF-1, IL-15
New Directions While TIL cell therapy is effective for treating melanoma, TIL cells cannot be produced from all patients since metastatic lesions cannot be biopsied from all patients and lymphocytes cannot be cultured from all biopsies. In addition, T cells from some patients have low affinity T cell receptors. To overcome this limitation several groups are investigating the use of genetically engineered T cells to treat cancer patients. Autologous peripheral blood lymphocytes are genetically modified with genes encoding high affinity TCR a and b chains. High affinity T cell receptor a and b chains from class I HLA-restricted T cell receptors from tumor reactive cytotoxic T cells have been cloned and transferred to T cells from cancer patients. These high affinity T cell receptors give the recipient cells the same antigen specificity as the donor T cells. Melanoma patients have been treated with a genetically modified T cells with MART-1-specific T cells. Synthetic chimeric antigen receptors are also being used to treat patients with cancer. T cells are being genetically modified with chimeric receptors using signaling chains from CD28, 41BB, and CD3 zeta plus antibodies directed to Her2/neu or CD19.
References Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the crosstolerization of CD8+ T cells. Nat. Immunol. 2001;2(11):1010–7. Berg M, Lundqvist A, McCoy P, Jr., Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivoexpanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341–55.
Clinical Applications of Activated Immune Cells
101
Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J. Immunol. Methods 2005;298(1–2):61–72. Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, Krensky AM, Stroncek DF. DC maturation strategies and related pathways: a transcriptional veiw. Curr. Opin. Immunol. 2010. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005;202(3):379–86. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PA. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97(5):1232–40. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916–22. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, Huttner K, Fritsch G. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy 2003;5(5):391–8. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2006;12(11):1150–60. Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol. Immunother. 2009;58(8):1329–36. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 2007;117(5):1195–203. Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL, Cornelissen JJ. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98(5):1358–64. Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99(10):3830–7. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115(5):925–35. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996;2(1):52–8. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106(1):376–83. Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J. Transl. Med. 2010;8(1):4. Kalinski P, Moser M. Opinion – Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 2005;5(3):251–60. Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 2009;5(3):379–90. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008;84(1):319–25.
102
L. Castiello et al.
Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 2006;12(10):1160–6. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41(5):483–93. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995;1(12):1297–302. Messmer D, Messmer B, Chiorazzi N. The global transcriptional maturation program and stimuli-specific gene expression profiles of human myeloid dendritic cells. Int. Immunol. 2003;15(4):491–503. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K, Gottlieb D. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2007;13(6):707–14. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, DeFor TE, Burns LJ, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105(8):3051–7. Moller I, Michel K, Frech N, Burger M, Pfeifer D, Frommolt P, Veelken H, Thomas-Kaskel AK. Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J. Immunother. 2008;31(5):506–19. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008;68(14):5972–8. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998;4(3):328–32. Nicolette CA, Healey D, Tcherepanova I, Whelton P, Monesmith T, Coombs L, Finke LH, Whiteside T, Miesowicz F. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007;25 Suppl 2:B47–60. Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert. Opin. Biol. Ther. 2009;9(6):725–36. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362(9393):1375–7. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009;21(2):233–40. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161):419–26. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005;202(5):673–85. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant. 2008;42(9):569–79. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995;333(16):1038–44. Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky J, Read EJ. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;3(1):19–29.
Part III
Circulating Patterns Associated with Chronic and Acute Immune Pathology
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects Damien Chaussabel, Nicole Baldwin, Derek Blankenship, Charles Quinn, Esperanza Anguiano, Octavio Ramilo, Ganjana Lertmemongkolchai, Virginia Pascual, and Jacques Banchereau
Abstract The blood transcriptome affords a comprehensive view of the status of the human immune system. Global changes in transcript abundance have been measured in the blood of patients with a wide range of diseases. This chapter presents an overview of the advances that have led to the identification of therapeutic targets and biomarker signatures in the field of autoimmunity and infectious disease. It also provides technology and data analysis primers as means of introducing blood transcriptome research to a broad readership. Specifically, we compare microarrays with some of the most recent digital gene expression profiling technologies available to date, including RNA sequencing. Furthermore, in addition to the basic steps involved in the analysis of microarray data we also present more advanced data mining approaches for blood transcriptional fingerprinting.
Blood Transcript Profiling A wide range of molecular and cellular profiling assays are now available to study the human immune system (Fig. 1). Among the systems-wide molecular profiling technologies genomics approaches are the most mature and scalable for high throughput use. The human genome can be investigated from two different angles. Sequence variations, which can be detected using for instance Single Nucleotide Polymorphisms (SNP) chips, permits the identification of common polymorphisms or rare mutations associated with diseases. Hundreds of thousands of SNPs can be typed using these platforms, yielding a genome-wide, hypothesis-free, scan of genetic associations for a given phenotype of interest. The second genome-wide profiling approach employed for the study of immune-mediated diseases consists in the measurement of transcript abundance. Generating transcriptional profiles on
D. Chaussabel (*) Baylor Institute for Immunology Research, Baylor Research Institute, 3434 Live Oak, Dallas, TX 75204, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_8, © Springer Science+Business Media, LLC 2011
105
106
D. Chaussabel et al.
Fig. 1 The immune profiling armamentarium. The number of high throughput molecular and cellular profiling tools available for the assessment of the human immune system from blood is increasing rapidly
a genome-wide scale is both straightforward and cost-effective, affording the most comprehensive view of the status of the human immune system to date. Indeed, such studies can inform us on mechanisms of pathogenesis and thereby create opportunities for discovering potential therapeutic targets and novel clinically relevant biomarkers (Alizadeh et al. 2000; Baechler et al. 2003; Bennett et al. 2003; Sarwal et al. 2003; Wright et al. 2003; Achiron et al. 2004; Batliwalla et al. 2005a; Griffiths et al. 2005; Pascual et al. 2005). Transcriptional profiles have been obtained from many human tissues; including for instance the skin (Deonarine et al. 2007; Panelli et al. 2007; Greco et al. 2010; Cole et al. 2001), muscle (Berchtold et al. 2009), liver (Frueh et al. 2001; Flanagan et al. 2009), kidney (Flechner et al. 2004; Bunnag et al. 2009) or brain (Glatt et al. 2005). Specifically, this review will focus on the use of blood transcript profiling. Blood is the pipeline of the immune system, with immune cells exposed to factors released in the bloodstream or present in peripheral tissues from which they re-circulate. It is an accessible tissue for which sampling can easily be standardized, with robust blood collection and RNA stabilization systems becoming widely available in recent years (Debey et al. 2006; Asare et al. 2008). In contrast with
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
107
many other tissues blood can also be sampled repeatedly over time, which constitutes a key property for monitoring the immunological status of human subjects.
Profiling Human Subjects in Health and Disease Profiling Autoimmune Diseases The field of autoimmunity has proved a fertile ground for blood transcriptional studies. The work has initially focused on diseases with clear systemic involvement such as SLE (Baechler et al. 2003; Bennett et al. 2003). This has contributed to the identification of a type 1 interferon signature in the blood of a majority of lupus patients, prompting the development of therapies targeting this pathway (Yao et al. 2009). Furthermore, the potential value of this and other blood transcriptional signatures for the assessment of disease activity has been examined (Sandrin-Garcia et al. 2009; Petri et al. 2009; Nikpour et al. 2008; Nakou et al. 2008; Bauer et al. 2009; Chaussabel et al. 2008). Systemic onset Juvenile Arthritis (SoJIA) is another disease with systemic involvement that greatly benefited from the study of blood transcriptional profiles, with this proof of principle work leading to the development of both therapeutic and diagnostic modalities (Pascual et al. 2005, 2008; Allantaz et al. 2007a, b). Diseases with specific organ involvement have also been the subjects of significant, yet not always extensive, blood profiling efforts. Thus blood signatures have been obtained from patients with multiple sclerosis (Achiron et al. 2004; Bomprezzi et al. 2003). Given the inaccessibility of the brain, blood constitutes a particularly attractive source of surrogate molecular markers for this disease. These efforts have yielded a systemic signature and identified potential predictive markers of clinical relapse and response to treatment (van Baarsen et al. 2008; Gurevich et al. 2009; Achiron et al. 2007a). Transcriptional signatures have also been generated in the context of dermatologic diseases. In this case the target organ being readily accessible, efforts have been focusing on profiling transcript abundance in skin tissues (Nomura et al. 2003; de Jongh et al. 2005). However, systemic involvement has been recognized in recent years to be an important component of autoimmune skin diseases and unique blood transcriptional profiles have also been identified for example in patients with Psoriasis (Batliwalla et al. 2005a; Stoeckman et al. 2006; Koczan et al. 2005). Blood transcriptional profiles have been generated in the context of many other autoimmune diseases. Indeed, the range of autoimmune/autoinflammatory diseases that have been investigated encompasses: SLE (Baechler et al. 2003; Bennett et al. 2003; Crow and Wohlgemuth 2003; Han et al. 2003), juvenile idiopathic arthritis (Pascual et al. 2005; Allantaz et al. 2007a; Ogilvie et al. 2007; Fall et al. 2007; Barnes et al. 2009), multiple sclerosis (Achiron et al. 2007b; Singh et al. 2007), rheumatoid arthritis (Edwards et al. 2007; van der Pouw Kraan et al. 2007; Lequerre et al. 2006; Batliwalla et al. 2005b), Sjogren’s syndrome (Emamian et al. 2009), diabetes (Kaizer et al. 2007; Takamura et al. 2007), inflammatory bowel disease
108
D. Chaussabel et al.
(Burczynski et al. 2006), psoriasis and psoriatic arthritis (Batliwalla et al. 2005a; Stoeckman et al. 2006), inflammatory myopathies (Greenberg et al. 2005; Baechler et al. 2007), scleroderma (Tan et al. 2006; York et al. 2007), vasculitis (Alcorta et al. 2007) and antiphospholipid syndrome (Potti et al. 2006). The body of work produced that focuses on blood transcript profiling in the context of autoimmune diseases has been covered at length in a recent review (Pascual et al. 2010).
Profiling Infectious Diseases Global changes in transcript abundance have also been measured in the blood of patients with infectious diseases. In this context, alterations of blood transcriptional profiles are a reflection of the immunological response mounted by the host against pathogens. This response is mediated by specialized receptors expressed at the surface of host cells recognizing pathogen-associated molecular patterns (Janeway and Medzhitov 2002). Different classes of pathogens signal through different combinations of receptors, eliciting in turn different types of immune responses (Aderem and Ulevitch 2000). This translates experimentally in distinct transcriptional programs being induced upon exposure of immune cells in vitro to distinct classes of infectious agents (Nau et al. 2002; Huang et al. 2001; Chaussabel et al. 2003). Similarly, patterns of transcript abundance measured in the blood of patients with infections caused by different etiological agents were found to be distinct (Ramilo et al. 2007). Predictably, dramatic changes were observed in the blood of patients with systemic infections (e.g., sepsis) (Pankla et al. 2009; Tang et al. 2009). However, profound alterations in patterns of transcript abundance were also found in patients with localized infections (e.g., upper respiratory tract infection, urinary tract infections, pulmonary tuberculosis, skin abscesses) (Allantaz et al. 2007a; Ramilo et al. 2007; Jacobsen et al. 2007). An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Measuring changes in host transcriptional profiles may therefore prove of diagnostic value even in situations where the causative pathogenic agent is not present in the test sample. Importantly, it may also help ascertain the severity of the infection and monitor its course. Infections often present as acute clinical events, thus it is important to capture dynamic changes in transcript abundance that occur during the course of the infection from the time of initial exposure. Blood signatures have been described in the context of acute infections caused by a wide range of pathogenic parasites, viruses and bacteria, including: Plasmodium (Griffiths et al. 2005; Franklin et al. 2009), respiratory viruses (Influenza, Rhinovirus, Respiratory Syncytial Virus) (Ramilo et al. 2007; Reghunathan et al. 2005; Popper et al. 2009; Zaas et al. 2009; Thach et al. 2005), Dengue virus (Ubol et al. 2008; Nascimento et al. 2009), Adenovirus (Popper et al. 2009), as well as Salmonella (Thompson et al. 2009), Mycobacterium tuberculosis (Jacobsen et al. 2007), Staphylococcus aureus (Ardura et al. 2009),
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
109
Burkholderia pseudomallei (Pankla et al. 2009) and in the general context of bacterial sepsis (Tang et al. 2009; Wong et al. 2009; Payen et al. 2008; Johnson et al. 2007). Some of those pathogens will persist and establish chronic infections (e.g., Human Immunodeficiency Virus, Plasmodium) that may lead to a state of latency (e.g., Tuberculosis), and transcript profiling may in those situations be used as a surveillance tool for the monitoring of disease progression or reactivation. Blood profiling of infectious diseases remains also limited in scale. In particular, additional studies will be necessary to ascertain dynamic changes occurring over time.
Profiling other Diseases Blood transcript profiling studies have been carried out in the cancer research field. While hematological malignancies have led the way (reviewed in (Staratschek-Jox et al. 2009)), blood profiles have also been obtained more recently from patients with solid tumors (Aaroe et al. 2010). Notably, these signatures can reflect the immunological or physiological changes effected by cancers but also by the presence of rare tumor cells in the circulation (Findeisen et al. 2008; Hayes et al. 2006; Martin et al. 2001). Blood signatures have also been obtained from solid organ transplant recipients in the context of both tolerance (Martinez-Llordella et al. 2008; Kawasaki et al. 2007; Brouard et al. 2007) and graft rejection (Flechner et al. 2004; Lin et al. 2009; Alakulppi et al. 2008). While such signatures can also be detected in biopsy material (Sarwal et al. 2003; Mueller et al. 2007; Scherer et al. 2003) blood offers the distinct advantage of being accessible for safely monitoring molecular changes on a routine basis. Some work has also been done in the context of cardiovascular diseases where inflammation is known to play an important role. Hence, profiles have been identified in a wide range of conditions, including stroke, chronic heart failure or acute coronary syndrome (Tang et al. 2001; Nakayama et al. 2008; Moore et al. 2005; Cappuzzello et al. 2009). Other efforts have yielded blood transcriptional signature in patients with neurodegenerative diseases (Maes et al. 2007; Lovrecic et al. 2009; Borovecki et al. 2005), in response to stress, environmental exposure (Peretz et al. 2007; McHale et al. 2009; Bushel et al. 2007), exercise (Kawai et al. 2007; Connolly et al. 2004) or even laughter (Hayashi et al. 2007). The body of published work would be too large to be cited in this review – and it is likely to be only the tip of the iceberg, with a lot more unpublished data scattered throughout the public and private space. However, the vast majorities of these studies are underpowered and sometimes lack even the most rudimentary validation steps. All too often primary data are not available for reanalysis either, reflecting a lack of enforcement of editorial policies, or the absence thereof in some journals. Hence one of the main challenges for this field is to move beyond the proof of principle stage and consolidate the wealth of data being generated.
110
D. Chaussabel et al.
Collectively, studies published thus far demonstrate that alterations in transcript abundance can be detected on a genome-wide scale in the blood of patients with a wide range of diseases. We have also learned that: (1) multiple diseases can share components of the blood transcriptional profile. This is for instance the case for inflammation or interferon signatures; (2) while no single element of the profile may be specific to any given disease it is the combination of those elements that makes a signature unique; (3) finally, the work that has been accomplished to date highlights the importance of carrying out analyses aiming at directly comparing transcriptional profiles across diseases. Indeed, much for instance can be learned about autoimmunity from studying responses to infection, and vice and versa. Furthermore, such efforts may eventually lead us closer towards a molecular classification of diseases.
Technology Primer (Fig. 1) Microarray technologies are limited by several factors, such as hybridization noise (background signal, nonspecific binding) and lack of sensitivity for transcripts expressed at very low or very high levels (dynamic range). Additional limitations derive from the fact that they rely on existing sequence knowledge and lack the capacity to quantify alternative messages, such as splice variants of a given gene. When considering human studies with potential clinical applications, perhaps the main limitation, however, is that direct comparability of data across batches and platforms is sometimes impossible. Real-time PCR technology is currently considered the gold standard for measuring transcript abundance. However, the number of transcripts that can be detected using this technique is limited. Products have been introduced recently that partially address this shortcoming. Alternative technology platforms have also become recently available, such as one developed by Nanostring, which can detect transcripts abundance for up to 500 transcripts with high sensitivity (Geiss et al. 2008). The approach is “digital” since it consists in counting individual RNA molecules. But a distinct advantage of this technology, which like microarrays is hybridizationbased, is that sample preparation needs are reduced to a minimum – for instance none of the steps involving enzymatic reactions. Also, given its high sensitivity, fast turnaround time, sample throughput and intermediate multiplexing ability this approach seems particularly promising for bedside applications. Methods relying on high-throughput sequencing for the genome-wide measurement of RNA abundance are also becoming available (Wold and Myers 2008). RNA-seq (RNA sequencing) (Sultan et al. 2008) starts with a population of RNA (total or fractionated, such as poly(A)+) that is converted to a library of cDNA fragments. High thoughput sequencing of such fragments yields short sequences or reads which are typically 30–400 bp in length, depending on the DNA-sequencing technology used. For a given sample, tens of millions of such sequences will then be uniquely mapped against a reference genome. The higher the level of expression
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
111
Fig. 2 Cutting-edge RNA profiling technologies. Several technology platforms are available for measuring RNA abundance on large scales. Microarray and Nanostring technologies rely on oligonucleotide probes to capture complementary target sequences. Nanostring and RNA-seq technologies measure abundance at the single molecule level, with results respectively expressed as molecule counts and sequence coverage. Microarray and RNA-seq technologies require extensive sample processing, which include amplification steps
of a given gene the higher the number of reads that will be aligned against it (Fig. 2). Thus, this approach does not rely on probe design and provides information on not only transcript abundance but also transcriptome structure (splice variants), noncoding RNA species such as microRNAs (miRNA), and genetic polymorphisms. The use of RNA-seq has not reached the mainstream. Indeed, challenges ahead are multiple, including sample preparation, storage of massive amounts of data and sequence alignment (Wang et al. 2009). In time, RNA-seq is expected to become sufficiently cost-effective and practical to eventually supersede microarray technologies.
Microarray Data Analysis For years the scale of blood transcriptional studies has been constrained by the cost of the technology. With the price tag on a commercial whole genome microarray decidedly below the $100 USD mark, it is not the case anymore. Also data analysis and exploitation, that has from the start been one of the challenges for transcriptome research, has now clearly become the main rate-limiting step.
112
D. Chaussabel et al.
Analysis Primer This section covers some of the basic steps and considerations involved in microarray data analysis. Per-Chip Normalization: This step controls for array-wide variations in intensity across multiple samples that form a given dataset. After background subtraction, a normalization algorithm is used to rescale the difference in overall intensity to a fixed intensity level for all samples across multiple arrays. Data filtering: Typically more than half of the probes present on a microarray do not detect a signal for any of the samples in a given analysis. Thus, a detection filter is applied to remove such probes. This step avoids the introduction of unnecessary noise in downstream analyses. Unsupervised analysis: The aim of this analysis is to group samples on the basis of their molecular profiles without a priori knowledge of their phenotypic classification. The first step consists in selecting transcripts that are expressed in the dataset (detection filter), and display some degree of variability (which will facilitate sample clustering). For instance, this filter could select transcripts with expression levels that deviate by at least twofold from the median intensity calculated across all samples. Importantly this additional filter is applied independently of any knowledge of sample grouping or phenotype (which makes this type of analysis “unsupervised”). Next, pattern discovery algorithms are often applied to identify molecular phenotypes or trends in the data. Clustering: Clustering is commonly used for the discovery of expression patterns in large datasets. Hierarchical clustering is an iterative agglomerative clustering method that can be used to produce gene trees and condition trees. Condition tree clustering groups samples based on the similarity of their expression profiles across a specified gene list. Other commonly employed clustering algorithms include k-means clustering and self-organizing maps. Class Comparison: Class comparison analyses identify genes differentially expressed among groups and/or time points. The methods for analysis are chosen based on the study design. For studies with independent observations and two or more groups, t-tests, ANOVA, Mann-Whitney U tests, or Kruskal-Wallis tests are used. For more complex studies (e.g., longitudinal) appropriate linear mixed model analyses are chosen. Multiple Testing Correction: Multiple testing correction (MTC) methods provide a means to mitigate the level of noise in sets of transcripts identified by class comparison (in order to lower permissiveness of false positives). While it reduces noise, MTC promotes a higher false negative rate as a result of dampening the signal. The methods available are characterized by varying degrees of stringency, and therefore they produce gene lists with different levels of robustness. • Bonferroni correction is the most stringent method used to control the familywise error rate (probability of making one or more type I errors) and can drastically reduce false positive rates. Conversely, it increases the probability of having false negatives.
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
113
• Benjamini and Hochberg false discovery rate (Benjamini and Hochberg 1995) is a less stringent MTC method and provides a good balance between discovery of statistically significant genes while limiting false positives. By using this procedure with a value of 0.01, 1% of the statistically significant transcripts might be identified as significant by chance alone (false positives). Class Prediction: Class prediction analyses assess the classification capability of gene expression data for a study subject or sample. K-nearest neighbors is a commonly used technique for this task. Using Euclidian or other measures of distance, this method identifies the user defined “k” number of closest observations for an unclassified sample. Class prediction is then determined by the lowest p-value, which is calculated for each group. The p-values are based on the likelihood of obtaining the observed number of neighbors for a specific class given the overall class proportion in the data set. Other available class prediction procedures include, but are not limited to, Discriminant Analysis, General Linear Model Selection, Logistic Regression, Distance Scoring, Partial Least Squares, Partition Trees, and Radial Basis Machine. Sample Size: The number of samples necessary for the identification of a robust signature is variable. Indeed, sample size requirements will depend on the amplitude of the difference between and the variability within study groups. A number of approaches have been devised for the calculation of sample size for microarray experiments, but to date little consensus exists (Dobbin et al. 2008; Jorstad et al. 2008; Pawitan et al. 2005; Yang et al. 2003). Hence, best practices in the field consist in the utilization of independent sets of samples for the purpose of validating candidate signatures. Thus, the robustness of the signature identified will rely on a statistically significant association between the predicted and true phenotypic class in the first and the second test sets.
Analysis of Significance Patterns The diagnosis of SoJIA takes weeks to months, as it is based on clinical criteria which lack specificity (Cassidy and Ross 2001). Indeed, initial symptoms mimic infections or malignancies and it is only when arthritis appears that the disease can be recognized. We surmised that the blood transcriptome of these children could be a source of diagnostic biomarkers. The profiles that differentiate SoJIA patients from healthy controls, however, were highly similar to those of children with febrile infectious diseases of both bacterial and viral origin (Allantaz et al. 2007a). Additionally, because SoJIA can present at any age during childhood, matching the control groups for this disease and for infections that predominate at earlier or later times during childhood was a challenge. Thus, we devised a custom meta-analysis strategy for biomarker selection relying on the analysis of patterns of significance (Chaussabel et al. 2005). This approach can be used to compare diseases across multiple datasets, each being analyzed in relation to its own set of healthy controls. First, statistical comparisons were performed between each group of patients
114
D. Chaussabel et al.
(SoJIA, S. aureus, S. pneumoniae, E. coli, influenza A, and SLE) and their respective control groups composed of age- and gender-matched healthy donors. The p-values obtained from each comparison were then subjected to selection criteria. This permitted us to identify genes significantly changed in SoJIA patients vs. their control group, and not in any of the other disease vs. their own control groups. The SoJIA-specific signature that we obtained using this algorithm was composed of 88 transcripts. Treatment with IL1 antagonists was able to extinguish this signature in the majority of patients. Using a more stringent analysis, 12/88 transcripts were used to correctly classify an independent group of patients during the systemic phase of the disease against healthy and febrile disease controls. These 12 genes were not dysregulated however in SoJIA patients who had resolved the systemic phase and were left with chronic arthritis, suggesting that they are specifically dysregulated in the initial phase of the disease, probably the time of greatest sensitivity to IL1 blockade. The specificity of 7/12 genes has been recently validated in an independent study of PBMC transcriptional profiles including different types of JIA patients (Barnes et al. 2009). The same type of analysis has allowed us to identify blood disease-specific transcriptional markers differentiating SLE patients from patients with diseases that also display a Type I IFN signature such as Influenza infection (Chaussabel et al. 2005).
A Modular Analysis Framework A myriad of approaches have been developed for the analysis of genome-wide transcriptional profiling data (Mootha et al. 2003; Segal et al. 2003a; Allison et al. 2006; Horvath & Dong 2008). The main challenges encountered while mining such data are several fold: (a) dimensionality, or how to cope with the fact that the number of parameters measured exceeds by several order of magnitude the number of conditions included in any given experiment; (b) noise; a direct consequence of the first point is that results from microarray analyses are particularly permissive to noise (false discovery); (c) data visualization is critical as it helps promote insight and supports data interpretation. Dimension reduction techniques can help address some of those issues. Several groups have developed approaches that consist in grouping genes into distinct units or “modules”. Those genes may be grouped together based on similarities in transcriptional patterns or function. Multiple approaches have been used for the construction of such modules (Chaussabel et al. 2008; Horvath and Dong 2008; Ruan et al. 2010; Segal et al. 2003b; Suthram et al. 2010; Ulitsky and Shamir 2009). We have developed a modular data mining strategy for the specific purpose of analyzing and interpreting blood transcriptional profiles (Chaussabel et al. 2008). This approach consists in a priori grouping sets of genes with similar transcriptional patterns. This is repeated for different datasets and subsequently when comparing the cluster membership of all the genes across those datasets, the genes with similar membership are grouped together to form a transcriptional module. Structuring the
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
115
data permits to focus downstream statistical testing on these sets of transcripts that form coherent transcriptional modular units. This is in contrast with more traditional approaches applying statistical tests iteratively for thousands of individual transcripts that are treated as independent variables. The modular transcriptional framework that we have developed constitutes a dimension reduction technique and as such can: a) facilitate functional interpretation; b) enable comparative analyses across multiple datasets and diseases; c) minimize noise and improve robustness of biomarker signatures; and d) yield multivariate metrics that can be used at the bedside. Data visualization is also of critical importance for the interpretation of large-scale datasets. We have developed a straightforward approach for mapping global transcriptional changes for individual diseases on a modular basis (Fig. 3 and interactive web version: www.biir.net/modules). Briefly, differences in expression levels between study groups are displayed for each module on a grid. Each position on the grid is assigned to a given module; a red spot indicates an increase and a blue spot a decrease in transcript abundance. The spot intensity is determined by the proportion of transcripts reaching significance for a given module. A posteriori, biological interpretation has linked several modules to immune cells or pathways (see legend of Fig. 3).
Interpretation Important technical and biological constraints must be taken into account when interpreting blood transcriptome data. For one, reproducibility issues remains a legitimate concern (Shi et al. 2006, 2008; Tan et al. 2003). It is important to avoid confounding the analysis with technical variables. For example, reuse of pre-existing data for direct group comparison should be avoided. Samples should be run if possible in one single batch. If this is not possible, case and control samples should be randomized across the different runs. Overall, the availability of cost-effective commercial platforms has reduced the number of formats used for analysis and contributes to enhance data quality and reproducibility when compared to early cDNA arrays. Meta-analysis of data obtained using different platforms and from different laboratories is possible, but one must proceed with caution. A common strategy consists in the use of a control group that is common to all datasets under study (e.g., non stimulated or healthy controls) (Allantaz et al. 2007a; Chaussabel et al. 2005; Butte and Kohane 2006; Rhodes et al. 2004). Disease heterogeneity is also an important initial limiting step. Thus, patient clinical characteristics and disease stages should be taken into account and carefully recorded at the time of sample collection. Furthermore, drug treatments and comorbidities may impact blood transcriptional signatures and those variables cannot always be isolated, as patients cannot be taken off treatments. These factors also pose significant challenges in terms of study design and downstream data analysis. We have found that including samples from recently diagnosed and untreated patients is useful to select biomarkers related to disease pathogenesis. Selective inclusion criteria can be subsequently relaxed to broaden the scope and potential clinical impact of a study.
116
D. Chaussabel et al.
Fig. 3 Modular analysis of blood leukocyte transcriptional profiles. (a) Gene expression levels from patients with acute S. pneumoniae infection and respective healthy volunteer PBMCs were compared (p < 0.05, Mann-Whitney U test). Graphs represent transcriptional profiles of genes that were significantly changed in modules M1.3, M1.5, M1.8 and M3.2. The results obtained for each of the 28 modules constituting this analysis framework are represented on the grid. Blue dots indicate modules for which transcript abundance is significantly lower in patients vs healthy (e.g., M1.3 and M1.8), red dots indicate modules for which transcript abundance is higher in patients (e.g., M1.5 and M3.2). Results obtained for the 28 PBMC transcriptional modules are displayed on a grid. Coordinates indicate module IDs (e.g., M2.8 is row M2, column 8). (b) Disease fingerprints: three additional datasets were similarly processed. Profiles were obtained from patients with Systemic Lupus Erythematosus, Liver transplant recipients under pharmacological immunosuppression infection and patients with metastatic melanoma. Functional interpretation is indicated on a grid by a color code
Working with pediatric populations is attractive because it is easier to accrue patients in the initial phases of disease and significantly less comorbidities and modalities of treatments will be encountered. The importance of implementation of common methods and standards for the collection of this type of information, samples and measurements cannot be stressed enough (Snyder et al. 2009; Whitney et al. 2003).
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
117
Finally, when interpreting results from blood transcriptome analyses it is important to consider that changes in transcript abundance might reflect two phenomena: (1) transcriptional regulation; (2) relative changes in cell composition. The later can also provide reliable and valid clinical correlate/biomarker signatures, as shown in patients with SLE who display plasma cell precursor and/or immature neutrophils signatures (Bennett et al. 2003). The analysis of purified cell subpopulations might represent a useful way to identify differences that would otherwise be masked when analyzing whole blood. Subpopulation frequencies (i.e., shifts in naïve, memory and/or effector populations of T and/or B cells) may still be responsible however for transcriptional differences between patients and controls. Cell purification techniques might also be a source of biased results. Positive selection might for example alter the steady state transcriptome by delivering signals through surface receptors, while enrichment purification methods tend to be more prone to contamination with other cell types. Another approach consists in deconvoluting whole blood transcriptional profiles “in silico”. This type of analysis attempts to deduce cellular composition or cell-specific levels of gene expression using statistical methodologies (Wang et al. 2006; Lu et al. 2003; Lahdesmaki et al. 2005; Abbas et al. 2009; Repsilber et al. 2010).
Conclusions Blood transcript profiling has earned its place in the molecular and cellular profiling armamentarium used to study the human immune system. Changes in transcript abundance in blood recapitulate both cellular and molecular events, thus providing a comprehensive snapshot of the immunological status of an individual. The interpretation of transcript profiling data generated from complex tissues such as blood is a challenge, but it is not an insurmountable one. Indeed, powerful analysis strategies are now available that can be used to streamline the exploitation of the massive amounts of data generated in the context of such studies. Whole genome transcript profiling has become both robust and cost-effective. Furthermore, in contrast with other immunological assays the collection and preservation of blood samples for microarray analysis can be easily standardized. Altogether these aspects makes this an assay of choice for large-scale immunomonitoring. Acknowledgements The work of the author is supported by the Baylor Health Care System Foundation and the National Institutes of Health (U19 AIO57234-02, U01 AI082110, P01 CA084512).
References Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, Hagen N, Skaane P, Lonneborg A, Sharma P, Borresen-Dale AL: Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010, 12(1):R7.
118
D. Chaussabel et al.
Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF: Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One 2009, 4(7):e6098. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M: Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004, 55(3):410–417. Achiron A, Gurevich M, Snir Y, Segal E, Mandel M: Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. Clin Exp Immunol 2007, 149(2):235–242. Achiron A, Feldman A, Mandel M, Gurevich M: Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007, 1107:155–167. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406(6797):782–787. Alakulppi N, Seikku P, Jaatinen T, Holmberg C, Laine J: Feasibility of diagnosing subclinical renal allograft rejection in children by whole blood gene expression analysis. Transplantation 2008, 86(9):1222–1228. Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA et al: Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007, 72(7):853–864. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503–511. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Wise C, Palucka K et al: Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007, 204(9):2131–2144. Allantaz F, Chaussabel D, Banchereau J, Pascual V: Microarray-based identification of novel biomarkers in IL-1-mediated diseases. Curr Opin Immunol 2007, 19(6):623–632. Allison DB, Cui X, Page GP, Sabripour M: Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006, 7(1):55–65. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, Allantaz F, Pascual V, Banchereau J, Chaussabel D, Ramilo O: Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One 2009, 4(5):e5446. Asare AL, Kolchinsky SA, Gao Z, Wang R, Raddassi K, Bourcier K, Seyfert-Margolis V: Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genomics 2008, 9:474. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V et al: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100(5):2610–2615. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13(1–2):59–68. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ et al: Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60(7):2102–2112. Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E et al: Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005, 11(1–12):21–29. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, Damle A, Ortmann WA, Perrone A, Kantor AB et al: Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005, 6(5):388–397.
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
119
Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC: Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60(10):3098–3107. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995, 57:289–300. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197(6):711–723. Berchtold LA, Larsen CM, Vaag A, Faulenbach M, Workman CT, Kruhoffer M, Donath M, Mandrup-Poulsen T: IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw 2009, 20(2):81–87. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O’Garra A. Nature. 2010 Aug 19;466(7309):973-7.PMID: 20725040 [PubMed – in process]. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS et al: Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003, 12(17):2191–2199. Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV et al: Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci U S A 2005, 102(31):11023–11028. Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, Baeten D, Zhang M, Ashton-Chess J, Braudeau C et al: Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007, 104(39):15448–15453. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, Kaplan B et al: Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009, 20(5):1149–1160. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F et al: Molecular classification of Crohn’s disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn 2006, 8(1):51–61. Bushel PR, Heinloth AN, Li J, Huang L, Chou JW, Boorman GA, Malarkey DE, Houle CD, Ward SM, Wilson RE et al: Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci U S A 2007, 104(46):18211–18216. Butte AJ, Kohane IS: Creation and implications of a phenome-genome network. Nat Biotechnol 2006, 24(1):55–62. Cappuzzello C, Napolitano M, Arcelli D, Melillo G, Melchionna R, Di Vito L, Carlini D, Silvestri L, Brugaletta S, Liuzzo G et al: Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics 2009, 38(3):233–240. Cassidy JT, Ross E: Juvenile Rheumatoid Arthritis. In: Textbook of Pediatric Rheumatology. 4th edn;W.B. Saunders Company, Philadelphia, 2001:218–321. Chaussabel D, Semnani RT, McDowell MA, Sacks D, Sher A, Nutman TB: Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 2003, 102(2):672–681. Chaussabel D, Allman W, Mejias A, Chung W, Bennett L, Ramilo O, Pascual V, Palucka AK, Banchereau J: Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci 2005, 1062:146–154. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I et al: A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. [see comment]. Immunity 2008, 29(1):150–164. Cole J, Tsou R, Wallace K, Gibran N, Isik F: Comparison of normal human skin gene expression using cDNA microarrays. Wound Repair Regen 2001, 9(2):77–85.
120
D. Chaussabel et al.
Connolly PH, Caiozzo VJ, Zaldivar F, Nemet D, Larson J, Hung SP, Heck JD, Hatfield GW, Cooper DM: Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol 2004, 97(4):1461–1469. Crow MK, Wohlgemuth J: Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5(6):279–287. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005, 125(6):1163–1173. Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL: A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 2006, 87(5):653–664. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF: Gene expression profiling of cutaneous wound healing. J Transl Med 2007, 5:11. Dobbin KK, Zhao Y, Simon RM: How large a training set is needed to develop a classifier for microarray data? Clin Cancer Res 2008, 14(1):108–114. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, Trepicchio WL, Larsen G, Foxwell BM, Brennan FM, Feldmann M et al: Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 2007, 13(1–2):40–58. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, Segal B, Rhodus NL, Moser KL: Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes Immun 2009, 10(4):285–296. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S et al: Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007, 56(11):3793–3804. Findeisen P, Rockel M, Nees M, Roder C, Kienle P, Von Knebel Doeberitz M, Kalthoff H, Neumaier M: Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol 2008, 33(5):1001–1010. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE: Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol 2009, 84(6):328–334. Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J, Chismar JD, Horvath S, Mondala T, Gilmartin T et al: Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004, 4(9):1475–1489. Franklin BS, Parroche P, Ataide MA, Lauw F, Ropert C, de Oliveira RB, Pereira D, Tada MS, Nogueira P, da Silva LH et al: Malaria primes the innate immune response due to interferongamma induced enhancement of toll-like receptor expression and function. Proc Natl Acad Sci U S A 2009, 106(14):5789–5794. Frueh FW, Hayashibara KC, Brown PO, Whitlock JP, Jr.: Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol Lett 2001, 122(3):189–203. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T et al: Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008, 26(3):317–325. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N, Han M, Liew CC, Tsuang MT: Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 2005, 102(43):15533–15538. Greco JA, III, Pollins AC, Boone BE, Levy SE, Nanney LB: A microarray analysis of temporal gene expression profiles in thermally injured human skin. Burns 2010, 36:192–204. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M et al: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57(5):664–678.
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
121
Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, Wathen A, Rockett KA, Mott R, Levin M, Newton CR et al: Genomewide analysis of the host response to malaria in Kenyan children. J Infect Dis 2005, 191(10):1599–1611. Gurevich M, Tuller T, Rubinstein U, Or-Bach R, Achiron A: Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells. BMC Med Genomics 2009, 2:46. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY: Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4(3):177–186. Hayashi T, Tsujii S, Iburi T, Tamanaha T, Yamagami K, Ishibashi R, Hori M, Sakamoto S, Ishii H, Murakami K: Laughter up-regulates the genes related to NK cell activity in diabetes. Biomed Res 2007, 28(6):281–285. Hayes DC, Secrist H, Bangur CS, Wang T, Zhang X, Harlan D, Goodman GE, Houghton RL, Persing DH, Zehentner BK: Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients. Anticancer Res 2006, 26(2B):1567–1575. Horvath S, Dong J: Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol 2008, 4(8):e1000117. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, Lander ES, Hacohen N: The plasticity of dendritic cell responses to pathogens and their components. Science 2001, 294(5543):870–875. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, Ziegler A, Kaufmann SH: Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007, 85(6):613–621. Janeway CA, Jr., Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197–216. Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS, Scalea TM: Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007, 245(4):611–621. Jorstad TS, Midelfart H, Bones AM: A mixture model approach to sample size estimation in twosample comparative microarray experiments. BMC Bioinformatics 2008, 9:117. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC: Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007, 92(9):3705–3711. Kawai T, Morita K, Masuda K, Nishida K, Sekiyama A, Teshima-Kondo S, Nakaya Y, Ohta M, Saito T, Rokutan K: Physical exercise-associated gene expression signatures in peripheral blood. Clin J Sport Med 2007, 17(5):375–383. Kawasaki M, Iwasaki M, Koshiba T, Fujino M, Hara Y, Kitazawa Y, Kimura H, Uemoto S, Li XK, Tanaka K: Gene expression profile analysis of the peripheral blood mononuclear cells from tolerant living-donor liver transplant recipients. Int Surg 2007, 92(5):276–286. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, Gross G, Kunz M: Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005, 15(4):251–257. Lahdesmaki H, Shmulevich L, Dunmire V, Yli-Harja O, Zhang W: In silico microdissection of microarray data from heterogeneous cell populations. BMC Bioinformatics 2005, 6:54. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, Daveau M, Mejjad O, Daragon A, Tron F et al: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006, 8(4):R105. Lin D, Hollander Z, Ng RT, Imai C, Ignaszewski A, Balshaw R, Freue GC, Wilson-McManus JE, Qasimi P, Meredith A et al: Whole blood genomic biomarkers of acute cardiac allograft rejection. J Heart Lung Transplant 2009, 28(9):927–935. Lovrecic L, Kastrin A, Kobal J, Pirtosek Z, Krainc D, Peterlin B: Gene expression changes in blood as a putative biomarker for Huntington’s disease. Mov Disord 2009, 24(15):2277–2281. Lu P, Nakorchevskiy A, Marcotte EM: Expression deconvolution: a reinterpretation of DNA microarray data reveals dynamic changes in cell populations. Proc Natl Acad Sci U S A 2003, 100(18):10370–10375. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM: Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007, 28(12):1795–1809.
122
D. Chaussabel et al.
Martin KJ, Graner E, Li Y, Price LM, Kritzman BM, Fournier MV, Rhei E, Pardee AB: Highsensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci U S A 2001, 98(5):2646–2651. Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benitez C, Pons JA, Parrilla P, Ramirez P et al: Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118(8):2845–2857. McHale CM, Zhang L, Lan Q, Li G, Hubbard AE, Forrest MS, Vermeulen R, Chen J, Shen M, Rappaport SM et al: Changes in the peripheral blood transcriptome associated with occupational benzene exposure identified by cross-comparison on two microarray platforms. Genomics 2009, 93(4):343–349. Moore DF, Li H, Jeffries N, Wright V, Cooper RA, Jr., Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H et al: Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005, 111(2):212–221. Mootha VK, Bunkenborg J, Olsen JV, Hjerrild M, Wisniewski JR, Stahl E, Bolouri MS, Ray HN, Sihag S, Kamal M et al: Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003, 115(5):629–640. Mueller TF, Einecke G, Reeve J, Sis B, Mengel M, Jhangri GS, Bunnag S, Cruz J, Wishart D, Meng C et al: Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007, 7(12):2712–2722. Nakayama M, Kudoh T, Kaikita K, Yoshimura M, Oshima S, Miyamoto Y, Takeya M, Ogawa H: Class A macrophage scavenger receptor gene expression levels in peripheral blood mononuclear cells specifically increase in patients with acute coronary syndrome. Atherosclerosis 2008, 198(2):426–433. Nakou M, Knowlton N, Frank MB, Bertsias G, Osban J, Sandel CE, Papadaki H, Raptopoulou A, Sidiropoulos P, Kritikos I et al: Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheum 2008, 58(11):3541–3549. Nascimento EJ, Braga-Neto U, Calzavara-Silva CE, Gomes AL, Abath FG, Brito CA, Cordeiro MT, Silva AM, Magalhaes C, Andrade R et al: Gene expression profiling during early acute febrile stage of dengue infection can predict the disease outcome. PLoS One 2009, 4(11):e7892. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA: Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002, 99(3):1503–1508. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA: Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008, 67(8):1069–1075. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY: Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 2003, 112(6):1195–1202. Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P: Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56(6):1954–1965. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C et al: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007, 8(1):R8. Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, Banchereau J, Lertmemongkolchai G, Chaussabel D: Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol 2009, 10(11):R127. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201(9):1479–1486. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, Banchereau J: How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 2008, 223:39–59.
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
123
Pascual V, Chaussabel D, Banchereau J: A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010, 28:535–571. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A: False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 2005, 21(13):3017–3024. Payen D, Lukaszewicz AC, Belikova I, Faivre V, Gelin C, Russwurm S, Launay JM, Sevenet N: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008, 34(8):1371–1376. Peretz A, Peck EC, Bammler TK, Beyer RP, Sullivan JH, Trenga CA, Srinouanprachnah S, Farin FM, Kaufman JD: Diesel exhaust inhalation and assessment of peripheral blood mononuclear cell gene transcription effects: an exploratory study of healthy human volunteers. Inhal Toxicol 2007, 19(14):1107–1119. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, Williams G, Bauer J, Gregersen P, Behrens T et al: Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009, 18(11):980–989. Popper SJ, Watson VE, Shimizu C, Kanegaye JT, Burns JC, Relman DA: Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infection. J Infect Dis 2009, 200(4):657–666. Potti A, Bild A, Dressman HK, Lewis DA, Nevins JR, Ortel TL: Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 2006, 107(4):1391–1396. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, Piqueras B, Banchereau J, Palucka AK et al: Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 2007, 109(5):2066–2077. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, Melendez AJ: Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol 2005, 6:2. Repsilber D, Kern S, Telaar A, Walzl G, Black GF, Selbig J, Parida SK, Kaufmann SH, Jacobsen M: Biomarker discovery in heterogeneous tissue samples – taking the in-silico deconfounding approach. BMC Bioinformatics, 11(1):27. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101(25):9309–9314. Ruan J, Dean AK, Zhang W: A general co-expression network-based approach to gene expression analysis: comparison and applications. BMC Syst Biol 2010, 4(1):8. Sandrin-Garcia P, Junta CM, Fachin AL, Mello SS, Baiao AM, Rassi DM, Ferreira MC, Trevisan GL, Sakamoto-Hojo ET, Louzada-Junior P et al: Shared and unique gene expression in systemic lupus erythematosus depending on disease activity. Ann N Y Acad Sci 2009, 1173:493–500. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O, Jr.: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003, 349(2):125–138. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F: Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003, 75(8):1323–1330. Segal E, Yelensky R, Koller D: Genome-wide discovery of transcriptional modules from DNA sequence and gene expression. Bioinformatics 2003, 19 Suppl 1:i273–i282. Segal E, Shapira M, Regev A, Pe’er D, Botstein D, Koller D, Friedman N: Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet 2003, 34(2):166–176. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY et al: The MicroArray Quality Control (MAQC) project shows interand intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24(9):1151–1161. Shi L, Perkins RG, Fang H, Tong W: Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol 2008, 19(1):10–18.
124
D. Chaussabel et al.
Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD: Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 2007, 258(1–2):52–59. Snyder M, Weissman S, Gerstein M: Personal phenotypes to go with personal genomes. Mol Syst Biol 2009, 5:273. Staratschek-Jox A, Classen S, Gaarz A, Debey-Pascher S, Schultze JL: Blood-based transcriptomics: leukemias and beyond. Expert Rev Mol Diagn 2009, 9(3):271–280. Stoeckman AK, Baechler EC, Ortmann WA, Behrens TW, Michet CJ, Peterson EJ: A distinct inflammatory gene expression profile in patients with psoriatic arthritis. Genes Immun 2006, 7(7):583–591. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A, Parkhomchuk D et al: A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321(5891):956–960. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, Butte AJ: Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol 2010, 6(2):e1000662. Takamura T, Honda M, Sakai Y, Ando H, Shimizu A, Ota T, Sakurai M, Misu H, Kurita S, Matsuzawa-Nagata N et al: Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochem Biophys Res Commun 2007, 361(2):379–384. Tan PK, Downey TJ, Spitznagel EL, Jr., Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM, Cam MC: Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003, 31(19):5676–5684. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC, Jr.: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45(6):694–702. Tang Y, Lu A, Aronow BJ, Sharp FR: Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol 2001, 50(6):699–707. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC: Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009, 37(3):882–888. Thach DC, Agan BK, Olsen C, Diao J, Lin B, Gomez J, Jesse M, Jenkins M, Rowley R, Hanson E et al: Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. Genes Immun 2005, 6(7):588–595. Thompson LJ, Dunstan SJ, Dolecek C, Perkins T, House D, Dougan G, Hue NT, La TT, Du DC, Phuong LT et al: Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi. Proc Natl Acad Sci USA 2009, 106:22433–22438. Ubol S, Masrinoul P, Chaijaruwanich J, Kalayanarooj S, Charoensirisuthikul T, Kasisith J: Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J Infect Dis 2008, 197(10):1459–1467. Ulitsky I, Shamir R: Identifying functional modules using expression profiles and confidencescored protein interactions. Bioinformatics 2009, 25(9):1158–1164. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL: Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008, 3(4):e1927. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP et al: Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66(8):1008–1014. Wang M, Master SR, Chodosh LA: Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics 2006, 7:328. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. Nature Rev 2009, 10(1):57–63.
Blood Transcriptional Fingerprints to Assess the Immune Status of Human Subjects
125
Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, Brown PO: Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003, 100(4):1896–1901. Wold B, Myers RM: Sequence census methods for functional genomics. Nat Methods 2008, 5(1):19–21. Wong HR, Cvijanovich N, Allen GL, Lin R, Anas N, Meyer K, Freishtat RJ, Monaco M, Odoms K, Sakthivel B et al: Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009, 37(5):1558–1566. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100(17):9991–9996. Yang MC, Yang JJ, McIndoe RA, She JX: Microarray experimental design: power and sample size considerations. Physiol Genomics 2003, 16(1):24–28. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA et al: Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60(6):1785–1796. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R: A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007, 56(3):1010–1020. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, III, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R et al: Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009, 6(3):207–217.
Innate Signatures of Immune Mediated Resolution and Persistence of Hepatitis C Virus Infections Robert E. Lanford
Abstract Hepatitis C Virus infections have a high propensity to induce lifelong persistent infections. A number of host and environmental variables have been shown to impact the rate of persistent infection and the outcome of interferon (IFN)-based therapies. This review briefly highlights a few of the relevant observations that have been made with regard to viral clearance. HCV infection induces a highly elevated interferon stimulated gene (ISG) response in the liver during both acute and chronic infections. The role of this response in containing the spread of the virus in the liver and in mounting an effective adaptive immune response is poorly understood. The fact that an elevated hepatic ISG response during chronic infection negatively correlates with the outcome of IFN therapy is counter-intuitive and remains to be explained satisfactorily. The failure of the T cell response to clear virus appears to reside in a deficiency in the CD4 T cell help leading to anergic CD8 T cells, which may also be related to whether the innate response properly orchestrates the adaptive T cell response early in infection. The importance of the innate response in the outcome of infection is illustrated by recent genome wide association studies revealing a remarkable correlation between genetic polymorphisms in IL28B (IFNl3) and clearance of infected cells whether during acute infection or IFN therapy, yet the mechanisms by which IFNl3 and other innate effectors influence HCV infection are currently poorly understood. Keywords Chimpanzee • Chronic infection • HCV • Hepatitis C virus • Hepatocyte • IL28 • Innate immune response • Interferon • Interferon lambda • ISG • Liver • Microarray • Persistent infection
R.E. Lanford (*) Department of Virology and Immunology, Southwest Foundation for Biomedical Research and Southwest National Primate Research Center, 7620 NW Loop 410, San Antonio, TX 78227, USA e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_9, © Springer Science+Business Media, LLC 2011
127
128
R.E. Lanford
HCV Disease and Therapy Three percent of the worldwide population is persistently infected with hepatitis C virus (HCV) including 4% of the U.S. adult population. Chronic infections develop in 50–85% of exposed individuals depending on a number of variables. The disease is typically asymptomatic or mild for several decades; however, cirrhosis develops in 10–20% of the chronic infections with an increased risk of end-stage liver disease and hepatocellular carcinoma. HCV infection is the leading cause of liver transplantation in the U.S., and hepatocellular carcinoma is now the most rapidly increasing cause of cancer death in the U.S. The current therapy for HCV infection is pegylated interferon-alpha (peg-IFNa) in combination with ribavirin for 48 weeks. This is a harsh therapy with significant side effects that many people are unable to complete. For those that complete therapy, the sustained virological response rates are 40–50% for genotype 1 and 80–90% for genotypes 2 and 3. The virus clearly plays are role in response to therapy, since specific genotypes have different response rates and sequence variation within a genotype influence outcome as well. The development of direct acting antivirals is a major effort at pharmaceutical companies, and many promising antivirals are in clinical trials at this time. However, these new drugs will be administered with peg-IFNa and ribavirin until an effective IFN-free cocktail can be developed. The most advanced trials are for the protease inhibitors, but nucleoside analogs, polymerase inhibitors and NS5A inhibitors are progressing through trials (Shimakami et al. 2009) as are novel therapies inhibiting cellular factors required by the virus such as miR-122 (Lanford et al. 2010) and cyclophilin (Flisiak et al. 2009) inhibitors.
Viral Clearance HCV infections have been studied intensely using a broad array of technologies in the hopes that a better understanding of the factors that influence progression to chronic infection will advance efforts to develop a vaccine and more efficacious therapies. The rate of persistent infection is difficult to determine in humans, since most acute infections go undetected. Common source exposures have provide valuable information on the rate of viral clearance, since all individuals have similar exposure (Kenny-Walsh and Irish 1999). The rate of viral clearance can be as high as 50% in young healthy adults with a single exposure. This compares favorably to a rate of 66% clearance for chimpanzees (Lanford 2006). In contrast, individuals repeatedly exposed or exposed to large doses of virus, such as intravenous drug users, hemophiliacs, and transfusion recipients, have persistent infection rates of 80–90% (Thomas et al. 2000). The importance of the dose of virus is particularly apparent in studies on genetic polymorphisms in HLA-C and NK cell KIR receptors which affect viral clearance only in low dose recipients, IV drug users, but not in transfusion recipients and hemophiliacs (Khakoo et al. 2004). Recently, genome
Innate Signatures of Immune Mediated Resolution
129
wide association studies revealed that variants in the IL28B (also known as IFNl3) region have a remarkable association with viral clearance during acute HCV infection (Thomas et al. 2009) and treatment with IFN-based therapies (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009). However, most studies on viral clearance have focused on direct analysis of the innate and adaptive immune responses.
HCV Viral Proteins Modulate the Innate Response HCV is a member of the Flaviviridae family. The genome is single-stranded RNA of positive sense. There are six major geneotypes with up to 30% divergence at the amino acid level. The 5’ RNA terminus is uncapped and contains an internal ribosome entry site for initiation of translation. Ten viral proteins are derived by proteolytic cleavage of a polyprotein encoded by a single open reading frame (Fig. 1). The structural proteins are organized at the amino terminus followed by the nonstructural (NS) proteins and components of the viral RNA replicase. The viral proteins include a capsid protein, two envelope proteins E1 and E2, a porin p7, an autoprotease NS2, a RNA helicase-serine protease NS3, a protease cofactor NS4A, a hydrophobic membrane protein NS4B, an RNA binding, phosphoprotein NS5A, and a viral RNA polymerase NS5B. HCV has developed a number of mechanisms for subverting the innate immune response. NS3/4a blocks both TLR3 and RIGI pathways and prevents the activation of IRF3 (Foy et al. 2003, 2005; Li et al. 2005) and NFkB, transcription factors involved in activation of the IFNb promoter.
Fig. 1 HCV viral genome and polyprotein. The HCV genome is depicted with the 5’ NCR containing an internal ribosome entry site (IRES) and the 3’ NCR including a conserved terminal 98 nucleotide stem loop structure involved in RNA replication. The open reading frame of the polyprotein is depicted as a cylinder with demarcation of the individual viral protein domains (C, e1, e2, p7 and NS2-NS5B), and the positions of some of the viral functions are indicated above. The NS3 and NS5A proteins are involved in the subversion of the host innate immune response that recognizes dsRNA and results in the induction of the type I IFN response. NS3 protease cleaves TRIF and IPS-1 blocking both the TLR3 and RIG-I pathways of IRF3 activation and type I IFN induction. NS5A binds PKR but is also known to have PKR independent mechanisms involved in blocking IFN production
130
R.E. Lanford
The TLR3 pathway is blocked by cleavage of TRIF (Li et al. 2005; Foy et al. 2003), while the RIGI/MDA5 pathway is blocked by cleavage of the adapter protein IPS-1 (aka CARDIF, MAVS, VISA) (Xu et al. 2005; Seth et al. 2005; Kawai et al. 2005; Meylan et al. 2005). NS5A is a phosphoprotein that contains a sequence known as the ISDR, or interferon sensitivity determining region. Sequence diversity in this region has been shown to correlate with the outcome of IFN therapy (Enomoto et al. 1996). This region interacts with PKR (Gale et al. 1998), but NS5A appears to be involved in several PKR-independent mechanisms of blocking the IFN response (Polyak et al. 2001). It is important to note that NS5A may play a role in blocking the response to exogenous IFNa, while NS3/4a prevents synthesis of IFNb and expression of IRF3-dependent genes. The core protein interacts with STAT1 and blocking the IFN-induced JAK-STAT pathway (Lin et al. 2006). Gene expression studies demonstrated the induction of TLR3 and RIG-I by IFNa in the liver of chimpanzees and in primary human hepatocytes (Lanford et al. 2006). Thus, TLR3 and RIGI may play a role in maintaining the high ISG expression levels and IFN production in hepatocytes during HCV infection, especially in newly infected cells prior to suppression by NS3. However, in other viral systems plasmacytoid dendritic cells (pDC) produce most of the type 1 IFN via interaction of viral RNA with TLR7. Conclusive studies on the source of the IFN inducing ISG expression in the liver during HCV infection have not been performed.
Acute HCV Infection and Intrahepatic Induction of ISGs Chimpanzees are an ideal animal model for probing the factors influencing clearance and persistence of HCV due to the high rate of resolution during acute infection. Bigger et al. (2001) and Su et al. (2002) initiated studies on viral–host interactions using microarray analysis in the chimpanzee model over 10 years ago. The initial studies examined changes in liver gene expression during acute-resolving infection. These were the first studies to utilize microarray technology in an animal model of an infectious disease. Remarkably consistent trends in gene expression were observed with two major waves occurring temporally across the acute infection, representing the innate and adaptive immune responses. During acute HCV infection, viremia rapidly increases within days of infection reaching near peak values within 1–2 weeks followed by a plateau phase with little change until detection of the T cell response 10–15 weeks after infection (Fig. 2). Also within days of infection, a rapid and pronounced increase in ISG expression occurs in the liver in parallel to viremia. The increase and decrease in hundreds of ISG transcripts during acute resolving infection parallels the rise and fall of viremia. A few genes are upregulated by as much as 100fold and many are up by 20-fold or more. Although HCV proteins are known to block aspects of the IFN response, in vivo there is a dramatic elevation of ISG expression in the liver. Among the most prominent ISGs are the chemokines IP-10 (CXCL10) and ITAC (CXCL11) which play important roles in recruiting T lymphocytes, dendritic cells
Innate Signatures of Immune Mediated Resolution
131
Fig. 2 Hepatic ISG response during acute HCV infection. The three panels illustrate the events during acute resolving HCV infection in chimpanzees. HCV viral RNA increases rapidly during the first week after infection and plateaus until the adaptive immune response emerges 8–12 weeks after infection often resulting in a very rapid decline in viremia and loss of infected cells. The viremia profile is paralleled by rapid increases and decreases in hepatic expression of hundreds of interferon stimulated genes (ISGs) some of which are directly involved in the IFN signal transduction pathway
and NK cells to the liver (Helbig et al. 2009). The role of hepatocytes, rather than other intrahepatic cell types, in the expression of critical chemokines in response to viral infection was confirmed in studies treating primary human and chimpanzee hepatocytes with IFNa and demonstrating the induction of ITAC (CXCL11), IP-10 (CXCL10), MIG (CXCL9) and MCP2 (CCL8) (Lanford et al. 2006). One aspect of the infection that must be taken into context of the events in the liver is the percentage of hepatocytes that become infected. Unlike HBV infection where 100% of the hepatocytes become infected, in HCV, a minor fraction of hepatocytes are infected at any one time. Based on the level of viral RNA present in the liver during the plateau phase less than 10% of hepatocytes are infected, thus something limits the spread of the virus in the liver (Bigger et al. 2004; Lanford et al. 2006, 2007), and the most likely candidate is the innate immune response potentially involving both the ISG response and the NK cells recruited to the liver by the induced chemokines. Although noncytolytic inhibition of viral replication by the ISG response probably plays a major role in the halt of viral spread, considerable cell death can be detected in the liver in association with a mild elevation in ALT prior to the appearance of the T cell response. Two sources of data other than viral RNA levels support the estimated low level of infected cells during HCV infection. Total virus production is estimated at 1 × 1012 particles per day (Neumann et al. 1998) or approximately one particle per hepatocyte, and recent studies using
132
R.E. Lanford
enhanced fluorescence microscopy methods have detected clusters of infected cells representing no more than 10% of the liver (Liang et al. 2009). Collectively, the data suggest that initially a low percentage of hepatocytes are infected, less than 10% in most infections. The dsRNA response in infected hepatocytes and the interaction of viral RNA with TLR7 on dendritic cells results in the production of type I IFN. Secreted IFN induces zones of resistant cells surrounding IFN producing cells resulting in a loss available replication space in the liver. The plateau phase ensues with a decrease in viral spread and no further increase in viremia. This may continue as a dynamic equilibrium of cell loss due to NK cell killing balanced by newly infected cells. Eventually a T cell response emerges and aids in the clearance of infected cells. T cell induced cytokines such as IFNg may help mediate clearance by suppressing viral replication. This model is consistent with inhibition of the IFN response by viral proteins if one assumes that newly infected cells respond to dsRNA and secrete IFN until the level of viral protein becomes sufficient to inhibit this pathway or that the IFN is primarily produced by pDCs which are not infected by HCV and not subject to the inhibition of IFN production by viral proteins. The link between the innate immune response and the adaptive immune response is well established. In addition to aspects of the innate immune response in priming the adaptive response, the innate response contains the virus and permits the adaptive response time to eliminate the infection. For HCV, the duration of this time is significant, since the T cell response is delayed for 8–12 weeks after infection for reasons that are not understood.
Chronic HCV Infection and Hepatic ISG Expression The changes in hepatic gene expression in chimpanzees with chronic HCV infection are remarkably similar to those observed during acute infection with a highly upregulated ISG response (Fig. 3). Selection of ten chronically infected animals with serum viral loads that varied by 1,000-fold revealed that ISG expression in the liver was highly elevated and that the degree of induction was independent of viral RNA level (Bigger et al. 2004). The data suggest that the ISG response is maximally upregulated in response to the virus even at relatively low levels of viral RNA. The highly elevated IFN response persists in the livers of these animals for decades with little evidence of pathology. The ISG response involves over 1,000 genes, and the response is largely tissue specific in comparing PBMC and liver (Lanford et al. 2006) with most of the commonly induced genes representing ISGs previously characterized in tissue culture. The functions of most the ISGs are unknown, but it is suspected that many have antiviral or immunomodulatory properties. In contrast to chimpanzees, humans can be classified as having high or low hepatic ISG during chronic infection prior to IFN therapy, and the high ISG phenotype negatively correlates with outcome of IFNa therapy (Chen et al. 2005; Feld et al. 2007). A similar observation has been made for serum levels of IP-10 (CXCL10) with
Innate Signatures of Immune Mediated Resolution
133
Fig. 3 Hepatic ISG response during chronic HCV infection. Microarray analysis was performed on liver samples from 15 HCV chronically infected animals and 6 uninfected animals using Affymetrix total genome human microarrays. Genes were filtered based on fold change in expression of >2.0 fold change with a p value of <0.02. The data are presented as a heat map with upregulated genes in red, downregulated genes in green and unaltered genes in black. Most genes upregulated in the HCV chronic liver are interferon stimulated genes (ISGs). Some genes are decreased in expression during HCV infection, as shown at the bottom of the heat map
134
R.E. Lanford
low pretreatment levels being predictive of successful therapy outcome (Lagging et al. 2006; Diago et al. 2006; Butera et al. 2005; Romero et al. 2006). Serum levels of IP-10 can be considered a surrogate marker for hepatic ISG levels during HCV infection since the bulk of IP-10 is being secreted by the liver. These observation are partially explained by the finding that chimpanzees have no increase in hepatic ISG expression following treatment with IFNa, presumably because the response is already maximally induced, and have no decrease in viral RNA in response to pegIFNa treatment (Lanford et al. 2007; Huang et al. 2007). Thus, chimpanzees represent the extreme in the nonresponsive, high ISG phenotype and are a model for the human null IFN response phenotype. Confirmation of this relationship came from studies with paired biopsies in humans demonstrating that ISG expression is induced from a low baseline in rapid responders to IFN, but the high ISG expression phenotype was unresponsive to exogenous IFN (Sarasin-Filipowicz et al. 2008). Two of these studies identified signature gene sets whose expression levels at baseline could accurately predict SVR. Only five genes were found in common between the two signature sets of 29 genes (Sarasin-Filipowicz et al. 2008) and 18 genes (Chen et al. 2005 6521 /id) and many of the genes in both sets were not ISGs. This may reflect that different parameters were used for patient selection, sustained viral response (SVR) vs. rapid response, but may also reflect the complexity of this phenotype. IFN nonresponders are not a uniform group and represent individuals with viral rebound after therapy, relapse during therapy and null response with no decrease in viral load. Patients with the highest probability for SVR can be identified during therapy based on the rate of decrease in viral RNA, with rapid responders (RR) having undetectable viremia at 4 weeks of therapy and a very high probability for SVR, in contrast to patients without an early viral response (EVR) of greater than 2 log decline in the first 12 weeks having almost no chance of a SVR. The factors contributing to the relationship between hepatic ISG levels and response to therapy may precede the development of a chronic infection and maybe reflective of genetic polymorphisms in the innate immune response (see below). However, uninfected chimpanzees destined to become null IFNa responders have a robust response to IFNa in both PBMC and liver, while chronically infected animals have a robust response only in PBMC with the liver having a maximally induced ISG response that is unresponsive to further stimulation (Lanford et al. 2007). Clearly, the null response to IFN therapy is not due to an obvious defect in the ISG response, on the contrary, it is the individuals with a lack of response to the virus (low ISG phenotype) that have a favorable outcome to IFNa therapy for reasons that are poorly understood.
IL28B (IFNl3) in HCV Viral Clearance and Response to Therapy In addition to the known viral factors (genotype, viral load, sequence variation) and host phenotype (sex, age, body mass index, fibrosis, alcohol consumption) influencing responsiveness, degrees of IFN responsiveness are likely due to multiple genetic variations in the IFN regulatory pathways that may be reflected by the levels of
Innate Signatures of Immune Mediated Resolution
135
hepatic ISG expression. Recent data from genome wide association studies indicate that IL28B (IFNl3) directly influences the outcome of infection (Thomas et al. 2009) and IFNa therapy (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009), but the mechanisms are not understood. The distribution of the protective genotype in different races seems to account at least in part for the racial differences in response to IFNa therapy and in outcome of acute infection. . Remarkably the protective genotype appears to be recessive, since only homozygous individuals seem to benefit. Associations were detected with SNPs in upstream, downstream, intron and exon regions of the IL28B gene. The responsive genotype for IFN therapy is associated with small increases in the levels of IL28 transcripts in PBMC (Suppiah et al. 2009; Tanaka et al. 2009), and a missense mutation involving a conserved lysine to arginine change at residue 70 of IL28B is in linkage disequilibrium with the upstream SNP with the highest association with outcome of infection (Thomas et al. 2009). Further studies will be required to determine the relevance of the increased expression or the missense mutation and the protective genotype. The lack of association with any polymorphisms in IL28A (IFNl2) is puzzling considering the 96% homology between IL28B and IL28A, but the two cytokines may not be expressed by the same cell types or under the same conditions. IFNls are members of the IL10 superfamily and utilize a heterodimeric receptor comprised of IL28RA and IL10R2 that has a more restricted tissue distribution than the receptor for type I IFNs. IL28RA is an ISG that is induced in the liver in response to IFNa in chimpanzees (Lanford et al. 2006) suggesting that the activity of IFNls would be enhanced during HCV infection and IFNa therapy. IFNl1 (IL29) and IFNl2 have potent HCV antiviral activity in vitro (Marcello et al. 2006; Robek et al. 2005; Zhu et al. 2005), and pegIFNl1 is currently in clinical trials for HCV (Miller et al. 2009). The innate immune response represents a major determinant of clearance in HCV infection due in part to its role in orchestrating the adaptive immune response. However, as described above, data from a number of studies suggest a more direct role in clearance. The genetic variations in IL28B that have a major impact on both the outcome of therapy and acute infection may be functionally related to the phenotypes of high and low hepatic ISG expression in chronic carriers that are associated with outcome of HCV therapy. One possible conclusion from these data is that predetermined characteristics of the innate response influence the adaptive response and together they determine resolution of infection. There are a number of critical steps involving the innate response that aid in priming and maturation of the T cell response including upregulation of MHC class I expression, maturation of dendritic cells, and stimulation of NK cell activity, but the full extent of the immunomodulatory properties of type I and III IFNs is unknown.
T Cell Response and Viral Clearance The correlates of a successful adaptive immune response to HCV have been reviewed in depth elsewhere and will only be briefly discussed here (Bowen and Walker 2005; Rehermann and Nascimbeni 2005). The adaptive immune response
136
R.E. Lanford
to HCV including the antibody and T cell response is highly delayed for reasons that are not understood and normally becomes detectable 8–12 weeks after infection coincident with the appearance of liver disease or a rise in serum ALT levels. One of the main predictors of HCV clearance during acute infection is an early and broad T cell response to multiple HCV epitopes (Diepolder et al. 1995; Cooper et al. 1999; Lechner et al. 2000; Thimme et al. 2001), while persistent infection is characterized by a delayed and narrow CTL response that becomes highly anergic as the infection progresses. Immune escape of class I epitopes is common (Weiner et al. 1995), while escape of class II epitopes in uncommon (Fuller et al. 2010). Mutations occurring outside of T cell epitopes that are not within the envelope region may represent conversion to a more fit consensus sequence (Cox et al. 2005b). Escape variants appear during acute infection with few new epitope specificities appearing during the chronic phase which is consistent with an anergic T cell response (Cox et al. 2005a). A number of markers have been shown to correlate with the exhausted phenotype including PD1, CTLA-4 and TIM-3, but the actual events that precede the failed T cell response are largely unknown. The correlation of PD-1 with T cell exhaustion or anergy is well established. Upregulation of programmed death-1 (PD-1) and downregulation of CD127 have been linked to functional exhaustion of T cells in chronic HCV and other infections (Day et al. 2006; Grakoui et al. 2006; Nakamoto et al. 2008; Radziewicz et al. 2007; Urbani et al. 2006) but not all anergic T cells display this phenotype. In chimpanzees that have cleared HCV and are rechallenged, the magnitude and duration of viremia are dramatically reduced or undetectable (Bassett et al. 2001; Lanford et al. 2004; Major et al. 2002; Nascimbeni et al. 2003; Bukh et al. 2008; Prince et al. 2005). These studies alone suggest that the adaptive immune response plays an essential role in viral clearance; however, a strong innate response is detected in the liver during rechallenge including the chemokines that recruit nonspecific macrophages, NK cells and dendritic cells that are involved in the secretion of proinflammatory cytokines. Thus, it is not possible to entirely discount the role of the innate response in the elimination of infected cells or clearance of viral RNA by noncytolytic mechanisms. As discussed above, genetic studies have confirmed the role of the NK response in controlling low dose exposures (Khakoo et al. 2004), and studies in humans have also demonstrated that prior exposure and clearance provide protection from chronicity during subsequent exposures (Mehta et al. 2002; Osburn et al. 2010). The most compelling evidence of the essential nature of the T cell response comes from antibody depletion of T cell subsets in the setting of rechallenge studies in the chimpanzee. Antibody mediated depletion of CD4 T cells prior to rechallenge in an animal that has previously cleared virus results in persistent infection, thus there is a continuous requirement for CD4 help of the CD8 CTLs (Grakoui et al. 2003). Depletion of CD8 T cells in the same setting prolongs the viremic phase until HCV-specific CD8 T cells return to the liver (Shoukry et al. 2003).
Innate Signatures of Immune Mediated Resolution
137
Conclusions The innate immune response performs several essential roles in the elimination or control of HCV infections. A rapid and prominent ISG response is detected in the liver involving hundreds of genes, many of which may exhibit direct antiviral activity. The source of the stimulus for the ISG response remains to be determined, but it is likely responsible for the containment of the infection, since only a low percentage of hepatocytes are infected during both acute and chronic infections. In addition, antigen nonspecific immune cells are recruited to the liver and activated by the chemokines and cytokines that are part of the robust ISG response. These innate effector cells may be responsible for killing infected cells prior to the appearance of the antigen specific T cell response. The ISG response that maintains the recruitment and activation of antigen nonspecific cells continues throughout the chronic phase, thus this same response may be responsible for a significant percentage of the cell killing occurring in the chronic phase as well, when the CD8 T cell response has become ineffective and anergic. Finally, the innate response plays an essential role in orchestrating the adaptive T cell response through the induction of HLA for antigen presentation, activation and maturation of dendritic cells and macrophages, and production of the chemokines required to home activated T cells to the liver. Genetic variations in the innate response such as the IL28B and KIR/ HLA-C polymorphisms suggest that the innate response may predetermine whether viral clearance or persistence occurs in HCV exposed individuals. The essential role of the T cell response is well documented, but it is not known whether the critical events determining persistence have occurred before it emerges and help define its effectiveness.
References Bassett SE, Guerra B, Brasky K et al Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection (2001) Hepatology 33: 1479–1487. Bigger CB, Brasky KM, Lanford RE DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection (2001) J Virol 75: 7059–7066. Bigger CB, Guerra B, Brasky KM et al Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees (2004) J Virol 78: 13779–13792. Bowen DG, Walker CM Adaptive immune responses in acute and chronic hepatitis C virus infection (2005) Nature 436: 946–952. Bukh J, Thimme R, Meunier JC et al Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain (2008) J Virol 82: 8183–8195. Butera D, Marukian S, Iwamaye AE et al Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C (2005) Blood 106: 1175–1182. Chen LM, Borozan I, Feld J et al Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection (2005) Gastroenterology 128: 1437–1444.
138
R.E. Lanford
Cooper S, Erickson AL, Adams EJ et al Analysis of a successful immune response against hepatitis C virus (1999) Immunity 10: 439–449. Cox AL, Mosbruger T, Lauer GM et al Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (2005a) Hepatology 42: 104–112. Cox AL, Mosbruger T, Mao Q et al Cellular immune selection with hepatitis C virus persistence in humans (2005b) J Exp Med 201: 1741–1752. Day CL, Kaufmann DE, Kiepiela P et al PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression (2006) Nature 443: 350–354. Diago M, Castellano G, Garcia-Samaniego J et al Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C (2006) Gut 55: 374–379. Diepolder HM, Zachoval R, Hoffmann RM et al Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection (1995) Lancet 346: 1006–1007. Enomoto N, Sakuma I, Asahina Y et al Interferon sensitivity determining sequence of the hepatitis C virus genome (1996) Hepatology 24: 460–461. Feld JJ, Nanda S, Huang Y et al Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response (2007) Hepatology 46: 1548–1563. Flisiak R, Feinman SV, Jablkowski M et al The cyclophilin inhibitor debio 025 combined with PEG IFN alpha 2a significantly reduces viral load in treatment-naive Hepatitis C patients (2009) Hepatology 49: 1460–1468. Foy E, Li K, Sumpter R et al Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling (2005) Proc Natl Acad Sci U S A 102: 2986–2991. Foy E, Li K, Wang CF et al Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease (2003) Science 300: 1145–1148. Fuller MJ, Shoukry NH, Gushima T et al Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection (2010) Hepatology 51: 378–387. Gale M, Blakely CM, Kwieciszewski B et al Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation (1998) Mol Cell Biol 18: 5208–5218. Ge D, Fellay J, Thompson AJ et al Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance (2009) Nature 461: 399–401. Grakoui A, Shoukry NH, Woollard DJ et al HCV persistence and immune evasion in the absence of memory T cell help (2003) Science 302: 659–662. Grakoui A, John Wherry E, Hanson HL et al Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway (2006) J Hepatol 45: 468–472. Helbig KJ, Ruszkiewicz A, Lanford RE et al Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro (2009) J Virol 83: 836–846. Huang Y, Feld JJ, Sapp RK et al Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C (2007) Gastroenterology 132: 733–744. Kawai T, Takahashi K, Sato S et al IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction (2005) Nat Immunol 6: 981–988. Kenny-Walsh E, Irish HRG Clinical outcomes after hepatitis C infection from contaminated antiD immune globulin (1999) N Engl J Med 340: 1228–1233. Khakoo SI, Thio CL, Martin MP et al HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection (2004) Science 305: 872–874. Lagging M, Romero A, Westin J et al IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients With HCV genotype 1 infection (2006) Hepatology 44: 1617–1625.
Innate Signatures of Immune Mediated Resolution
139
Lanford RE The Chimpanzee model of HCV (2006). In: R. F. Schinazi, E. R. Schiff (Eds.), Framing The Knowledge of Viral Hepatitis. pp. 197–218. Lanford RE, Guerra B, Bigger CB et al Lack of response to exogenous interferon-alpha in the liver of HCV chronically infected chimpanzees (2007) Hepatology 46: 999–1008. Lanford RE, Guerra B, Chavez D et al Cross-genotype immunity to hepatitis C virus (2004) J Virol 78: 1575–1581. Lanford RE, Guerra B, Lee H et al Genomic response to interferon-alpha in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (2006) Hepatology 43: 961–972. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection (2010) Science 327: 198–201. Lechner F, Wong DK, Dunbar PR et al Analysis of successful immune responses in persons infected with hepatitis C virus (2000) J Exp Med 191: 1499–1512. Li K, Foy E, Ferreon JC et al Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF (2005) Proc Natl Acad Sci USA 102: 2992–2997. Liang Y, Shilagard T, Xiao SY et al Visualizing hepatitis C virus infections in human liver by two-photon microscopy (2009) Gastroenterology 137: 1448–1458. Lin W, Kim SS, Yeung E et al Hepatitis C Virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain (2006) J Virol 80: 9226–9235. Major ME, Mihalik K, Puig M et al Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge (2002) J Virol 76: 6586–6595. Marcello T, Grakoui A, Barba-Spaeth G et al Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics (2006) Gastroenterology 131: 1887–1898. Mehta SH, Cox A, Hoover DR et al Protection against persistence of hepatitis C (2002) Lancet 359: 1478–1483. Meylan E, Curran J, Hofmann K et al Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus (2005) Nature 437: 1167–1172. Miller DM, Klucher KM, Freeman JA et al Interferon lambda as a potential new therapeutic for hepatitis C (2009) Ann N Y Acad Sci 1182: 80–87. Nakamoto N, Kaplan DE, Coleclough J et al Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization (2008) Gastroenterology 134: 1927–1937, 1937.e 1–2. Nascimbeni M, Mizukoshi E, Bosmann M et al Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees (2003) J Virol 77: 4781–4793. Neumann AU, Lam NP, Dahari H et al Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy (1998) Science 282: 103–107. Osburn WO, Fisher BE, Dowd KA et al Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection (2010) Gastroenterology 138: 315–324. Polyak SJ, Khabar KSA, Paschal DM et al Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response (2001) J Virol 75: 6095–6106. Prince AM, Brotman B, Lee DH et al Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model (2005) J Infect Dis 192: 1701–1709. Radziewicz H, Ibegbu CC, Fernandez ML et al Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression (2007) J Virol 81: 2545–2553. Rehermann B, Nascimbeni M Immunology of hepatitis B virus and hepatitis C virus infection (2005) Nat Rev Immunol 5: 215–229.
140
R.E. Lanford
Robek MD, Boyd BS, Chisari FV Lambda interferon inhibits hepatitis B and C virus replication (2005) J Virol 79: 3851–3854. Romero AI, Lagging M, Westin J et al Interferon (IFN)-[gamma]-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-[alpha]2a and ribavirin for chronic hepatitis C virus infection (2006) J Infect Dis 194: 895–903. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al Interferon signaling and treatment outcome in chronic hepatitis C (2008) Proc Natl Acad Sci U S A 105: 7034–7039. Seth RB, Sun L, Ea CK et al Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF3 (2005) Cell 122: 669–682. Shimakami T, Lanford RE, Lemon SM Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities (2009) Curr Opin Pharmacol 9: 537–544. Shoukry NH, Grakoui A, Houghton M et al Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection (2003) J Exp Med 197: 1645–1655. Su AI, Pezacki JP, Wodicka L et al Genomic analysis of the host reponse to hepatitis C virus infection (2002) Proc Natl Acad Sci U S A 99: 15669–15674. Suppiah V, Moldovan M, Ahlenstiel G et al IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy (2009) Nat Genet 41: 1100–1104. Tanaka Y, Nishida N, Sugiyama M et al Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C (2009) Nat Genet 41: 1105–1109. Thimme R, Oldach D, Chang KM et al Determinants of viral clearance and persistence during acute hepatitis C virus infection (2001) J Exp Med 194: 1395–1406. Thomas DL, Astemborski J, Rai RM et al The natural history of hepatitis C virus infection - Host, viral, and environmental factors (2000) JAMA 284: 450–456. Thomas DL, Thio CL, Martin MP et al Genetic variation in IL28B and spontaneous clearance of hepatitis C virus (2009) Nature 461: 798–801. Urbani S, Amadei B, Tola D et al PD-1 expression in acute hepatitis C is associated with HCV-specific CD8 exhaustion (2006) J Virol 80: 11398–11403. Weiner A, Erickson AL, Kansopon J et al Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant (1995) Proc Natl Acad Sci U S A 92: 2755–2759. Xu LG, Wang YY, Han KJ et al VISA is an adapter protein required for virus-triggered IFN-beta signaling (2005) Mol Cell 19: 727–740. Zhu H, Butera M, Nelson DR et al Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication (2005) Virol J 2: 80.
Immune Signatures and Systems Biology of Vaccines F.M. Buonaguro, M.L. Tornesello, and L. Buonaguro
Abstract Vaccines represent a strategic successful tool to prevent or contain diseases with high morbidity or mortality. However, despite the extensive and wide use, we still have a limited knowledge on mechanisms underlying the effective elicitation of protective immune responses by vaccines, which represents the final outcome of a effective cooperation between the innate and adaptive arms of the immunity. Immunity is made of a multifaceted set of integrated responses involving a dynamic interaction of thousands of molecules, whose list is constantly updated to fill the several empty spaces of this puzzle. The recent development of new technologies and computational tools allows to perform a comprehensive and quantitative analysis of the interactions between all of the components of immunity over time. Here we review the role of the innate immunity in the host response to vaccine antigens and the potential of systems biology in providing relevant and novel insights in the mechanisms of action of vaccines in order to improve their design and effectiveness. Keywords Innate immunity • PRRs • PAMPs • TLRs • APCs • Adaptive immunity • Vaccine • Adjuvants • Immune memory • Systems biology • Immunogenomics • Proteomics
L. Buonaguro (*) Lab. Mol Biology and Viral Oncogenesis and AIDS Reference Center, Istituto Nazionale Tumori “Fond. G. Pascale”, Via Mariano Semmola, 1, 80131 Naples, Italy e-mail:
[email protected] F.M. Marincola and E. Wang (eds.), Immunologic Signatures of Rejection, DOI 10.1007/978-1-4419-7219-4_10, © Springer Science+Business Media, LLC 2011
141
142
F.M. Buonaguro et al.
Vaccine Development Immune Response The mammalian immune system is based on two arms, innate and adaptive immunity. The innate immune system recognizes invading pathogens through receptors defined pathogen recognition receptors (PRRs), is relatively nonspecific and does not induce immune memory. The innate immune system acts at the first early phase of the immune response, involves cellular (macrophages, dendritic cells [DCs], neutophils, natural killers) and humoral components (cytokines and chemokines) and is crucial for triggering and amplifying the adaptive immune response. The second late phase of the immune response is carried out by the adaptive immunity, involving cellular (T and B lymphocytes) and humoral components (antibodies), which plays a major role in eliminating pathogens. A hallmark of the adaptive immunity is its ability to generate a pathogen-specific immunological memory, based on clonal lymphocytes which are readily activated at a later encounter with the same foreign antigen in the form of vaccine or pathogen (Kaech et al. 2002). The fundamental property of the immune system as whole “to generate an antigenspecific immunological memory” is the basis for vaccination, which represents the most effective measure in preventing and treating infectious and noninfectious diseases. To this aim, the goal of a successful vaccine is to induce long-term protective immunity. An effective vaccine needs to mimic as close as possible the “real” biological entity from which it is derived (i.e., pathogen, cancer cell); therefore, it is recognized by the host immune system as real “danger” and initiates the cascade of molecular and cellular events involving the innate immune system and, downstream, the adaptive immunity to establish the immunological memory. However, most successful vaccines have been empirically derived and the immunological mechanisms underlying the effective induction of long-term protective immunity remain largely unknown (Plotkin 2005; Rappuoli 2004). Several levels of cross-talks between the innate and adaptive immune systems are required for an effective immune response. In particular, it is a recent acquisition that induction of co-stimulatory molecules and secretion of cytokines and chemokines by the cells of the innate immune system significantly affect the quality and quantities of T and B cells of the adaptive immune system. In this chapter, we will address the current understanding of the molecular and cellular events in immune response to vaccine antigens and the most advanced experimental system levels strategies involved in these studies.
Vaccines Most of the current successful vaccines are based on live attenuated or inactivated pathogen “particles” carrying their own unique and specific antigens, with definite main characteristics distinguishing the two strategies.
Immune Signatures and Systems Biology of Vaccines
143
The live attenuated vaccines are a weakened form of the “wild” viruses with a limited replication of the virus in the host upon injection. Live attenuated viral vaccines, indeed, carry the native pathogen-associated molecular signals “PAMS” (i.e., viral genetic material) which trigger the activation of the innate immune system binding to the PRRs. These particles, closely mimic a natural infection and spread to multiple host immune organs or tissues where are taken up by DCs or other antigen presenting cells (APCs) which migrate towards lymphoid organs to present the antigens to T and B lymphocytes and initiate adaptive immune response . They elicit immune responses similar to those from natural infections and often are effective after a single administration (Bachmann et al. 1998). However, such vaccines may cause mild-to-severe adverse effects in patients, often as consequence of the limited replication in the host. On the contrary, the inactivated vaccines cannot replicate due to irreversible damage of genetic material induced by heat or chemical treatment. They are safer than live vaccines, lacking of any replication in the host, but generally less effective, requiring multiple administrations to boost the immune response antibody titer over time. The inactivated vaccines are made as whole cell or as subunit vaccines, the latter based on the delivery of the individual viral proteins relevant for conferring protective immunity. Recent advances in genomics and proteomics have provided essential tools to develop alternative nonreplicating vaccine strategy, including recombinant proteins, synthetic peptides, DNA, particulate structures (i.e., Virus-Like Particles). Nonreplicating vaccines activate innate responses only at their site of injection and, considering the high number of DCs in the skin dermis (Banchereau and Steinman 1998), intradermal skin immunization may result in a more effective induction of protective immune responses reducing the vaccine dose (Mikszta et al. 2006; Pancharoen et al. 2005; Van et al. 2009). However, while the selected antigens, free of any potentially infectious material, offer important safety advantages, they are not always effectively processed and presented by the immune system. In particular, it has been shown that subunit split influenza vaccine is much less efficient than live or heat-inactivated whole viruses in activating expression of co-stimulatory molecules (CD80, CD86, CD40) and human leukocyte antigen-DR (HLA-DR) as well as production of IFN-g upon in vitro stimulation of PBMC. Therefore, most formulations of nonliving vaccines must include an adjuvant as “danger” signal to trigger a sufficient activation of the innate system and, downstream, of the adaptive immune response (Pashine et al. 2005).
Innate Immunity and Vaccine Recognition Pathogen recognition receptors (PRRs) are expressed constitutively in the host on cells of the innate immune system (i.e., Antigen-presenting cells, APCs) and detect foreign antigens in the form of pathogen or vaccine (Akira et al. 2006; Pulendran and Ahmed 2006), activating specific signaling pathways to drive biological and
144
F.M. Buonaguro et al.
immunological responses. Among the PRRs, a key role is played by Toll-like receptors (TLRs) which are widely expressed on innate immune cells (including DCs, macrophages, mast cells, neutrophils), endothelial cells, and fibroblasts. Recent findings show that functional TLRs are expressed also on epithelial as well as cancer cells (Sato et al. 2009). Their expression is regulated rapidly in response to foreign antigens (including vaccines), a variety of cytokines, and environmental stresses (Beutler 2004; Germain 2004; Janeway and Medzhitov 2002; Takeda et al. 2003). TLRs are type I integral membrane glycoproteins with extracellular domains containing varying numbers of leucine-rich-repeat motifs and a cytoplasmic signaling domain homologous to that of the interleukin-1 receptor (IL-1R), termed the Toll/IL-1R homology domain (Bowie and O’Neill 2000). To date, 12 members of the TLR family have been identified in mammals and different TLRs are expressed extra or intracellularly. In particular, TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface, whereas TLR3, 7, 8, and 9 are found almost exclusively in intracellular compartments such as endosomes (Akira et al. 2006; Pulendran and Ahmed 2006). TLRs recognize structural components shared by many bacteria, viruses and fungi (Takeda et al. 2003). Examples of such components include lipopolysaccharides (LPS; recognized by TLR4) (Poltorak et al. 1998; Shimazu et al. 1999), lipopeptides (by cooperation of TLR2 with TLR1 or TLR6) (Alexopoulou et al. 2002; Ozinsky et al. 2000; Takeuchi et al. 2001, 2002), viral single- or double-stranded RNA (by TLR7 with TLR8 and by TLR3, respectively) (Alexopoulou et al. 2001; Diebold et al. 2004; Heil et al. 2004; Hemmi et al. 2002), bacterial or viral DNA containing CpG motifs (by TLR9) (Ahmad-Nejad et al. 2002; Latz et al. 2004b) and flagellin (by TLR5) (Hayashi et al. 2001). Although much research has focused on the TLR family as innate sensing receptors, other important families of PRRs are plasma-membrane and cytoplasmic receptors, including the C type lectins and NOD proteins (Akira et al. 2006; Geijtenbeek et al. 2004; Inohara et al. 2005). The C type lectins such as DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN) and DC-associated C-type lectin-1 (Dentin-1) recognize a range of microbial stimuli from pathogens such as HIV, HCV, Helicobacter pylori, and Mycobacterium tuberculosis (den Dunnen et al. 2009). NOD proteins recognize components of intracellular bacteria (Inohara et al. 2005). Furthermore, viral nucleic acids can also signal through TLR-independent mechanisms. For example, RIG-I and melanoma differentiation-associated gene 5 (Mda5; also called helicard), both intracellular RNA helicases, can sense dsRNA (Yoneyama et al. 2004, 2005; Yoneyama and Fujita 2009) (Fig. 1).
Innate Signaling and Translation to the Adaptive Immune Response The interaction between TLRs expressed on innate immune cells and the foreign antigen expressed by the vaccine triggers a downstream signaling cascade leading
Immune Signatures and Systems Biology of Vaccines
145
Fig. 1 Schematic representation of the structure and main signaling pathways of the PRR families
to several cellular processes, including production of proinflammatory cytokines and chemokines (Takeda and Akira 2007). TLR activation results in the engagement of signaling intermediates, including myeloid differentiation factor-88 (MyD88), Toll–interleukin (IL)-1 receptor (TIR)-associated-protein (TIRAP, also known as MAL); Toll receptor-associated activator of interferon (TRIF), Toll receptor-associated molecule (TRAM), IL-1 receptor-associated kinases (IRAK) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) (Akira et al. 2006; Takeda and Akira 2007). The endpoint of this signaling cascade is the activation of transcription factors (IRF3, IRF7, AP-1, NF-kB) inducing the activation of inflammatory cytokine genes, such as TNF-b, IL-6, IL-1b, and IL-12. Consequent to the TLR-ligand interaction, APCs uptake and process vaccine antigens to be exposed on cell membrane surface in association to major histocompatibility complex (MHC) molecules for efficient presentation to adaptive immune cells (Villadangos and Young 2008). In order to be effective, this process requires the full activation and maturation of APCs characterized by the increased expression of co-stimulatory molecules (CD40, CD80, CD86), production of chemokines (TNF-alpha, RANTES, MIP1a, MIP1b) and their migration from the infection site to the regional lymph node, where the induction of T and B cell responses occurs. Among APCs, DCs are known to have the unique and most potent capacity to provide antigen-specific activation as well as co-stimulatory signals to naïve T cells and possibly B cells, representing the bridging cell between the innate and adaptive immune system (Alvarez et al. 2008; Pasare and Medzhitov 2005; von Andrian and Mempel 2003).
146
F.M. Buonaguro et al.
Hitting Innate Immune System by Vaccines The antigen screening by DCs is mediated by TLRs and the engagement of TLR by the vaccine antigen allows the APCs to identify nonself foreign antigens, resulting in enhanced immunogenicity and presentation of the antigen by MHC molecules. Consequently, vaccine formulations should be able to activate the innate PRRs, in order to be successful in eliciting an effective adaptive immune response. For most currently licensed vaccines, the degree of engagement of TLRs has not been studied, with only few exceptions. The Bacillus Calmette–Guerin (BCG) has been shown to engage the TLR-2 and 4 (Tsuji et al. 2000; Uehori et al. 2003); the Haemophilus influenzae type b (HiB) vaccine, conjugated with neisserial outermembrane protein complex (OMPC), interacts with the TLR-2 (Latz et al. 2004a); the live attenuated yellow fever vaccine has been demonstrated to activate multiple DC subsets via TLRs 2, 7, 8 and 9 (Querec et al. 2006). For many other licensed vaccines the engagement of TLRs has not been documented but it is possible to guess based on studies performed on the original virus from which the vaccine is derived. In general, TLR activation is very likely to play a key role in the protective immunity induced by live attenuated vaccines. Single-stranded RNA of live attenuated (cold adapted) influenza vaccines, indeed, are likely to activate TLR 3 and 7 during intra-cellular replication leading to the up-regulation of inflammatory cytokines (Diebold 2008; Lund et al. 2004). Similarly, TLR9 has been demonstrated to be activated by bacterial and viral DNA containing unmethylated CpG motifs (Hemmi et al. 2000, 2003). On the contrary, there is no evidence to date that the immunogenicity of vaccines composed of killed pathogens or subunit elements is mediated by TLR engagement and may explain the generally observed lower and short-lasting immune response. In these cases, the vaccine effectiveness may greatly benefit from the addition of an adjuvant in the formulation. Very few adjuvants are approved for human use, including Alum, MF59 (Ott et al. 1995), MPL (Baldridge and Crane 1999), AS04 (consisting of MPL adsorbed on alum), (Keam and Harper 2008; Tong et al. 2005), immunopotentiating reconstituted influenza virosomes (IRIVs) (Gluck et al. 2004; Holzer et al. 1996) and Cholera toxin B subunit (CTB) (Ryan and Calderwood 2000). Of these, only MPL is known to engage a TLR (TLR-4), being a nontoxic derivative of the lipopolysaccharide (LPS) of Salmonella Minnesota. Many new vaccine adjuvants are under development and, since the recognition of the TLRs as key molecules for the effective activation of adaptive immune response, most of them are selected because of their properties to activate TLRs and evaluated in preclinical and human clinical trials (Fraser et al. 2007; Kang and Compans 2009; Kwissa et al. 2007b; Lahiri et al. 2008; Reed et al. 2009). Recent evidence suggests that several adjuvants might function in a TLRindependent pathway. Intracellular NOD-like receptors (NLRs) and retinoic acid inducible gene (RIG)-like receptors might play an important role in this regard. Activation of these pathways might play a significant role in adjuvant activity of some bacterial-product-based vaccine adjuvants (e.g., cell wall, flagellin or RNA based) (Ishii and Akira 2007; Monie et al. 2009).
Immune Signatures and Systems Biology of Vaccines
147
TLRs Signaling for a Potent and Prolonged Adaptive Immune Responses The ultimate goal of vaccination is to induce potent as well as long-term protective immunity, which is a hallmark of adaptive immunity. The long-term protective immunity is provided by the vaccine antigen-specific immune effectors and the induction of immune memory cells that can be efficiently and rapidly reactivated upon pathogen exposure. Adaptive immune responses are initiated in the T cell-rich areas of the secondary lymphoid organs, where antigen-bearing DCs migrate from the site of vaccination to encounter naïve T cells which undergo to clonal expansion and differentiation into effector CD4+ T helper cells or CD8+ cytotoxic T lymphocytes (CTL). In particular, antigen-specific activated CD4+ T-helper cells support the generation and maintenance of both humoral antibody-based B cell and cellular CD8+ CTL responses. CD4+ T-helper cells, indeed, can be directed into a Th1, Th2 or T-Reg polarization upon direct contact with antigen-bearing APCs and induction by specific cytokines (Groux et al. 1997; McGuirk and Mills 2002; Moser and Murphy 2000; Mowen and Glimcher 2004; O’Garra and Robinson 2004; O’Garra and Vieira 2004). The polarized cells can antagonize each other’s actions, by blocking either the polarized maturation of the opposite cell type or its receptor functions (Lafaille 1998). Consequently, the T-helper cells polarization will ultimately lead the adaptive immune system toward either a cellular T-cell, sustained by CD8+ CTL (Th1), or a humoral antibody (Th2) or a tolerance (T-Reg) response. After removal of the antigen, a subset of polarized activated effector T cells survive and further differentiate into long-lasting memory T cells whose numbers are maintained over time, in order to readily induce an immune response at subsequent encounters with the same antigen (Kaech et al. 2002). Needless to say that generation of a potent memory response after vaccination is a crucial point that has to be addressed during an effective vaccine design. The considerable amount of available information on the role of the TLRs to link innate with adaptive immunity allows to exploit these biological properties on a knowledge-based approach, to optimize both magnitude and type of immune as well as memory response induced by vaccine candidates.
Vaccines Inducing Humoral or Cellular Immune Response Most vaccines licensed so far induce a long-lasting protective humoral adaptive immune response and have been successful because the targeted pathogens can be entirely prevented by appropriate amounts of immunoglobulin G antibodies in the serum (Rappuoli 2007; Robbins et al. 1995, 1996). Nevertheless, although not experimentally proven, a common belief is that for some vaccines, the induced protection seems to go beyond the effect mediated by the antibodies alone (Belshe et al. 2007; Kimberlin and Whitley 2007).
148
F.M. Buonaguro et al.
In the last years, the development of vaccines able to elicit also an effective cellular adaptive immune response is considered of high priority. In fact, if antibodybased vaccines provide prevention and protection from infection, T-cell–based vaccines may be relevant in controlling an established chronic infection, such as HCV and HIV viruses (Houghton and Abrignani 2005; Korber et al. 2009; RerksNgarm et al. 2009; Sallberg et al. 2009), or a cancer (Banchereau et al. 2009; Draper and Heeney 2010; Sioud 2009). In this respect, the engagement of TLRs by the vaccine antigen, besides the upregulation of co-stimulatory molecules in the APCs, leads mainly to production of Th-1 cytokines like IL-1, IL-6, TNF and IL-12 (Brightbill et al. 1999). In particular, the TLR-3 ligand poly I:C, a synthetic analog of dsRNA, has been shown to have a potent adjuvanting effect in several experimental systems (Asahi-Ozaki et al. 2006; Longhi et al. 2009; Navabi et al. 2009). A modified imidazoquinoline ligand for the TLR7 (3M-019) has also been shown to be a potent adjuvant for protein vaccines (Johnston et al. 2007) and TLR7/8 agonists enhanced the generation of Th1 response and CD8 T cell proliferation of HIV Gag protein (Wille-Reece et al. 2006). Bacterial unmethylated CpG DNA is recognized by TLR9 and the therapeutic potential has been well documented in different pathophysiological conditions like cancer, infectious disease and asthma (Krieg 2006, 2008). A combination of CpG DNA and the TLR8 synthetic agonist, R-848, induced an enhanced production of antibody and memory T cell against the HBS-Ag vaccination (Ma et al. 2007). CpG DNA induced a significant enhancement of the magnitude of the cytokine production, antigen-specific CD8+ T cell response and control of viral loads after challenge with SIV (Kwissa et al. 2007a). Finally, CpG DNA induced rapid and strong antigen-specific T cell responses to melanoma antigen A (Melan-A; identical to MART-1) in a phase I clinical trial (Speiser et al. 2005). Likewise, TLR ligands have been identified to further stimulate Th2 responses (Agrawal et al. 2003; Dillon et al. 2006; Dillon et al. 2004; Redecke et al. 2004). Bacterial lipoproteins, like outer-surface lipoprotein (OspA), have been found to exert adjuvant function in Lyme disease vaccination engaging the TLR1 (Alexopoulou et al. 2002; Thomas and Fikrig 2002). Flagellin, which is present in the flagellar structure of many bacteria, is recognized by TLR5 and has been shown to greatly enhance immune response to influenza vaccine candidate (Huleatt et al. 2008). Only a subset of the TLRs (TLRs 3, 4, 7, and 9) expressed on plasmacytoid DCs can induce type 1 interferons, which are important for antiviral defense (Gilliet et al. 2008; Liu 2005). Furthermore, aiming to improve the immunological memory of the antigen delivered with the vaccine, TLR ligands like poly I:C and CpG DNA have been shown to enhance the survival of activated CD4+ T helper cells, through NF-kB activation, both in vitro and in vivo without any help from the APCs (Gelman et al. 2004). In a subsequent study using poly I:C or CpG DNA, it was observed that fully functional CD8 memory cells were generated without any CD4 help in the presence of TLR ligands (Assudani et al. 2008; Hervas-Stubbs et al. 2007). Furthermore, TLR7/8 agonist has been shown to enhance both effector and memory T cell response to HIV gag antigen(Wille-Reece et al. 2006).
Immune Signatures and Systems Biology of Vaccines
149
Platform of System Levels Analyses Systems Biology in Vaccine Studies The innate immune system is at the interface between the vaccine antigen and the host’s adaptive immune response, therefore, the evaluation of the molecular effects induced by vaccines on PRRs biology is of high relevance. Studying molecular signatures that are induced rapidly after antigen presentation will predict, indeed, the subsequent development of protective immune responses, enabling the evaluation of the efficacy or immunogenicity of untested vaccines in the general population or the identification of unresponsive individuals to vaccination. Furthermore, the predictive signatures would uncover new correlates of protection and further decipher the biological mechanisms by which such molecular signatures modulate vaccine-induced immunity and protection. In order to have new insights into the complex nature of the interactions within the ménage à trois among the three player of this game (vaccine, innate and adaptive immunity), it is necessary to employ the detailed level of investigation provided by systems biology approaches. The advancement of high-throughput technologies, together with the extensive identification of new genes, proteins and other biomolecules in the “omics” era, has facilitated large-scale biological measurements. The new experimental paradigm of systems biology aims to consider a biological system as not just a set of distinct elements, but rather as a complex product of the inter actions among these elements and their relationship with the surrounding environment. Despite the increasing use of such approaches in prognosis and therapy response prediction in oncology (Alizadeh and Staudt 2000; Potti et al. 2006; Sorlie et al. 2001) as well as in autoimmunity and infections (Chaussabel et al. 2008; Ramilo et al. 2007), they have only recently been applied to vaccinology (Fig. 2).
Role of Transcriptomics Transcriptomics represents the most widely used methods for studying the immune response on a genome-wide scale, enabling to identify specific set of genes and pathways differentially regulated upon encounter with a foreign antigen. DNA microarray technology has led to several new insights into interactions between pathogens and innate immunity, which represent the background information for understanding and predicting the host response to vaccines (Elkon et al. 2007; Jenner and Young 2005; Leber et al. 2008; McCaffrey et al. 2004; RicciardiCastagnoli and Granucci 2002). The near future of transcriptomics is represented by new technologies, including next-generation sequencing (Wang et al. 2009) and exon and microRNA arrays. However, in order to reduce the number of meaningless observations, the results generated by transcriptomics studies need to be integrated by meta-analysis
150
F.M. Buonaguro et al.
The technologies of Systems Biology Genomics • High throughput DNA sequencing
Transcriptomics • Gene transcript measurement • SAGE • gene chips • microarrays
Proteomics • • • • • •
Mass spectometry 2D – PAGE Protein chips Yeast-2-hybrid X-ray NMR
Metabolomics • NMR • X-ray • Capillary electrophoresis
Genetics • SNPs • miRNA profiling • SiRNA screens • ENU random mutagenesis
Computational Biology and mathematical modeling
Data integration leveraging multi-disciplinary collaboration
Biomarker discovery Rationale vaccine design Biomarkers for responsiveness
Fig. 2 Systems biology approaches for vaccine studies interactions and the implications on translational research
performed on multiple independent datasets, in order to select only genes behaving similarly across several independent experiments. Meta-analysis requires access to several accessible data and in the last years several publicly available databases of innate (and adaptive) immunology-related transcriptomics datasets have been created, including the reference database of immune cells (RefDIC) (Hijikata et al. 2007), the immune response in silico database (IRIS) (Abbas et al. 2005) and the innate immune database (IIDB) (Korb et al. 2008) (for a more complete list of databases, please refer to Ref. (Gardy et al. 2009)). Furthermore, in order to improve integration of immunology datasets of these different databases, the Immunological Genome Project initiative has been recently established with the ambitious goal to combine immunology and computational biology laboratories in a systems-level approach (Heng and Painter 2008). Meta-analysis combining data from 32 in vitro human studies enabled the identification of an expression signature made of a cluster of 511 genes, which are induced in many different cell types in response to exposure to several different pathogen species and designated as the “common host response” (Jenner and Young 2005). In particular, these genes can be divided in few discrete clusters including cytokine genes, IFN-stimulated genes (ISGs), transcriptional factors and components of signal transduction pathways, genes that limit the immune response and allow the cell to return to its unactivated state as well as genes that have not previously been associated with the immune response. The identification of this shared transcriptional program to foreign antigens among different host cells, even outside of the immune system, suggest the evolution of a multicellular and multicompartmental line of host defense to infection.
Immune Signatures and Systems Biology of Vaccines
151
Proteomics Proteomics gives a comprehensive picture of the immune interactome, representing the interactions involving the genes and gene products known to participate in the immune response. Although much of these data was present in the biomedical literature, they were not organized in databases crucial for systems-level analyses. The first attempt to build an innate immunity-specific interaction database was a map of the mammalian TLR signaling network (Oda and Kitano 2006). More recently, the InnateDB project has been established and more than 7,000 innate immunity-relevant interactions involving 2,000 human and mouse genes have collated, reviewed, annotated and made available, up to now (Lynn et al. 2008). The relevance of proteomics data in the vaccinology field is represented by new insights in the host–pathogen innate immunity interactome which can be readily and valuably transferred to vaccine development. Several viral proteins, indeed, are involved in viral evasion of the innate immune system through interactions with key proteins in innate immunity pathways (Bowie and Unterholzner 2008) and, in this respect, a proteome-wide map of the interactions between hepatitis C virus-encoded proteins and human proteins has been recently described (de Chassey et al. 2008). Furthermore, few databases have been recently established to provide online resources describing known host-pathogen protein interactions (Ceol et al. 2010; Chatr-aryamontri et al. 2009; Driscoll et al. 2009; Navratil et al. 2009). In addition to studies on protein-to-protein interactions, a field of active research is focused on how innate immune response is influenced by post-translational modifications and protein dynamics. The so-called “phosphoproteomics” will help understanding the dynamics of the innate immune response signaling cascades, providing a global picture of protein phosphorylation as marker of the cellular signal transduction, to identify the complete “kinome” of a cell. Proof of concept of such approach have been recently reported (Bakal et al. 2008; Stahl et al. 2009).
RNAi and miRNA to Study Innate Immunity Functional annotation of several genes in a single experimental series is now possible by large-scale RNAi screens, in which genes are progressively knocked down using appropriate inhibitory RNA molecules. This technology has the potential to rapidly identify innate immune signaling genes involved in host-pathogen interactions and allowed the identification of the host proteins involved in HIV and West Nile virus infections (Brass et al. 2008; Krishnan et al. 2008). Similarly, the profiling of miRNAs expression can provide valuable information on how these post-transcriptional regulators of gene expression can modulate genes relevant to innate immunity and, therefore, the immune response itself.
152
F.M. Buonaguro et al.
Microarray-based platforms that enable the profiling of miRNA expression on a large or even global scale are also now available (Yin et al. 2008) and recently the leukocyte miRNA response to LPS stimulation has been investigated (Schmidt et al. 2009; Vasilescu et al. 2009; Zhou et al. 2009).
Genetic Polymorphisms in Innate Immunity Genes Genetic polymorphisms can adversely affect expression of genes as well as proteins of the innate immune system and, consequently, host-pathogen interactions and molecular signaling. This represents an additional level of analysis to be included in the global evaluation of factors involved in the host response to foreign antigens (Bochud et al. 2007a; Dickinson and Holler 2008; Georgel et al. 2009; Misch and Hawn 2008). The association between polymorphisms in TLR9 gene and clinical course of HIV-1 infection (Bochud et al. 2007b) as well as susceptibility to tuberculosis and specific polymorphisms in the TLR2 gene have been described (Ogus et al. 2004; Yim et al. 2006; Yoshida et al. 2009). Two nonsynonymous SNPs in the extracellular domain of TLR4 found to be in linkage disequilibrium and polymorphisms in the TLR4 gene have been associated with an increased susceptibility to several infections (Ferwerda et al. 2007, 2008; Lorenz et al. 2002; Miyairi and DeVincenzo 2008; Nguyen et al. 2009; Rezazadeh et al. 2006), although these findings are controversial and not consistently confirmed (Allen et al. 2003; Read et al. 2001; Smirnova et al. 2003). Implications on infectious diseases progression of polymorphisms in other TLRs genes have been reported (Pine et al. 2009; Velez et al. 2010; Wurfel et al. 2008).
Systems Biology for Prediction of Vaccine Immunogenicity Systems level studies have been recently performed to identify gene “signatures” in humans predicting immune responses to yellow fever vaccine (YF-17D) (Gaucher et al. 2008; Querec et al. 2009) and VLP-based HIV vaccine (Aricò et al. 2005; Buonaguro et al. 2006, 2009a; Monaco et al. 2009). In parallel, a role for TLRs polymorphisms in immune response to vaccines has been demonstrated for measle (Dhiman et al. 2008), rubella (Ovsyannikova et al. 2010) and pertussis (PT) (Kimman et al. 2008). Gene Signatures of Yellow Fever Vaccine YF-17D Subjects vaccinated with YF-17D showed a significant variable response over time in terms of both magnitude of the antigen specific CD8+ T cell responses
Immune Signatures and Systems Biology of Vaccines
153
and neutralizing antibody titers. Gene transcriptional profile of early innate immune genes in PBMCs from vaccinated individuals showed that vaccination with YF-17D induced in most of the vaccinees a molecular signature including several genes involved in innate sensing of viruses and antiviral immunity. It was also recently reported that the YF17D virus activates DCs by triggering their TLR2, 7, 8, and 9 (Querec et al. 2006). Among these, indeed, were observed genes encoding innate sensing receptors (i.e., TLR7, RIG-I), transcription factors that regulate the expression of type I IFNs, IFN regulatory factor 7 (IRF7) and signal transducer and activator of transcription 1 (STAT1). Furthermore, genes encoding proteins in the complement pathway (i.e., C1QB) and the inflammasome were induced. In particular, a group of transcription factors, including IRF7, STAT1 and ETS2, were identified as key regulators of the early innate immune response to the YF-17D vaccine (Gaucher et al. 2008; Querec et al. 2009). In particular, ETS2 is involved in immune response since its expression is up-regulated in activated and proliferating T cells (Bhat et al. 1990; Gallant and Gilkeson 2006) and induces in IL-12 p40 (Th1) and IL-5 (Th2) gene expression (Blumenthal et al. 1999; Sun et al. 2006). Furthermore, the enhanced transcription of several downstream genes that play critical roles in the maturation and differentiation of T cells, B cells, NK cells, and macrophages was observed (Gaucher et al. 2008). The upregulation of this antiviral molecular signature for more than 2 weeks post vaccination is possibly reflecting the ongoing stimulation of innate immune cells in response to viral replication of the live attenuated YF-17D vaccine, which peaks at 7 days (Monath 2005). However, there was no correlation between the induction of these genes and the magnitude of the CD8+ T cell or neutralizing antibody response, possibly implying that the observed molecular signature is only due to the virus replication. Further bioinformatics approaches, applied in a second YF-17D vaccine trial, identified two genes — solute carrier family 2, member 6 (SLC2A6) and eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4) – that did correlate (at 90% accuracy) with the magnitude of antigen specific CD8+ T cell responses and antibody titers. In particular, EIF2AK4 regulates protein synthesis in response to environmental stresses by phosphorylating elongation initiation factor 2a (eIF2a) (Richter and Sonenberg 2005; Ron and Walter 2007). Indeed, YF-17D vaccination induced the phosphorylation of eIF2a as well as the formation of stress granules, and other genes involved in the stress response pathway correlated with the CD8+ T cell response (Querec et al. 2009). The TnF receptor superfamily, receptor 17 (TnFRSF17), which is a receptor for B cell-activating factor (BAFF), was shown to be a key gene in the predictive signatures. BAFF, indeed, is thought to optimize B cell responses to B cell receptorand TlR-dependent signaling (Hoek et al. 2009; Khan 2009). Furthermore, PBMCs isolated from YF17D-vaccinated volunteers display a mixed T helper cell phenotype with the induction of a mixed Th1/Th2 profile (Gaucher et al. 2008; Santos et al. 2008).
154
F.M. Buonaguro et al.
Gene Signatures of HIV-VLPs Vaccine Similar studies have been performed using a baculovirus-expressed HIV-VLPs developed in our laboratory. These HIV-VLPs induce HIV-1-specific CD4+ and CD8+ T-cell responses and cross-clade neutralizing antibodies in immunized BALB/c mice (Buonaguro et al. 2002). Moreover, the intraperitoneal and intranasal administration of HIV-VLPAs in mice induces antibody responses at systemic and mucosal (vaginal and intestinal) levels (Buonaguro et al. 2005, 2007). Baculovirus-expressed HIV-VLPs induced maturation and activation of monocytederived DCs (MDDCs) from HIV-1 seronegative subjects and this effect was partially mediated by the internal Toll-like receptors 3 and 9. The HIV-VLP-activated MDDCs produced a pattern of cytokines indicative of both Th1 and Th2 pathways and induced primary and secondary responses in autologous human CD4+ T cells in an ex vivo immunization assay (